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RÉSUMÉ 
 
L'épidémie de l'infection au virus de l'immunodéficience humaine (VIH) constitue 
une crise majeure en santé publique de nos jours. Les efforts de la communauté 
internationale visent à rendre les traitements antirétroviraux (TARV) plus accessibles 
aux personnes vivant avec le VIH, particulièrement dans les contextes à ressources 
limitées. Une observance quasi-parfaite aux TARV est requise pour tirer le maximum 
de bénéfices thérapeutiques à l'échelle individuelle et à l'échelle populationnelle. 
Cependant, l’accroissement de la disponibilité des TARV s'effectue dans des pays 
africains qui disposent de systèmes de santé fragiles et sous-financés. Ceux-ci 
souffrent également d'une pénurie de personnel de santé, lequel joue un rôle central 
dans la mise en oeuvre et la pérennité des interventions, notamment celle du soutien à 
l'observance thérapeutique. 
 
La présente étude ethnographique relate l'expérience de personnel de santé dans la 
fourniture des services de soutien à l'observance dans un contexte de ressources 
limitées et d'accroissement de l'accès aux TARV. L'étude a été menée dans deux 
centres hospitaliers de la capitale du Burkina Faso, Ouagadougou. 
 
Trois conclusions principales sont mises au jour. Tout d'abord, une bonne 
organisation – tant logistique que matérielle – dans la provision de services de soutien 
à l'observance est capitale. L’infrastructure d’observance doit aller au-delà des unités 
de prise en charge et s’intégrer au sein du système de santé pour assurer un impact 
durable. De plus, la provision des TARV dans le cadre d'une prise en charge médicale 
exhaustive est essentielle pour un soutien à l'observance efficace. Ceci implique la 
présence de professionnelles de santé en nombre suffisant et disposant d‘outils pour 
soutenir leur pratique clinique (tests de laboratoire, traitements pour infections 
opportunistes), ainsi que des mécanismes pour leur permettre d’aider les patients à 
gérer la vie quotidienne (gratuité des services, programmes d’alphabétisation et 
soutien psychosociale). Enfin, une amélioration de la coordination des programmes 
VIH au niveau national et international est nécessaire pour assurer une prise en 
charge cohérente au niveau local. La programmation conçue dans les pays étrangers 
qui est incomplète et de courte durée a un impact majeur sur la disponibilité de 
ressources humaines et matérielles à long terme, ainsi que sur les conditions de travail 
et de prestation de services dans les unités de soins.  
 
 
Mots-clés: virus de l’immunodéficience humaine, traitement antirétroviral, 
observance thérapeutique, Afrique subsaharienne, personnel de santé, systèmes de 
santé, ethnographie hospitalière. 
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ABSTRACT 
 
The human immunodeficiency virus (HIV) epidemic is the most pressing public 
health crisis of modern times. Present international focus targets expanding access to 
life-saving antiretroviral treatment (ART) for people living with HIV/AIDS – referred 
to as treatment scale-up- in contexts with limited resources. Near perfect adherence to 
ART regimens is required to maximize individual and public health outcomes. ART 
is being scaled-up in African countries with under-funded, fragile health systems. 
These health systems are further plagued by a shortage of health professionals who 
play a critical role in the implementation and sustainability of ART programmes, 
including the provision of adherence support.  
 
This ethnographic study sought to explore the experience of health providers in 
addressing adherence to ART in settings of limited resources where ART is being 
scaled-up. The study took place in two hospital centres in the capital city of Burkina 
Faso; Ouagadougou.   
 
The study led to three broad conclusions. First, good organization is imperative in the 
delivery of adherence support services, both in terms of logistics and materiality. This 
infrastructure must extend beyond the level of the hospital ward, to the level of the 
health sector in order to ensure a sustainable impact. Second, the provision of ART 
within a comprehensive package of care is an essential component of effective 
adherence support. This involves equipping providers with tools to assist them in 
their clinical practice (laboratory monitoring, treatment for opportunistic infections, 
and additional staff) as well as mechanisms for them to help patients negotiate the 
trials of daily life (gratuity of care, literacy support, psychosocial support). Third, 
there is a need for improved coordination of nationally and internationally-led HIV 
programming for coherent service provision at the local level. Limited and short-term 
external funding affects the long-term availability of material and human resources, 
as well as working conditions and service provision on the wards.  
 
The results of the study contribute to the existing academic literature on ART 
adherence, to the design of future research projects, and to the organization of 
adherence support services.  
 
 
Key words: human immunodeficiency virus, antiretroviral treatment, adherence, Sub-
Saharan Africa, healthcare providers, health systems, hospital ethnography. 
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RELEVANCE OF THE STUDY 
 
The human immunodeficiency virus (HIV) epidemic is the most pressing public 
health crisis of modern times. The magnitude of the HIV epidemic requires informed, 
comprehensive and effective action at all levels of society. Present international 
efforts aim to expand access to life-saving antiretroviral treatment (ART) for people 
living with HIV/AIDS – often referred to as treatment scale-up. A number of large - 
scale ART distribution programmes have been implemented in sub-Saharan Africa, 
rendering lifesaving treatment available to an ever-increasing number of individuals. 
Increased access to treatment has been credited with prolonging the lives of 
individuals for whom an HIV diagnosis was equated with a death sentence just a few 
years ago.  
 
Despite the positive implications of these treatment programmes, in general little 
attention has been paid, until now, to monitoring of patient adherence. Near-perfect 
adherence to ART is essential for positive treatment outcomes, including improved 
clinical status of the individual. Sub-optimal adherence compromises treatment 
success and fosters the development of HIV strains that are resistant to current ART 
regimens. These resistant strains can be transmitted between individuals.  Lack of 
emphasis on adherence support in scale-up programmes thus poses a serious threat 
not only to individual patient outcomes, but also to public health.  
 
ART scale-up is being carried out in African countries with largely under-funded and 
fragile health systems. These health systems are further plagued with a chronic 
shortage of health professionals due to lack of resources and emigration to more 
favourable job markets in higher-income countries. This deficit in health 
professionals is especially devastating to the health sectors of low-and-middle-
income countries (LMIC) that are heavily reliant on manpower to implement health 
interventions, including adherence support for patients on ART. Despite the crucial 
role of the health provider in such contexts, human resources are an often-overlooked 
component in health system planning.  
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Healthcare professionals across Africa are faced with the logistical challenge of 
treating the massive influx of HIV patients that accompanies the increased access of 
ART and providing them with a continuum of care (including adherence support) that 
is essential for positive treatment outcomes.  
 
This ethnography aimed to study the question of adherence support for patients on 
ART from the perspective of the health provider. It is important to examine this issue 
from the health provider’s perspective for several reasons.  First, there have been 
recent calls by the international HIV/AIDS community for more operations research 
to assess the impacts of treatment scale-up on health systems.  A description of how 
adherence to ART is currently being addressed provides practitioners and policy-
makers with an evidence-based understanding of the present context. Second, an in-
depth understanding of the difficulties faced by health professionals in their daily 
work caring for HIV patients helps to highlight barriers to adherence support and 
identify possible targets for improvement and further research. Third, a survey of 
recommendations on how adherence support for patients can be improved valorizes 
the perspectives of healthcare providers and fosters a more participative approach to  
health system development. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER TWO: LITERATURE REVIEW
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Human Immunodeficiency Virus 
 
In 2007 there were 33.2 million people around the world infected with human 
immunodeficiency virus (HIV) - the virus that leads to acquired immune deficiency 
syndrome (AIDS) - including 2.5 million new infections (UNAIDS/WHO, 2007). In 
the same year 2.1 million AIDS-related deaths were reported.  While HIV is present 
in all regions around the globe, it disproportionately affects Sub-Saharan Africa. This 
region alone accounts for more than two thirds of all infections; that is 22.5 million 
cases.  
 
The magnitude of the epidemic makes it the most significant public health problem in 
recent history (Harries, Nyangulu, Hargreaves, Kaluwa, & Salaniponi, 2001). The 
International Federation of Red Cross and Red Crescent Societies recently released a 
report identifying HIV and AIDS as “a global disaster” (International Federation of 
Red Cross and Red Crescent Societies, 2008). HIV produces devastating impacts on 
individual health by suppressing the immune system and leaving the body vulnerable 
to opportunistic infections – a sign of progression toward AIDS and, ultimately, 
death. HIV is transmitted between individuals through blood and bodily fluids during 
sexual intercourse, from mothers to infants (during pregnancy, childbirth and 
breastfeeding), and contact with contaminated blood (for example, through blood 
transfusions and the sharing of intravenous drug needles). The highly transmissible 
nature of HIV poses a substantial threat to population health and sustainable 
development.   
 
The impacts of the HIV epidemic are far-ranging. Over 10 years ago, Danzinger 
identified several areas of impact of HIV and AIDS on low and middle income 
countries (LMIC), on individual, household, social, and economic levels (Danzinger, 
1994). Despite improvements in treatment access, HIV continues to wreak havoc on 
societies across Sub-Saharan Africa. It has been shown to negatively impact 
macroeconomic development in highly affected countries. Modelling studies have 
shown that HIV has a detrimental effect on the gross domestic product (GDP) of 
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countries where it is endemic, adding a further barrier to sustainable development in 
some African countries (Ventelou, Moatti, Videau, & Kazatchkine, 2008). For 
example, in four African countries (Angola, Central African Republic, Cameroon and 
Côte d’Ivoire) the HIV epidemic was estimated to account for a 1% loss in GDP 
growth per year between 2000 and 2010 when compared to a scenario without the 
HIV epidemic (Ventelou, et al., 2008).  
 
A sizeable amount of resources at the international, national and community levels 
has been invested to counteract the HIV pandemic. Investments have targeted a range 
of activities; from preventive to therapeutic. In recent years, much effort has been 
attributed to rendering treatment for HIV available in LMIC (WHO, 2008b). A 
number of large-scale antiretroviral treatment (ART) distribution programmes have 
been implemented in sub-Saharan Africa to respond to the HIV epidemic, rendering 
lifesaving treatment available to an ever-increasing number of individuals.  
 
 
Antiretroviral Treatment  
 
There is now widespread acceptance at the international level that access to ART is 
essential in mitigating the impact of HIV/AIDS. ART functions by halting the 
replication of HIV, thus reducing the amount of virus in the body (viral load) and the 
destruction of CD4 cells (an integral component of the immune system and the virus’ 
preferred target) (WHO, 2002). The main goal of ART is to slow the individual’s 
clinical progress from HIV to AIDS and, ultimately, death. Treatment allows HIV 
positive individuals to live longer, more productive lives and to care for their children 
(Harries, et al., 2001). 
ART is not only essential in treating HIV, but also in preventing its spread. Findings 
from studies in African settings have shown that individuals on ART engage in less 
sexual risk behaviour (Kennedy, O'Reilly, Medley, & Sweat, 2007). Increased 
availability of treatment may encourage individuals to seek voluntary counselling and 
testing (VCT) services and to disclose their HIV status to their sexual partners 
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(Harries, et al., 2001). A study in Bostwana recorded a five-fold increase in voluntary 
HIV testing after decentralization rendered ART locally available (Warwick, 2006). 
Evidence also exists that as ART decreases the viral load of infected individuals, the 
possibility of transmission may also be reduced (Quinn, et al., 2000). In 2008, a 
group of Swiss physicians released a controversial statement declaring that HIV 
positive individuals who are adherent to ART and who do not suffer from any other 
sexually transmitted infections (STIs) cannot sexually transmit HIV to their partners 
(Vernazza, Hirschel, Bernasconi, & Flepp, 2008). Projections made in 2005 estimated 
that if a quarter of patients in Africa were placed on treatment, up to 1.3 million new 
infections could be prevented after just five years (Akileswaran, Lurie, Flanigan, & 
Mayer, 2005).  
 
There are several global initiatives that seek to improve access to ART in resource-
limited countries. In 2003, the World Health Organization (WHO) announced its 
innovative “3 by 5” initiative; a programme aiming to provide three million people 
infected by HIV in LMIC with ART by 2005 (WHO, 2003b). The WHO “3 by 5” 
initiative was founded upon a public health approach that aimed to develop treatment 
programmes that reach as many people in need as possible (WHO, 2006b). Although 
the target was attained after the 2005 deadline, the initiative is credited with 
contributing to substantial improvements in access to treatment by increasing 
visibility and political pressure on donors. Other renowned donors that drive ART 
access initiatives include the Global Fund for AIDS, tuberculosis and malaria 
(GFATM), launched in 2002, and the President’s Emergency Plan for AIDS 
Response (PEPFAR), initiated in 2003 (UNAIDS, 2007). Various governmental, non-
governmental and faith-based organizations also play key roles in broadening ART 
accessibility.  
 
The current goal dominating the international donor scene is “universal access to HIV 
prevention, treatment, care and support by 2010” (UNAIDS, 2007). The commitment 
was first established at the Gleneagles Meeting of the Group of Eight countries in 
2005 and reaffirmed at the 2005 United Nations (UN) General Assembly World 
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Summit (UNAIDS, 2007). Significant progress in ART availability and access has 
been achieved since the adoption of the universal access goal; between 2006 and 
2007 alone, one million more individuals in LMIC were prescribed ART (De Cock & 
De Lay, 2008). Attainment of this goal, however, will be compromised in the absence 
of increased financial pledges from the international community (UNAIDS, 2007).  
 
The adoption of these grand objectives would not have been possible without the 
drastic decline in prices of antiretroviral drugs (ARVs) over the last few years. 
Activist groups and NGOs have maintained pressure on governments and 
pharmaceutical companies to render ART more accessible to impoverished 
populations (Buvé, Kalibala, & McIntyre, 2003). In Burkina Faso, for instance, the 
monthly price of ART paid by patients dropped from around US$800 at the end of 
1998 to about US$100 by June 2001 (V.-K. Nguyen, Grennan, Peschard, Tan, & 
Tiendrébéogo, 2003). Today, ART in Burkina Faso costs patients approximately 
US$3 per month (Sanou, 2008).  
 
International trade regulations protecting intellectual property initially constituted a 
significant barrier to accessibility of ART in LMIC.  Competition from generic ART 
manufacturers in India, Brazil and Thailand, as well as the activist pressure just 
mentioned above helped to bring down prices and reform those international 
regulations. The World Trade Organization adopted the Doha Declaration on the 
Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement on Public 
Health November 14, 2001 stating that Member countries had a “right to protect 
public health and, in particular, to promote access to medicines for all” (World Trade 
Organization, 2001).  This agreement allows countries without the capacity to 
manufacture pharmaceuticals domestically to import lower-cost generic ARVs in the 
interest of public health. In 2002, several ARVs were added to the WHO Essential 
Medicines List, affirming HIV as a public health priority (Laing, Waning, Gray, 
Ford, & Hoen, 2003).  
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Adherence to Antiretroviral Treatment  
The attainment of the positive health benefits of ART is contingent not only on the 
availability of drugs, but also on near-perfect adherence to medication regimens. 
Indeed, as Kim and Gilks once stated in an editorial to the New England Journal of 
Medicine: “Adherence support, rather than regimen potency, may be the single most 
critical determinant of long-term success” of treatment programmes (Kim & Gilks, 
2005).  
 
The WHO provides the following definition of adherence: “the extent to which a 
person’s behaviour – taking medication, following a diet, and/or executing lifestyle 
changes - corresponds with agreed recommendations from a health care provider” 
(WHO, 2003a). The definition of “adherence” distinguishes itself from that of 
“compliance” in its reflection of the active role played by the patient in the treatment 
process.  
 
No gold standard exists for measuring adherence. Patient self-report is the most 
commonly used method; patients are asked to recall how many doses they missed 
over a certain period of time (Goudge, Ngoma, & Schneider, 2004). Pill counting, 
provider assessments, pharmacy records, and the medication event-monitoring system 
(a system whereby a microchip in the pill container records information about the 
date and time the container is opened) are also used. These methods all have 
drawbacks and thus can only serve as proxies for measuring actual adherence rates.  
 
There is no consensus in the literature on optimal levels of adherence (Walsh, 
Pozniak, Nelson, Mandalia, & Gazzard, 2002). Some researchers consider adherence 
to more than 95% of doses to be essential in maximizing virological outcomes 
(Paterson, et al., 2000).  More potent antiretroviral drug combinations with a higher 
“genetic threshold” for resistance, as well as more long-acting drugs, have been 
introduced from the late 1990s (V.-K. Nguyen, personal communication, August 3, 
2008).  It is now thought that these more potent regimens are more “forgiving” of 
lower adherence, although an optimal threshold has yet to be identified.  
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Suboptimal adherence has been associated with poorer patient outcomes and the 
appearance of mutations in HIV strains that render them resistant to current 
medication regimens (Sethi, Celentano, Gange, Moore, & Gallant, 2003; Weiser, et 
al., 2003). The academic community has published appeals for more pro-active 
monitoring of patients on ART that aims to identify adherence problems before 
treatment becomes ineffective for a particular person (Bangsberg, 2008). Of grave 
importance to public health is that these resistant strains have the potential to be 
transmitted to uninfected partners (Hecht, et al., 1998).  Harries and colleagues, 
therefore, cautioned that treatment scale-up must be carried out within a structured 
framework in order to optimize positive benefits and to avoid “antiretroviral anarchy” 
– that is, “widespread and unregulated access” to ART (Harries, et al., 2001).  
Integral to this perspective is the concept of excellent patient adherence to treatment 
and medical follow-up (Harries, Makombe, Schouten, Ben-Smith, & Jahn, 2008) 
 
Despite the importance of adherence support in ensuring treatment success, most 
large-scale ART programmes have, until recently, paid little attention to the issue, 
focusing instead on the numbers of people accessing treatment. A review of ART 
monitoring by international, regional and national institutions in Southern African 
countries suggested that adherence is a largely neglected indicator (Shamu, 2004). 
UNAIDS and WHO monitoring of population adherence rates is limited to a 
quantitative indicator of adherence to measure the number of people still on treatment 
at certain time points. Furthermore, a recent WHO update on the goal of universal 
access only briefly broached the subject of adherence to treatment (WHO, 2008b).  
 
The WHO recommends that the scale-up of ART programmes be implemented within 
a public health approach, summarized as follows:  
 
“The public health delivery of ART focuses on maximizing survival at the 
population level through standardized sequencing of the available ARVs, 
delivered to individuals by means of simplified approaches and supported by 
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clinical and basic laboratory monitoring. It encompasses the guiding 
principles of chronic disease management with a strong focus on ART 
adherence and integrated, decentralized health care delivery linked to 
reduction of HIV transmission.” (WHO, 2006a) 
 
Four guiding principles have been developed in line with this approach to minimize 
drug resistant HIV strains:  “(1) appropriate ART access, prescribing and usage; (2) 
fostering adherence; (3) supporting prevention of HIV transmission; and (4) 
appropriate action based on surveillance and monitoring results” (WHO, 2006c).  
 
The public health approach in South Africa was compared to an individualized 
approach in Switzerland (Keiser, et al., 2008). The authors reported similar outcomes 
in both cohorts of patients newly initiated to ART. They recommended, however, that 
patients, particularly in South Africa, would benefit from more precocious 
prescribing of ART.  
  
It has been found that ART scale-up programmes in Africa have been successfully 
implemented and have achieved positive outcomes (Akileswaran, et al., 2005; Touré, 
et al., 2008),  including high adherence rates (Akileswaran, et al., 2005). A meta-
analysis reported that adherence rates in Sub-Saharan Africa compare favourably to 
those in North America and surpass them in some contexts (Mills, et al., 2006). Most 
of such studies, however, include relatively small numbers of participants and little 
emphasis on monitoring (Akileswaran, et al., 2005) and adherence (Harries, et al., 
2001). Furthermore, many of the treatment programmes studied benefited from 
technical and financial resources from partners in Northern countries, which 
differentiates them from the actual context of scale-up in many African countries 
(Boileau, et al., 2008). A study on ART adherence in Mali and Burkina Faso by the 
pro-ARV group revealed that only 58.5% of the sample was optimally adherent 
(Aboubacrine, 2006). ART programmes in Africa have also reported significant 
numbers of patients lost to follow-up (Ndiaye, 2008; Touré, et al., 2008). 
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Determinants of Adherence to Antiretroviral Treatment 
 
Adherence is a multidimensional issue that goes far beyond the individual 
characteristics of the patient. The WHO has outlined five dimensions of adherence 
for chronic conditions: patient-related factors, condition-related factors, therapy-
related factors, health system/healthcare team factors, and social/economic factors 
(WHO, 2003a).  
 
Patient-related factors  
Patient characteristics have often been reported as significant determinants of 
adherence to ART (Malcolm, Ng, Rosen, & Stone, 2003; Singh, et al., 1999). Several 
adherence studies have focused on demographic factors. In a longitudinal study of 
American HIV patients, African-American ethnicity, low income and education 
levels, and substance use were independently associated with lower levels of 
adherence (Golin, et al., 2002). Similar findings were reported elsewhere (Catz, 
McClure, Jones, & Brantley, 1999; Gordillo, del Amo, Soriano, & Gonzàlez-Lahoz, 
1999; Moatti et al., 2000). Other studies, however, have found demographic factors to 
be unreliably associated with medication-taking behaviour (Holzemer, Bakken 
Henry, Portillo & Miramontes, 2000) and suggest that they not be used as predictors 
of adherence (Lerner, Gulick & Neveloff Dubler, 1998). 
 
Research has suggested that adherent patients differ from their non-adherent 
counterparts in terms of health beliefs and attitudes (Malcolm, et al., 2003; Smith et 
al., 1997). Adherent patients have been found to have higher perceived self-efficacy 
concerning medication-taking ability (Catz, Kelly, Bogart, Benotsch, & McAuliffe, 
2000). 
 
Psychosocial factors have also been found to influence patient adherence to ART. In 
a cross-sectional study, depression was found to be more prevalent among non-
adherent patients than adherent patients (39% versus 17%) (Starace et al., 2002). 
Similar findings were later supported in a longitudinal study (Spire et al., 2002). 
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Social support (Catz, et al., 2000) (Holzelmer et al., 1999, DiMatteo, Lepper & 
Croghan, 2000), coping behaviour (Singh et al., 1999), quality of life (Holzelmer et 
al., 1999), level of education and awareness of health issues (Kalichman, 
Ramachandran, & Catz, 1999; Smith, Rapkin, Morrison, & Kammerman, 1997), and 
drug or alcohol use (Moatti et al., 2000) have also been associated with adherence 
behaviour.  
 
Despite this considerable pool of research on individual attributes, few personal 
factors have been found to be consistently associated with adherence (Ammassari, et 
al., 2002).  
 
Condition- related factors  
Few studies have been carried out on the impact of illness-related factors on 
adherence (Garcìa & Côté, 2003). Evidence suggests that the duration of illness and 
severity of symptoms may have an impact on adherence, but diverging findings from 
different studies imply that the direction of the effect is unclear (Garcìa & Côté, 
2003). For example, a cross-sectional study showed that patients with lower CD4 
levels were less adherent to treatment (Gordillo, del Amo, Soriano, & Gonzàlez-
Lahoz, 1999). This finding, however, requires further investigation of the 
directionality of the effect due to the cross-sectional design of the study.   
 
Therapy-related factors  
Complexity of medication regimen has often been found to affect adherence to ART, 
with more complex treatment schedules acting as a deterrent (Ammassari, et al., 
2002). Indeed, ART regimens are considered to be among the most complex 
prescribed to control chronic conditions (Chesney, Morin, & Sherr, 2000). The 
complexity of these regimens is due to several factors, including: “pill burden, 
dosing, dietary instructions, number and type of different medications prescribed, 
convenience, and ability to incorporate the treatment regimen into a daily routine” 
(Trotta, et al., 2002). Unpleasant side effects have also been cited by patients as a 
reason for missing doses (Sullivan, et al., 2007). It has been suggested that in order to 
optimize adherence to ART treatment regimens should be made as simple as possible, 
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dosage scheduling should be adapted to the patient’s lifestyle, and patients should be 
equipped with information to effectively anticipate and manage side-effects (Trotta, 
et al., 2002).  
 
Healthcare Team & Health System Factors 
 
Healthcare Team Factors  
Health providers play an essential part in the implementation of health interventions, 
particularly in limited resource settings (Rowe, de Savigny, Lanata, & Victoria, 
2005). ART distribution programmes are no exception.  
 
The positive effects of a good patient-provider relationship on adherence behaviour 
have often been discussed in the academic literature (Maddigan, Majumdar, & 
Johnson, 2005; Sajatovic, et al., 2005). The influence of the patient-provider 
relationship is particularly important in the context of HIV where adherence to ART 
is crucial to positive treatment outcomes (Ickovics & Meade, 2002). Several 
qualitative studies on factors that favour ART adherence cite the necessity of a good 
quality patient-provider relationship (Lewis, Colbert, Erlen, & Meyers, 2006; 
Murphy, Johnston Roberts, Hoffmann, Molina, & Lu, 2003; Stone, et al., 1998). 
Russell et al. (2004) found that seropositive patients who were more satisfied with the 
quality of their relationship with their provider were more adherent to treatment 
regimens. In one South African study examining adherence to tuberculosis treatment, 
the presence of caring health professionals who offered emotional support was found 
to favour adherence (K. A. Rowe, et al., 2005). 
 
While the central role of the provider in promoting patient adherence to ART has 
been demonstrated through research, it is less clear whether this knowledge has 
translated into clinical practice.  A qualitative study conducted in the United States 
showed that most physicians discuss adherence to ART with their patients (Johnston 
Roberts & Volberding, 1999).  In another qualitative project, researchers found that 
most physicians believed that promoting adherence was part of their role, however 
the majority surveyed decried the fact that work conditions did not allow them to 
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spend an adequate amount of time on this task (Golin, Smith, & Reif, 2004). 
Physicians have reported patient non-adherence to treatment recommendations to be a 
significant challenge to clinical practice (Malta, Petersen, Clair, Freitas, & Bastos, 
2005).  
 
Due to the importance optimal adherence to ART, it is fundamental that an open and 
culturally acceptable dialogue on this subject exist between the patient and the 
provider (Malta, et al., 2005). It has been suggested that interventions to promote 
ART adherence should include a multidisciplinary team of providers (Stone, 2001). 
 
 Health system-related factors  
Health systems can influence patient adherence to long-term therapies in a variety of 
ways, including: cost of health services, provider availability, continuity of care, and 
modalities of communication with patients (WHO, 2003a). An ethnography of 
tuberculosis patients in urban Bolivia found that structural determinants of the health 
system such as hidden costs, poor access, discrimination, and maltreatment were 
factors associated with non-adherence to treatment (Greene, 2004).  
 
Despite the importance of health system determinants, little research has been carried 
out on the subject with respect to adherence to ART.  For instance, in a review of 
adherence specific to ART, only health system aspects related to the provider were 
discussed, with a brief mention of poor programme implementation (WHO, 2003a). 
Thus, factors in the health system that affect adherence to ART need to be further 
clarified. The following determinants could serve as potential starting points: health-
care infrastructure, drug stock shortages, and financing mechanisms (including user 
fees) (Castro, 2005).  
 
Social and economic factors  
In an essay on studying adherence from a biosocial perspective, Castro suggests 
studying the following contextual factors: socioeconomic factors (e.g. poverty, cost 
of treatment, transportation costs), social capital (e.g. social status, social support), 
and cultural models of health and disease (e.g. transmission, healers) (Castro, 2005).  
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A review conducted by the WHO on adherence to long-term treatments showed that 
several social and economic factors affect adherence, including:  
 
“Poor socioeconomic status, poverty, illiteracy, low level of education, 
unemployment, lack of effective social support networks, unstable living 
conditions, long distance from treatment centre, high cost of transport, high 
cost of medication, changing environmental situations, culture and lay beliefs 
about illness and treatment, and family dysfunction.” (WHO, 2003a).  
 
Few social and economic determinants of adherence have been studied in relation to 
ART. A cross-sectional study was conducted on the social, cultural, economic and 
structural determinants of adherence to ART in a population of HIV patients in 
Botswana (Weiser, et al., 2003). The investigators found treatment cost to be the most 
significant barrier to adherence, with 70% of the patients surveyed citing it as a 
problem and 44% claiming that it prevented them from effectively adhering to 
treatment regimens. Frequent gaps in treatment were also attributed to financial 
barriers.  
 
Addressing Adherence to Antiretroviral Therapy 
Low-cost adherence interventions have been found to be cost-effective in terms of 
healthcare utilization and health outcomes (WHO, 2003a). A comprehensive strategy 
to ensure adherence to ART should address a range of determinants across the above-
mentioned categories (Stone, 2001). To date, most adherence interventions have 
focused on patients characteristics and ignored broader systemic determinants of 
adherence (Goudge, et al., 2004). It is important to avoid placing a disproportionate 
amount of responsibility for adherence on the patient as many personal determinants 
of adherence are beyond the control of the individual (Malcolm, et al., 2003). “A 
stronger commitment to a multidisciplinary approach is needed in order to make 
progress in this area. This will require coordinated action from health professionals, 
researchers, health planners and policy-makers” (WHO, 2003a). 
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Antiretroviral Therapy and Health Systems 
 
HIV cases were first detected across Africa in the 1980s. This was also around the 
time when structural adjustment programs championed by the International Monetary 
Fund (IMF) and the World Bank in an effort to stabilize volatile economies in LMIC 
were forcing African governments to drastically reduce social spending, including in 
the health sector (Peabody, 1996). One of the direct impacts of these policies was a 
reduction in national investments in health, resulting in disastrous consequences for 
public health systems (Ridde, 2007). HIV, therefore, arrived at a time when health 
systems across the continent were already struggling to meet the needs of their 
populations.  
 
The Alliance for Health Policy and Systems Research defines a health system as “all 
the organizations, institutions and resources that are devoted to producing health 
actions and whose primary intent is to improve health”(Alliance for Health Policy 
and Systems Research, 2004). A health system has four essential functions: service 
provision, resource generation, financing and stewardship.  
 
Health systems in LMIC currently face a multitude of barriers to effective 
functioning, ranging from organizational to financial (Travis, et al., 2004).  Years of 
constrained budgets have left public healthcare systems across Africa in a state of 
decay (Ridde, 2007).  
 
The scaling-up of health interventions first requires a thorough understanding of “the 
range and intensity of constraints that apply in specific contexts” (Hanson, Ranson, 
Oliveira-Cruz, & Mills, 2003). With the advent of expanded access to ART through 
national and international funding, precarious health systems with limited human 
resources are now faced with the logistical challenge of responding to the treatment 
needs of an influx of HIV patients (Kober & Van Damme, 2004b).  Concern has been 
voiced that ART scale-up will divert scarce resources away from other health 
priorities and negatively impact the overall provision of health services. On the other 
  
18 
hand, some believe that scale-up has the potential to strengthen weakened health 
systems if appropriately implemented (El-Sadr & Abrams, 2007).  
 
Global health interventions, such as ART scale-up, face the logistical decision of 
taking a vertical, disease specific approach or a more horizontal approach that seeks 
to integrate existing health services (Travis, et al., 2004). If ART programmes are 
integrated into the public health system, they can improve overall service delivery as 
well as working conditions for staff (El-Sadr & Abrams, 2007; Pfieffer, et al., 2008). 
Such an approach, while more beneficial in the long-term, may be more complex to 
implement initially. A more vertical approach, on the other hand – that is, HIV 
services that are implemented in parallel to existing health services- may accentuate 
existing inequities in healthcare, weaken the public health system, and divert scarce 
resources away from the public health sector (Chopra, 2005; EQUINET, 2004). 
Furthermore, such approaches are unlikely to contribute to the attainment of long-
term objectives such as the Millennium Development Goals (Travis, et al., 2004).  
 
It is important to clarify, however, that the distinction between vertical and horizontal 
programmes is rarely dichotomous (Oliveira-Cruz, Kurowski, & Mills, 2003). The 
definition is rather based on a continuum that is highly contingent on factors such as 
“internal organization and structure of the health system, for instance levels of 
decentralization; health system capacity and dependence on donor support for 
funding of basic infrastructure; demographic and epidemiological profile; and 
international priorities and politics” (Oliveira-Cruz, et al., 2003). 
 
Much advocacy exists to ensure that ART distribution programmes are implemented 
in a way that strengthens health systems (EQUINET, 2004). This implies not only 
ensuring a steady supply of antiretroviral drugs but also training of staff, 
strengthening of laboratory capacities, and ensuring psychosocial and adherence 
support for patients (Buvé, et al., 2003). As one WHO Knowledge Management 
Advisor put it, “we must rebuild health systems as we confront the epidemic” 
(Bailey, 2004).  
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There is an overall dearth of academic literature on approaches to strengthening 
health systems (Travis, et al., 2004). Limited research on this subject, as well as the 
recent implementation of many ART scale-up initiatives, means that the impacts of 
the programmes are yet to be determined (El-Sadr & Abrams, 2007; Wyss & Wiess, 
2005). “The roll-out of HAART in Africa represents a gigantic experiment as many 
of the important determinants for its possible success or failure are unknown; these 
need to be explored through research at the same time the roll-out is occurring” 
(Jaffar, et al., 2005). One major concern is the sustainability of ART programmes 
once international funding - including that of such massive donors as PEPFAR and 
the Global Fund to Fight AIDS, TB and malaria - ceases (Wyss & Wiess, 2005). 
There have been increasing calls from the international HIV/AIDS community (most 
recently at the XVII International AIDS Conference in Mexico City) for more 
operations research – defined as “applied research focused on specific problems to 
give specific operational answers” – to assess the implementation of ART scale-up 
with an objective of improving it through the use of available resources (De Cock, 
2008). Inherent to this type of research is the need to assess how ART services are 
presently being dispensed.  
 
 
ART and Human Resources for Health  
 
One facet of health systems that has been the focus of much research in recent years 
is human resources for health. The global importance of this issue was highlighted in 
2006 when it was chosen as the theme of the WHO annual report. Health providers 
play an essential part in the implementation of health interventions, particularly in 
limited resource settings (A. K. Rowe, et al., 2005). In a report jointly published by 
UNAIDS and PEPFAR (2007) it was acknowledged that the goal of “universal access 
to comprehensive prevention programmes, treatment, care and support” by 2010 
would not be attainable without strengthening health systems and significantly 
expanding the health workforce (UNAIDS & PEPFAR, 2007). ART scale-up is 
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highly dependent on “well-skilled and motivated personnel with clinical, nursing, 
counselling, laboratory and/or pharmaceutical skills” (Wyss, 2004).  
 
Despite the recognized importance of health human resources at the global level, 
health policies of LMIC often pay insufficient attention to this integral component of 
the health system (Dussault & Dubois, 2003; Wyss, 2004).  When it is taken into 
account it is usually incomplete and of limited scope (Dussault & Dubois, 2003). This 
oversight threatens the ability of the health sector to put international donor 
contributions to effective use. “Millions of dollars, for example, have been invested 
to ensure the availability of AIDS and tuberculosis drugs but hardly any funding has 
been committed to ensure that there is a sustainable workforce to administer these 
drugs” (O'Neil, 2008).  
 
The attainment of health goals in LMIC is further compromised by the current 
worldwide shortage of health professionals. The WHO estimates that the world is 
presently lacking over 4 million health workers. Nowhere is the situation as dire as in 
Sub-Saharan Africa (WHO, 2006d).  This region alone accounts for 24% of the 
global burden of disease but disposes of only 3% of the world’s health workforce, 
with most of these professionals concentrated in urban areas. 
 
Global Crisis in Human Resources for Health  
The current crisis in health human resources in many LMIC has been attributed to the 
expansion of the global job market, which has facilitated the move of health 
professionals from rural to urban areas and from impoverished to richer countries 
(WHO, 2006d). Movement toward developed countries has been further facilitated 
due to health professional shortages in those countries (Stilwell, et al., 2003).  
 
There exists a plethora of literature on the individual reasons for the migration of 
health workers (Eastwood, et al., 2005; Gilson & Erasmus, 2005). Salary is by far the 
most common reason invoked as motivation for migrating to a high-income country 
(Astor, et al., 2005; L. Nguyen, et al., 2008). Not only is salary considered 
insufficient, but its allocation often delayed and sporadic (Health Workforce 
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Challenges: Lessons from Country Experiences, 2004). However, many other factors 
are influential in the decision process, including dissatisfaction with the work 
environment. Muula and Maseko (2006) describe the lamentable working conditions 
of health centres in Malawi: overload of work, limited resources, lack of career 
advancement, non-stimulating work environment, lack of access to continuing 
education possibilities, and discriminatory recruitment practices. It is these conditions 
that lead to stress, burnout, depression and demotivation, ultimately pushing health 
professionals to leave their jobs and often to migrate abroad (Industrial Health 
Research Group and the South African Municipal Workers Union, 2005).  
 
The HIV epidemic further aggravates the crisis by increasing the demand for health 
services and by directly impacting health professionals, many of whom are infected 
with HIV themselves (UNAIDS & PEPFAR, 2007). In a qualitative study conducted 
in Cape Town, South Africa to assess the experiences of nurses dealing with an influx 
of HIV patients, low morale and frustration were rampant among the staff (Lehman & 
Zulu, 2005). Nurses also reported an expansion of their roles to deal with the 
multifaceted nature of HIV, unbearable workloads that negatively influenced quality 
of care, inadequate training to deal with HIV, and negative psychological impacts 
such as guilt, depression and fear of exposure.  
 
Addressing Human Resources for Health in Health Policies  
Reformed health sector management and leadership are crucial in addressing the 
current health professional crisis in LMIC (O'Neil, 2008). Not only must human 
resources be taken into account in health sector policies, it is equally important to 
consider the motivation of the health professionals themselves (Franco, Bennett, & 
Kanfer, 2002). Motivation of health workers, or lack thereof, can have a profound 
impact on the attainment of goals in the health sector, including quality of care. 
Health worker motivation can be affected by organizational factors, but also by 
greater sociocultural determinants (Franco, et al., 2002).  
 
A comprehensive plan to address low morale among health professionals (and, in 
turn, the threat of migration from the workforce) should involve a mix of financial 
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and non-financial incentives (Mathauer & Imhoff, 2006). A qualitative study carried 
out in Benin and Kenya among health professionals supported the theory that non-
financial incentives such as recognition, professional development and training 
opportunities, and ensuring a well-resourced and organized work environment can 
positively impact morale in the health workforce (Mathauer & Imhoff, 2006). 
“Clinical workers require management and administrative systems to work if they are 
to be effective” (McCoy, PcPake, & Mwapasa, 2008). ART programs have particular 
management needs in terms of drug procurement, laboratory capacity, and 
information (McCoy, et al., 2008).  
 
Proposed health sector reforms should include an analysis of the potential impacts of 
the reforms on the health workforce. Equally important is the communication of 
reforms to health professionals in a transparent manner so that the greater 
organization goals may be clearly understood (Franco, et al., 2002). Health sector 
reforms should also take into account the interdependence of different categories of 
health professionals (Dussault & Dubois, 2003). This requires a systemic perspective 
of health human resources (Dussault & Dubois, 2003) taking into account 
characteristics of the health system as well as greater contextual factors. A 
multisectoral response to human resources for health is crucial for the scale-up of 
ART (Wyss, 2004).  
 
 
SUMMARY 
 
Unprecedented amounts of international funds have been attributed in recent years to 
improve availability of ART for individuals living with HIV across Africa. To date, 
these programmes have not invested sufficiently in adherence support for patients on 
treatment, despite the fact that research has shown suboptimal adherence to be 
detrimental to both individual and public health outcomes.  
 
Patient adherence to treatment is influenced by multiple factors from the individual to 
the societal level.  While individual determinants of adherence have been relatively 
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well studied, there is a dearth of information on health system-related factors and 
adherence. Studies have shown that a good relationship between the patient and the 
provider can have a positive influence on patient adherence behaviour. This is likely 
to be a key area for targeting the improvement of adherence support provided to 
patients.  
 
With the expansion of treatment access, fragile health systems in LMIC are coping 
with an increase in HIV patients seeking ART. It is unclear how these health systems 
are responding to this scale-up of ART services. Health systems in most Sub-Saharan 
African countries are further constrained by a critical shortage of health professionals. 
As healthcare providers have been shown to be an integral component in health 
interventions, the implementation of adherence support services may thus be 
compromised. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER THREE: CONTEXT 
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General 
 
Burkina Faso is a small landlocked country bordered on the south by Côte d’Ivoire, 
Ghana, Togo, and Benin and to the north by Mali and Niger. The country’s Sahel 
climate implies that it is often plagued by devastating droughts (World Bank, 2003), 
though in 2007 heavy rains and flooding caused widespread damage and several lost 
lives (IRIN, 2007). Both types of severe climate conditions wreak havoc on Burkina’s 
agriculture-based economy and, in turn on food security among the population 
(World Bank, 2003). 
 
Burkina Faso (formerly known as Upper Volta) became an independent nation from 
the colonial rule of France in 1960. The country is divided into administrative regions 
of provinces, departments and villages (Ministère de la santé du Burkina Faso, 2000). 
It is among the poorest countries in the world, ranking 176 out of 177 countries on 
the human development index with a score of 0.370 (UNDP, 2008). The country’s 14 
million inhabitants live mainly in rural areas. The urban population represents only 
18% of the total, though this proportion is growing, consistent with the global trend 
of urbanization. Nearly 30% of the population scrapes by on less than a dollar US a 
day and over 70% survives on less than two dollars US per day.  
 
Quantitative indicators paint a bleak picture of the population health status in Burkina 
Faso. The overall life expectancy at birth is 52 years (UNICEF, 2008). The under-five 
mortality rate is 204 per 1000 live births and the infant mortality rate is 123 per 1000 
live births. Burkina is a high fertility country with a national average of 6.4 live births 
per woman pending survival of childbirth – no easy feat with an adjusted1 maternal 
mortality rate of 700 per 100 000 live births.  Only 25% of the adult population is 
literate and primary school net enrolment is 45% of school-age children.  
 
                                                
1 UNICEF, WHO and UNFPA evaluate the country reported maternal mortality ratio on a periodic basis and 
make adjustments to account for problems of underreporting and misclassification of maternal deaths and to 
develop estimates for countries with no data. The reported maternal mortality ratio for Burkina Faso from 
2000-2006 was 480 maternal deaths per 100 000 live births.  
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Despite a low human development index, it cannot be overlooked that Burkina Faso 
benefits from a relatively stable socio-political context as compared to other West 
African nations. The country’s current president, Blaise Compaoré, took power in 
October 1987 following a coup d’état. Since the 1990s, however, the country has 
engaged in a democratization process (World Bank, 2003). Blaise Compaoré was 
elected for a third presidential term in 2005 with an overwhelming 80% of the 
popular vote in an election that was deemed free and fair by most international 
observers (U.S. Department of State, 2008).  
 
The country is enriched by its cultural, linguistic and religious diversity (World Bank, 
2003). The predominant cultural group, found mainly in and around the capital city of 
Ouagadougou, is Mossi and comprises about half of the country’s population. Three 
major religions are practiced in Burkina Faso: Islam (52%), Christianity (21%) and 
Animism (26%) (Nougtara, et al., 2008).  
 
Recent social unrest in the country was sparked by the rising prices of food and oil, a 
phenomenon observed in several low-income countries around the world. Les 
manifestations contre la vie chère (Protests against the high cost of living) began in 
February 2008 in Bobo-Dioulasso, the country’s second largest city, and quickly 
spread to Ouagadougou (RFI, 2008). Intermittent protests and strikes were held over 
the following months to highlight what the protesters interpreted as government 
inaction over the rising cost of basic necessities.  
 
 
Health sector 
 
Health services in Burkina Faso remain largely under public control despite a 
growing number of private health centres (mainly in urban areas) and a continued 
reliance on traditional medicine (World Bank, 2003). The non-governmental sector 
also plays a non-negligible role in providing health and social services to the 
population. NGOs, other organizations (faith-based and secular) as well as twinning 
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initiatives (e.g. the French ESTHER project) work in parallel with the state and 
provide a range of health services, mainly targeted at vulnerable populations (World 
Bank, 2003). 
 
Care in the public sector is dispensed on a cost-recovery basis and these fees often act 
as a barrier to accessing healthcare for the poorer segments of the population 
(Nougtara, et al., 2008). Medication costs present a further economic burden on 
households. A 2003 household survey found that 75% of household health 
expenditures went toward purchasing medications (Ministère de la santé du Burkina 
Faso, 2005a).  
 
Public health services are organised into three levels (Ministère de la santé du 
Burkina Faso, 2005a). Primary care is dispensed at the district level through Centres 
de santé et promotion sociale (CSPS- Health and social promotion centres). At the 
second level, more advanced care is available at Centres médicales avancés (CMA – 
Medical centres with surgical ward). The tertiary level of care consists of referral 
hospitals at both the regional (9) and national (3) levels. These centres provide the 
most advanced care in the country and also serve as training and research centres.  
 
Like many African countries, Burkina Faso suffers from a deficit in human resources 
for health. The most recent WHO health workforce data from 2004 indicate that the 
country has 708 physicians (5/100 000 inhabitants), 6 557 nursing and midwifery 
personnel (50/100 000 inhabitants), and 343 pharmacists (3/100 000 inhabitants) 
(WHO, 2008a). Bodart et al. (2001) reported that 95% of health personnel and 
institutions are part of the public sector, but these numbers hide the stark inequalities 
in geographic distribution of the workforce. A 2003 World Bank report found that 
despite accounting for merely 10% of the country’s population, the major cities of 
Ouagadougou and Bobo-Dioulasso benefited from 54% of doctors, 33% of nurses, 
57% of midwives and 59% of pharmacists (World Bank, 2003).  
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The deficiencies in health manpower reflect a lack of planning and management of 
the health workforce (World Bank, 2003). The country’s training centres graduate 
insufficient numbers of health workers on a yearly basis. Furthermore, lack of 
continuing education opportunities and specialized training mean that personnel are 
often maladapted to the changing health contexts in which they are working. Health 
professionals who wish to further their education are usually obliged to leave the 
country to study elsewhere.  
 
Burkina Faso implemented a series of health sector reforms as of 1992 (Nougtara, et 
al., 2008). Health sector reforms were broadly grouped into four categories: 
decentralization, liberalization of health services, reform of the pharmaceutical sector, 
and hospital reform. A retrospective study was conducted looking at the impact of 
macroeconomic adjustment policies on health resources and the consequences of 
health policies initiated between 1983 and 2002 (Haddad, Nougtara, & Fournier, 
2006). The findings suggest that while both physical access to health services and the 
availability of generic drugs improved, financial barriers still greatly hindered 
utilization, particularly among the poor. Though reforms led to an increase in 
recruitment across all categories of health professional (except pharmacists), this 
augmentation benefited mainly urban areas and perpetuated urban-rural disparities. 
The study also found that public health services are plagued by poor quality rendering 
them unappealing to the population, a finding echoing Bodart et al. (2001). An in-
depth socio-anthropological analysis highlighted that the poorest of the poor were 
most penalized by the reforms and no effort had been made to integrate concepts of 
equity in the changes (Ridde, 2008).  
 
A study on factors contributing to Burkina Faso’s poorly performing health system 
concluded that reforms have been largely unsuccessful in inspiring confidence in 
public health services among the population, as attested by a continuous drop in 
service utilization over an extended period of time (Bodart, Servais, Mohamed, & 
Schmidt-Ehry, 2001). The authors made the following recommendations to redress 
the situation: 1) make human resources for health a priority; 2) adjust the health 
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expenditure budget such that more funds are directed toward rural areas; 3) 
strengthen decentralized administrative structures; and 4) redefine the role of the 
Ministry of Health (Bodart, et al., 2001).  
 
In 2000, the government adopted the Plan National de Développement Sanitaire 
2001-2010 (PNDS – National Health Development Plan 2001-2010) to address the 
poor performance and quality of Burkina Faso’s health sector (Ministère de la santé 
du Burkina Faso, 2000). The PNDS includes eight intermediary objectives: increase 
national health coverage, improve quality and utilization of health services, 
strengthen action against transmissible and non-transmissible diseases, reduce 
transmission of HIV, develop human resources for health, improve the efficacy of the 
health sector, increase financing of the health sector, and strengthen the institutional 
capacities of the Ministry of Health. The implementation of the PNDS is financed by 
the government, debt relief funds, external donors, and the country’s population 
through cost-recovery mechanisms (Ministère de la santé du Burkina Faso, 2005a).  
 
 
HIV and AIDS 
 
Like most countries in the African sub region, Burkina Faso has been affected by the 
HIV pandemic. Prevalence data from 2005 suggest that 2% of the adult population is 
living with HIV (WHO/UNAIDS, 2008). According to a 2001 UNDP report the 
driving factors of the epidemic in the country are poverty, migration, rapid population 
growth, urbanisation, sexual behaviour, and poor reproductive health.  
 
National Response to the HIV Epidemic 
Government recognition of the HIV epidemic and response to it has grown since the 
first cases were detected in the country in 1986 (SP/CNLS-IST, 2005). Since 1998 
the government of Burkina Faso has made clear its commitment to fighting the HIV 
epidemic (UNDP, 2001). The national response is coordinated at the highest level of 
government; that is by the Permanent Secretariat of the National Council for the 
Struggle against HIV/AIDS and STIs (SP/CNLS-IST – Secrétariat Permanent du 
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Conseil national de lutte contre le SIDA et les IST) under the Office of the President 
(UNDP, 2001).  
 
In 1998, a strategic planning committee was assembled which led to the development 
and adoption of the Strategic Framework of the Fight Against HIV/AIDS 2001-2005 
(Cadre stratégique de lutte contre le VIH/SIDA 2001-2005) (UNDP, 2001). The 
Framework called for a multisectoral response to the epidemic, including actors from 
the public sector, the private sector, the community sector and religious groups. A 
Round Table of donor organizations was held in June 2001 in order to discuss 
financing possibilities to implement the Strategic Framework (Presidence du 
Faso/CNLS-IST, 2008). This meeting led to a commitment of 90% of the resources 
necessary to implement the Strategic Framework which included four strategic axes: 
(1) strengthening of strategies to curb the transmission of HIV and STIs; (2) 
strengthening of epidemiological surveillance of the epidemic; (3) the improvement 
of the quality of care of persons infected and affected by HIV; and (4) the expansion 
of the response, the promotion of partnerships and multisectoral coordination.  
 
A second Strategic Framework was elaborated for 2006-2010 period and adopted in 
2005 (CNLS-IST/Secretariat Permanent, 2005). Another Round Table of donors led 
to almost complete financing of the 160.6 billion fCFA (approximately US$380 
million) plan. The framework is in line with the Strategic Framework for Poverty 
Reduction, the country’s 2001-2010 National Health Development Plan (see previous 
section), as well as the Millennium Development Goals and New Partnership for 
African Development (NEPAD) objectives. It contains the following strategic axes: 
(1) strengthening of prevention strategies and promotion of voluntary counselling and 
testing; (2) strengthening of access to care and comprehensive medical and 
community care for people living with HIV; (3) strengthening of the protection and 
support for people living with HIV and those affected by HIV/AIDS and other 
specific groups; (4) strengthening of partnership, coordination, and mobilisation of 
resources; and (5) strengthening of epidemiological surveillance of the epidemic, 
monitoring and evaluation and the promotion of research.  
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Antiretroviral Treatment in Burkina Faso 
ARVs first became available on a very limited basis in the early 1990s (V.-K. 
Nguyen, et al., 2003). These brand name drugs were sold at private pharmacies in 
Ouagadougou at an extremely high cost to the individual. The cost of ART not only 
acted as a barrier to access for the majority of HIV patients, but those who could 
afford to buy drugs often did so in an “irrational” manner; that is, buying them 
sporadically and/or taking them in inefficient doses.  
 
During the same period, some HIV positive individuals were able to access ARVs 
through drug donations (V.-K. Nguyen, et al., 2003). Drug donations occurred on an 
individual-to-individual basis, through the burkinabè diaspora, or through group-to-
group donations. These exchanges occurred mainly in the community sector and also 
did not guarantee a continuous supply of medications.  
 
In an effort to regulate the supply of ARVs in the country, in 1999 the government 
licensed ARVs and authorized the Centrale d’Achat des Médicaments Essentiels 
Génériques et des Consommables Médicaux (CAMEG) to import them (V.-K. 
Nguyen, et al., 2003). The CAMEG began in 1994 as a pilot project in response to the 
devaluation of the national currency, the franc CFA (fCFA), that was carried out as 
part of the country’s structural adjustment programme (CAMEG, 2008). As a country 
that relies primarily on imports to supply its pharmaceutical needs, the devaluation of 
the currency had a profound impact on the health sector. Prior to the CAMEG’s 
implementation, the country’s pharmaceutical portrait could be characterized as 
follows: inadequate supply of medications in the health sector, low accessibility to 
medications for the poor, and regulations limiting the adoption and integration of 
generic medications into the market.  
 
In December 1997, an evaluation commission composed of national and international 
experts deemed the pilot project a success (CAMEG, 2008). The commission 
recommended that the CAMEG be registered as a non-profit association with 
financial and judicial independence. The actual mandate of the CAMEG has three 
main objectives:  
  
32 
1. To provide both public and private health structures with generic 
medications, medical and laboratory materials, dental material and 
products, and other medical materials;  
2. To acquire pharmaceutical products under the best financial 
circumstances; 
3. To guarantee the availability of these products according to the quality 
norms in place.  
 
In order to obtain the best possible market prices, the CAMEG issues calls for tenders 
from pharmaceutical companies. The procurement process takes place in two phases: 
the pre-selection of suppliers and the consultation of suppliers. This procedure is 
continuous and distributors and brands often vary. A tangible outcome of this 
procedure is the frequent changing of packaging and appearance of the drugs that are 
distributed to patients, despite the fact that the chemical composition remains 
essentially the same.  
 
Since the CAMEG began importing ARVs in 1999, prices have dropped 
dramatically, largely as a result of international pressure on pharmaceutical 
companies to reduce prices and the increased availability of generic forms of the 
drugs (V.-K. Nguyen, et al., 2003). Accessibility to the drugs has increased 
considerably as a result. Between 2002 and 2005 the number of people receiving 
treatment improved significantly from 675 to 6 666 (SP/CNLS-IST, 2005). 
According to the most recent WHO/UNAIDS data, 13 000 people are currently 
receiving ARVs in Burkina Faso, representing approximately 39% of people living 
with HIV in need of treatment in the country (WHO/UNAIDS, 2008).   
 
Funding for the purchase of ARVs by the CAMEG is provided largely by 
international donors. Government financing of treatment actually reduced from 
64.3% in 2002 to 35 % in 2004 (SP/CNLS-IST, 2005). Financial support is provided 
by a variety of multilateral donors, including, but not limited to, the following: the 
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highly-indebted poor country (HIPC) initiative, Ensemble pour une solidarité 
thérapeutique hospitalière en réseau (ESTHER), the World Bank, and the GFATM.  
 
A three-country case study – including Burkina Faso- on the impacts of the GFATM 
on health systems was published in 2005 (Wyss & Wiess, 2005). The report found 
that financing from the Global Fund allowed for more collaboration of stakeholders at 
the national level, capacity strengthening of tertiary and referral health structures, and 
increased availability of ART, among other things. Funding, however, did not 
alleviate shortages in human resources for health. Due to the brief nature of the 
report, additional research is required to elaborate upon several findings.  
 
On August 28, 2007 the SP/CNLS-IST signed a second grant agreement with the 
GFATM under the sixth round of HIV/AIDS grants (The Global Fund to Fight AIDS, 
2008). The total amount requested was approximately US$71.4 million. The grant 
came into effect on October 1, 2007 and as of August 2008 about US$8.4 million had 
been disbursed. One of the main objectives of the grant is to “Improve accessibility 
and quality of therapeutic treatment and care, and the follow-up of PLWHAs, 
including co-infected people (TB/HIV)”, which includes ensuring the availability of 
ARVs (SP/CNLS-IST, 2006). The proposal estimates that the grant will “allow ARV 
care and treatment for 20 000 PLWHA by the end of 2010”.  
 
At the time the present study was carried out, patients were asked to pay a 
contribution of 5 000 fCFA (about US$10) per month for their ARV treatment, an 
amount fixed in 2005 (Wyss & Wiess, 2005). According to a brief case study 
conducted in 2005, at the time there was no clearly defined plan as to what the sums 
collected would eventually be used for (Wyss & Wiess, 2005). Exemptions for those 
determined to be indigent (see “Results” section) are common. The monthly 
contribution per person for ART has since dropped to 1 500 fCFA (about US$3) 
(Sanou, 2008).  
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Though treatment is highly subsidized, the contribution requirement has been highly 
contested by groups advocating for gratuity of ARVs (Association Actions 
traitements, 2004). In June 2008 a symposium was held in Ouagadougou on the 
lessons learned about access to ART in the country (Livre des résumés, 2008). 
Several papers were presented that discussed the financial barriers to accessing ART. 
A heated debate ensued among participants – researchers, government and NGO 
representatives – on the feasibility of ART gratuity in Burkina Faso (V.Ridde,  
personal communication, June 2008).
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Objective of the Study 
 
A significant amount of national and international resources have recently been 
invested in Burkina Faso (most notably through GFATM) to improve ART 
availability for HIV patients in the country. As mentioned in the “Literature Review”, 
the success of ART is dependent on more than just drugs and must be delivered 
within a comprehensive package of care. Adherence support services are a central 
component of this package. Little is known about the context of ART provision at the 
site of distribution in Burkina Faso and which support services are provided to 
patients.  
 
The government and its partners rely mainly on the public health system to dispense 
ART. The available literature has shown that health systems in sub-Saharan Africa 
are fragile and under-resourced. Burkina Faso is no exception. Studies demonstrate 
that the public health system performs poorly and inspires little confidence in its 
users. Health services are dispensed on a cost-recovery basis that hinders access for 
the country’s largely impoverished population.  
 
While the government has shown a strong commitment to addressing the HIV 
epidemic, it has not shown the same commitment in the past towards human 
resources in the health sector. Like many countries in sub-Saharan Africa, Burkina 
Faso suffers from a critical shortage of health manpower due in part to poor planning 
at the national level. Given that the dispensation of HIV-related services, including 
adherence support, is heavily dependent on healthcare providers, it is unclear how 
scale-up of ART has affected service provision at the level of the ward.  
 
The objective of the present ethnographic study was to explore the perspectives of 
healthcare providers on the issue of adherence support at two hospital sites (three 
wards) in a context where ART availability is being scaled-up.  
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This objective lead to the formulation of the following research question: What are 
the experiences of healthcare providers in addressing patient adherence to ART in a 
context of treatment scale-up?  
 
 
CONCEPTUAL FRAMEWORK 
 
Ethnographic research implies the firsthand exploration of a particular setting by the 
researcher (Atkinson, Coffey, Delamont, Lofland, & Lofland, 2001). It is an 
inductive process that seeks an in-depth understanding of an issue through the use of 
various methods (see “Methods” section). In recognition of this, the conceptual 
framework adopted was large in scope and acted largely as a guideline rather than a 
structured approach to allow for considerable flexibility in both the data collection 
and analysis phases.   
 
Hospital Ethnography 
The hospital as an object of ethnographic study has been discussed in academic 
journals (Long, Hunter, & van der Geest, 2008; van der Geest & Finkler, 2004). 
Interest in hospital ethnography developed in the post-colonial period of the 20th 
century, when anthropologists began to turn a reflexive gaze toward their own 
societies (Long, et al., 2008).  
 
There are two opposing perspectives in the field as to how the hospital should be 
perceived in relation to greater society. According to one paradigm, the hospital is 
viewed as a world apart from the prevailing context, an island in itself (van der Geest 
& Finkler, 2004). An alternate viewpoint suggests that life within the hospital is as an 
extension of life outside the institution.  
 
“The authors contend that life in the hospital should not be regarded in 
contrast with life outside the hospital, the ‘‘real’’ world, but that it is shaped 
by everyday society. The hospital is not an island but an important part, if not 
the ‘capital’, of the ‘mainland’.”(van der Geest & Finkler 2004) 
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The second approach was maintained in the present ethnography. The hospital is 
recognized as a setting where a panoply of factors inherent to a range of different 
levels – individual, hospital, health system, societal, and international – influences the 
behaviour of healthcare providers and patients on the ward.  
 
This conceptual framework guided the data collection and the resulting analyses by 
compelling the ethnographer to interpret interviews, observed events, and document 
sources from a reflexive perspective that recognized individual behaviour as infallibly 
linked to the prevailing context in which it occurred. The results thus take into 
account the broader context and attempt to explain how the interplay of determinants 
both within and outside the hospital compound penetrate the ward and influence the 
provision of adherence services for patients on ART. 
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Study Design  
 
The present project is an ethnographic study looking at the experiences of health 
providers in addressing adherence to ART in a context of limited resources where 
ART is being scaled-up. Savage (2000) has argued for greater inclusion of 
ethnography in health research. Ethnography is a highly contextualized and reflexive 
approach that seeks to understand phenomena in a natural setting from the 
perspectives of both the researcher and the researched (see “Conceptual framework”). 
This method can be particularly useful in health research in studying the organisation 
of health services. It has been further argued that qualitative methods are currently 
underused in the study of adherence and can be particularly useful in providing in-
depth information about adherence such as access and reasons for non-adherence 
(Sankar, Golin, Simoni, Luborsky, & Pearson, 2006).  
 
 
Context of the study and the ethnographer’s position 
 
The choice of setting for this study – two hospitals in Ouagadougou, Burkina Faso - 
was motivated in part by ease of access, and in part by familiarity.  
 
The initial objective of the study was to look at human resources in the field of 
HIV/AIDS, with a particular emphasis on the role they play with respect to patient 
adherence to ART. As my fieldwork progressed, however, it became apparent that to 
understand adherence in this context, it was necessary to look beyond individual 
patient and provider interactions and study the influence of more systemic 
determinants of adherence support such as availability of resources (including drugs), 
socioeconomic and other external pressures (such as research projects). 
 
I joined the Appui aux Traitements Anti-rétroviraux en Afrique de l’Ouest 
(Supporting Antiretroviral Treatment in West Africa – ATARAO) research group in 
November 2006. The group is a partnership between researchers in Canada, Burkina 
Faso, and Mali. Over the ten-month period prior to my departure for Burkina Faso, I 
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participated regularly in group meetings and email correspondence of the Montréal 
team. In this way, I followed the progress of the project from the planning to the 
implementation phase.  
 
The ATARAO cohort study was officially implemented in January 2007 in both 
Burkina Faso and Mali. The main goal of the project was to prospectively follow 400 
HIV patients newly prescribed ART in each country. A subsidiary objective was to 
build research capacity among the African team members and junior Canadian 
researchers, including students like myself. While the funding for the project is 
provided entirely by a Canadian donor (Canadian Institutes of Health Research), 
teams of local researchers were established in both study countries. The study was 
preceded by a pilot study which took place in 2005 in partnership with the same local 
principal investigators. A longstanding relationship thus exists between the Canadian 
and the African partners.  
 
The ATARAO study distinguishes itself from many North-South collaborations by 
the fact that there are no Canadian team members stationed permanently in the field 
and African partners work for national research centres (Costello & Zumla, 2000). 
Each country team is responsible for the management and implementation of the 
project at the country level while the Montreal team coordinates the overall project 
and the bulk of scientific production. The Montreal team periodically carries out 
training and monitoring missions. Two public health doctoral students studying at the 
Université de Montréal each spent five months in the field assisting with project 
implementation. In theory, the present study could have been carried out anywhere in 
Africa where ART is being scaled-up. However, the established relationship and the 
presence of the ATARAO country team meant that access to the field was greatly 
facilitated by the African partners.  
 
I chose to conduct my fieldwork with the ATARAO project in Burkina Faso instead 
of Mali as I had previously visited the country for a brief period in 2006 while I was 
living in the neighbouring country of Ghana. As time and financial constraints 
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permitted only for a relatively short fieldwork period of three months, I considered it 
prudent to go to a city that I was already somewhat familiar with. This proved to be a 
wise decision as my familiarity with Ouagadougou quickly afforded me the 
independence necessary to move between study sites with ease.  
 
Prior to my arrival in Burkina Faso, it was made explicitly clear to both me and to the 
local team by the Canadian principal investigator of the study that my role in the 
project would be that of a student researcher. This implied being exempted from all 
coordination and administrative duties related to project implementation. This 
decision, taken with good intentions, proved to be largely unrealistic due to the 
unpredictable factors at play on the field (described below).  
 
The ATARAO project in Burkina Faso was implemented at three participating study 
sites: two wards at a major public referral hospital and one ward in a small, non-profit 
medical centre. A fourth site in the community sector desisted from the project at an 
early stage of project implementation due to conflicting interests.  
 
Site One is classified as a centre medical (medical centre), which means that there are 
no surgeries conducted (aside from caesarean section deliveries) and no 
hospitalisations (aside from paediatric and deliveries). Founded in the 1960s by 
Italians of a Catholic religious order, it is now run by an Italian paediatrician (Vice-
Province Camillienne du Burkina Faso, 2007). The centre specialises in maternal and 
infant care and services mainly people of lower socioeconomic status. ART has been 
available for adults since 2003 and for children since 2004. Site One receives 
technical support in HIV care from hospitals and a university in Italy through the 
ESTHER project.  
 
Site Two is a referral and teaching hospital. There were two participating study wards 
at this hospital: Ward A and Ward B. Both wards receive a significant number of HIV 
patients and are involved in the prescription of ART. Since 2002 the hospital has 
benefited from the technical support of the French-led ESTHER project. The initial 
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goal of the ESTHER collaboration was to support the development of a specialized 
HIV centre and, eventually, the implementation of a day hospital.  
 
At each site there was one ATARAO interviewer, aside from Ward B at Site Two 
where there were two (a second interviewer was transferred there after the desistance 
of the fourth site to help address the large influx of patients). The interviewers, along 
with a designated physician in the ward, were responsible for recruiting patients for 
the study and conducting interviews at three-month intervals over a one-year period. 
As will be discussed later on, the interviewers were quickly integrated into life on the 
ward and were often asked to carry out tasks other than those for which they were 
explicitly hired. Two project coordinators were responsible for overseeing activities 
on the study sites and responding to any issues raised by the interviewers. The 
coordinators were also responsible for managing logistical and financial issues and 
reporting back to the burkinabè principal investigator who is himself a senior 
physician at Site Two.  
 
Shortly after my arrival in the field, it became apparent that the designated 
coordinators were much too occupied with their full-time positions2 to adequately 
support the work of the interviewers. As I was present on the study sites on a daily 
basis, particularly at Site Two, I naturally became the relay person between the 
interviewers and the coordinators. This turn of events accorded me the added 
advantages of establishing credibility among hospital staff and providing me with 
duties other than those related to my personal research – in some ways affording me 
with a point of entry to conduct a certain degree of “negotiated interactive 
observation” (Wind, 2008).  
 
Van der Geest and Finkler have addressed the complicated nature of the role of the 
ethnographer in hospital ethnography (van der Geest & Finkler, 2004). The nature of 
work in a hospital setting often confines the ethnographer to one of two roles: health 
                                                
2 One coordinator held a full-time position in government as part of a team overseeing the activities of a 
major international HIV funding initiative. The other coordinator was a full-time nurse at one of the study 
sites.  
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professional or patient. Studies investigating the perspective of the health 
professional most often involve the ethnographer adopting the role of health provider. 
While not a trained healthcare worker, my ad-hoc role as middle-woman between the 
interviewers and the coordinators provided me with the legitimacy to spend several 
months on the project sites interviewing professionals and interacting with patients. 
On a more personal level, the small contribution I made toward the overall project 
functioning assuaged my guilt of carrying out research in an environment where no 
able hands remain idle.   
 
 
Ethical Considerations 
 
Ethics board approval for the ATARAO project was obtained from le Comité 
d'évaluation scientifique et de l’éthique de la recherche Équipe Hôpital Notre-Dame 
du CHUM (ND 07.013) and the Centre Hospitalier National in Burkina Faso.  
Ethical approval for the present study was also obtained from Comité d’éthique de la 
recherche de la Faculté de medicine of the Université de Montréal (CERFM 85(07) 
#257). There were no expected negative consequences for study participants. 
Particular attention was paid to render the identities of the participants anonymous in 
the present document.  
 
 
Participants and Recruitment 
 
The strategy used in the selection of participants was based on the premise that in 
order to understand the phenomenon under study a diverse array of perspectives 
needed to be collected (Giacomini, Cook, & for the Evidence-Based Medicine 
Working Group, 2000). Interview participants were selected using a judgement 
approach. The judgement sample implies recruiting those individuals who will most 
efficiently contribute to answering the research questions (Marshall 1996). This 
selection may be based on practical knowledge of the context, available literature and 
information gained through the study itself (Marshall 1996).  
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Participants of the study were HIV/AIDS healthcare providers working at one of the 
two study sites. With the help of one of the ATARAO project coordinators and senior 
physicians on the wards, health providers who were known to play an active role in 
the care of HIV patients were approached by the researcher to take part in the study. 
The selection process aimed to ensure that the perspective of each type of provider 
implicated in HIV care was represented. Often the participants themselves suggested 
individuals who they felt could offer an informed opinion on the subject matter – 
which contributed to a snowballing effect. There was one instance where a potential 
participant was approached and later declined an interview; one doctor in Ward B 
was approached and consented verbally to an interview but was transferred to a 
hospital in a rural region before an interview date was scheduled. The final sample of 
interview participants included physicians (7), nurses/midwives (5), pharmacists (2), 
lay counsellors (2), research interviewers (4), and one NGO representative. Two 
participants were approached for second interviews. Thus, a total of 23 formal 
interviews were conducted (see Appendix 1 for a breakdown of participants by site).  
 
 
Instruments & Sources of Data  
 
Semi-structured interviews  
A semi-structured questionnaire with open-ended questions was used during the 
interviews (Appendix 2). The design can be characterized as a focused interview 
since it allowed the interviewer to broach a series of predetermined themes while 
leaving participants considerable freedom in terms of responses (Boutin, 2000). A 
process of respondent validation was undertaken; after each interview, information 
that was unclear or needed to be further expanded upon was compiled in a list to be 
discussed in subsequent interviews (Pope & Mays, 2000).  This technique was used 
as a method to improve the quality and rigor of the study. Two participants who were 
particularly informative were each interviewed a second time – a nurse and a lay 
counsellor.  
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Observation 
Observation was also undertaken in the three study settings. Observation is a valuable 
complement to semi-structured interviews (Grawitz, 2001). It is often used in 
qualitative research as a method of confirming data collected by other means - 
referred to as methodological triangulation (Pope & Mays, 2000). The necessity of 
adding an observation component to qualitative studies is aptly highlighted by the 
following quote: “Questioning the validity of checklists and the prevailing 
methodological orthodoxy in qualitative research is useful, but of greater relevance is 
the need to promote (and teach) a more observational paradigm for qualitative health 
research” (Power, 2001).   
 
I observed activities in the wards, often engaging in informal conversations with 
those present (staff, patients, family members, other visitors). Observations were 
recorded in a logbook. This allowed me to gain a better understanding of the logistics 
of the ART distribution programme (i.e. layout of the setting, patient pathway, 
ambiance, etc.). Questions arising from observations were recorded and addressed to 
participants during formal interviews. Likewise, information provided during 
interviews was often confirmed through observation. These two methods were thus 
highly complimentary.   
 
As mentioned previously, my presence on the study sites was legitimized by the role I 
played in the ATARAO research project. The tasks I carried out aimed to ease the 
workload and improve the work situation of those involved in the project: transferring 
materials and information between the sites, transporting blood samples to the 
laboratory, conducting quality control of the data, directing patients, and providing 
psychosocial support to the interviewers. These activities – which often had me 
running around the hospital – helped me to integrate the daily life of the sites, 
particularly at Site Two where I spent most of my time3. This shift in my role 
occurred naturally, though perceptively, and also marked the transition from non-
                                                
3 This was due to several factors, namely:  there were two participating wards at Site Two, a higher 
patient volume, and a greater number of staff to interview.  
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participant observation to “negotiated interactive observation” (Wind, 2008). “The 
concept of negotiated interactive observation captures what happens when you are 
doing fieldwork without at the same time assuming that you become one of ‘them’”. 
Wind (2008) introduced this concept, arguing that it is an alternative to the more 
contentious concept of participant observation. Participant observation implies that 
the observer participates, that he integrates himself into the group; “that he is almost 
forgotten as an observer, but remains present as an individual” (Grawitz 2001). 
Participant observation is the Achilles’ heel of hospital ethnography as playing the 
role of patient or healthcare provider is often impossible or ethically questionable 
(van der Geest & Finkler, 2004). While my integration was clearly limited by several 
barriers (language, ethnicity, and short time-frame), these minimal tasks, consistent 
with the concept negotiated interactive observation, greatly enriched my 
understanding of the context.  
 
 Document review  
Written documents were used to corroborate and elaborate on ideas raised in 
interviews and observation periods, acting as a third complimentary method. Aside 
from traditional academic sources (PubMed, Medline, etc.), media sources, 
government documents and donor reports were consulted to add depth and context to 
the findings. A variety of local sources of documentation was collected through 
contact persons on the field and internet searches. Examples of documentation used 
include: national guidelines for the care of HIV patients, prototypes of patient files 
and monitoring cards, grant proposals, national strategic plans on HIV/AIDS, and 
conference proceedings. These sources mainly served to contextualize data obtained 
through interviews and observation, adding historical, political and sociocultural 
depth to the study.  
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Data Collection Procedure 
 
Interviews and observation were performed over a three-month period, from 
September to December 2007. Each participant was asked to give his/her informed 
consent prior to participating in the study (Appendix 3). Interviews were conducted 
by the ethnographer and took place at the work-site during regular work hours. All 
interviews were carried out in French, the official language of Burkina Faso and one 
spoken fluently by the participants and myself. As all health care providers in the 
three settings are fluent in French, no potential participants were excluded due to 
language barriers. Interviews lasted between 20 minutes and an hour and a half. An 
audio-recording device was used with the participant’s permission to allow the interviewer 
to interact more fluidly with the provider.  Interview data was transcribed by the 
researcher for use in the analyses. Citations used in the present document were 
translated free-hand by the ethnographer. Actual participant names were omitted to 
preserve confidentiality.  
 
A logbook was used to record observational data and the ethnographer’s reflections 
on the research process. Each logbook entry includes date and location.  
 
 
Data Analysis 
 
Once all interview data had been transcribed, a narrative analysis was conducted for 
each of the settings studied: Site One, Ward A, Ward B, the Day Hospital, and the 
Pharmacy. Four main reasons for conducting a narrative analysis in ethnographic 
research have been described: “concern with the meaning of experience, voice, 
human qualities on personal or professional dimensions, and research as a story” 
(Cortazzi, 2001). The narratives were based on typical situations that I had observed 
on the wards and were supported by interview data, informal conversations, and 
document review. Each narrative was designed to illustrate a set of themes that were 
particular to the setting and recurrent throughout the interviews conducted at the 
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respective sites. The five narratives range between approximately 1 800 words to 
4 500 words.  
 
Once the five narratives were complete, they were first analyzed separately to extract 
recurring themes at each site. The themes were then compared and contrasted across 
sites. The final analysis, elaborated upon in the following “Results” section is the 
synthesis of themes common to all sites (e.g. ARV lifecycle) and particular to each 
setting (e.g. adherence infrastructure).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER SIX: RESULTS  
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OVERVIEW  
 
The present Results section is a product of the analysis of the provider’s perspective 
on the provision of adherence support for patients on ART. While a more complete 
discussion of the study question would include the patient’s perspective, this was 
beyond the scope of the present ethnography.  
 
Several determinants emerged from the study that affect the provision of ART 
support by providers. The main factors that emerged were not individual such as 
provider behaviour, but rather determinants of more macro systems; ranging from the 
ward, to the health system, to the socioeconomic context, and finally to the 
international level. These I have termed “systemic adherence inhibitors” to reflect 
how they have the potential to impede the adherence support provided by the health 
professional to the patient and, ultimately, the adherence behaviour of the patient 
himself.  
 
Systemic adherence inhibitors have been grouped into three categories that are each 
elaborated upon in the sections to follow: ART supports, daily life, the ARV 
lifecycle, and external pressures. The results section will conclude with a discussion 
on the evolving context of HIV care in Burkina Faso.  
 
The results section is schematized in the following diagram where concentric circles 
depict the increasingly macro systems that impact the provider’s provision of 
adherence support to patients on ART.  
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Figure 1. Schematic representation of results 
 
Prior to delving into the above-mentioned themes, it seems à propos here to provide a 
brief description of the context of HIV care at each of the three sites.  
 
 
Context of Care 
 
This section will discuss the contexts of care at each of the three sites. Although each 
ward specializes in HIV care, they differ in terms of patient characteristics, entry 
point for care, the patient pathway of care, and human resources, among other things. 
The following descriptions seek to provide the reader with the necessary background 
information that will assist in the contextualization of subsequent results.  
 
Site One 
Prevention of mother-to-child transmission (PMTCT) is the main door of entry for 
HIV care at Site One. About 600 PMTCT-referred patients are followed here, three-
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quarters of whom are already receiving ART. Women are referred to the adult ward 
after testing positive for HIV at the VCT centre of the Santé maternelle et infantile 
(SMI - Mother and Infant Health Unit). One doctor described the care provided at 
Site One as follows, “it’s actually like a continuity” (Doctor, Site One), referring to 
how women who receive prenatal care at the centre often continue consulting for 
other services for themselves and their children.  
 
VCT services began at the SMI in May 2002 (Vice-Province Camillienne du Burkina 
Faso, 2007). During the morning prenatal consultations, two midwives educate 
pregnant women about HIV and the importance of getting tested. Those who wish to 
be tested then go to the VCT office (located just down the hall from the SMI waiting 
room) where they undergo an HIV test free of charge, administered by one of two 
midwives.  
 
“Now those who wish come do their test. The test is free…and voluntary. We 
don’t force them.” (Midwife, Site One)  
 
The midwife concedes, however, that not enough women come forward voluntarily to 
be tested. Indeed, a study conducted at Site One between May 2002 and April 2004 
found that less that one fifth of pregnant women at the SMI accepted VCT after group 
counselling (Pignatelli, et al., 2006).  
 
“Not many. For now there are not many who adhere to it. Not as many as we 
would like.” (Midwife, Site One) 
 
If the HIV test is negative, the woman is asked to return in three months for her 
regular prenatal follow-up. If it is positive, she is sent to undergo laboratory tests 
(CD4 count, haematology, etc.) - which are also provided free of charge to pregnant 
women - and is referred to the adult HIV care ward. The woman will continue 
consulting the midwives for pregnancy-related issues, but will receive HIV care, 
including ART, from a doctor in the HIV ward.  
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If the woman’s CD4 count indicates that she does not yet require ART she is seen 
every three months by one of the doctors in the HIV ward for monitoring. At the 27th 
week of pregnancy, a midwife at the SMI gives her Zidovudine tablets. The pills are 
to be taken twice daily. Three additional pills are given in a separate pouch, to be 
taken at the onset of labour. The midwives insist upon the importance of adherence to 
the medication in order to protect infants from HIV. At each subsequent prenatal visit 
the midwife counts the number of remaining pills in the box to ensure the woman is 
taking her Zidovudine tablets correctly. If adherence problems are detected, a 
discussion between the woman, the doctor and the midwife ensues to determine how 
the situation can be remedied.   
 
Three physicians share the consulting responsibilities of PTMCT-referred patients in 
the adult ward: a senior Italian doctor who is in charge of the ward, a young female 
burkinabè doctor who has been working there for less than a year, and a young 
female Italian intern. There are no nurses in this ward so it is the midwives – two of 
them – who assist the doctors during consultations. It is an arrangement born of 
necessity; the Italian doctors depend on translators to communicate with their mainly 
Mooré-speaking patients. Over time it has become the norm of care and the midwives 
assist the local doctor as well, though only for the PMTCT-referred patients.  
 
“Otherwise, we help. We consent, we take the pressure, we look at the 
conjunctiva. Otherwise, the medical visit, it’s the doctor who examines the 
patient. But we’re there. If there is the pressure to be taken, we take it. The 
weight we take. We look at the conjunctiva…The medication as well, we can 
explain to the woman how to take them. Give the medications. But only in the 
presence of the doctor.” (Midwife, Site One) 
 
There is another local male doctor in the ward who sees adult HIV patients who are 
not referred by the PMTCT, of which there are approximately 220. These patients are 
referred mainly from the general adult consultation ward. This doctor sees patients 
alone; that is, without the help of the midwives. Nonetheless, he works in “close 
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collaboration” with the senior doctor on the ward and consults him regularly with 
respect to difficulties and other issues that arise in patient care.  
An ATARAO interviewer is present on the site to conduct interviews and 
occasionally assists the doctors with the psychosocial counselling of patients. 
 
Site Two: Ward A 
Since 2003, HIV care at the hospital has been regular in the internal medicine ward. 
Until recently, all HIV patients who arrived at the hospital were referred there. They 
have the largest patient roster at the hospital, totalling over 2 000 patients (1 500 on 
treatment), and the most experience in HIV care. Most patients are referred here, 
either from the NGO sector, smaller health centres, or the hospital emergency ward.  
 
Ward A was created in 2005 as a subdivision of internal medicine specifically for 
HIV/AIDS patients. It is located on the third floor of the main building of the 
hospital, across from the general internal medicine ward. Ward A caters to both 
inpatients and outpatients with HIV. In November 2007, all outpatient services were 
transferred to a brand-new Day Hospital, a separate building in the inner courtyard of 
the hospital grounds. In-patient services remained on the third floor.   
 
The core staff on the ward consists of the following: six doctors, three nurses (two of 
whom are specialized in adherence counselling and ART prescription renewals), four 
mediators (lay counsellors), three part-time psychosocial counsellors, and five 
orderlies. One ATARAO interviewer is also present for the duration of the research 
project.  
 
Prescription renewal was added to the duties of nurses trained in the Diplôme Inter-
Universitaire (Inter-University Diploma - DIU) in 2006 to help manage the large 
influx of patients arriving for treatment. The DIU was initiated in 2004 with the 
assistance of various national and international partners (WHO, ESTHER, Sidaction, 
the Société française de lutte contre le Sida and the CFAO) and presided over by the 
Chief of Internal Medicine of Site Two (Sidwaya, May 17, 2004). The programme 
aims to contribute to an improvement in medical care for people living with HIV in 
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francophone Sub Saharan Africa. The month-long course is attended by 
professionals, community workers, and people living with HIV across francophone 
Sub-Saharan Africa.  
 
When the nurses are busy, the psychosocial counsellors sometimes renew 
prescriptions, though they are not authorized to do so unless a nurse is present. The 
psychosocial counsellors were recruited from the NGO sector specifically for another 
research project taking place on the ward. They are considered “patient experts” as 
they themselves are HIV positive and have experienced many of the situations 
encountered by the patients. Until the end of 2007 they were responsible for only the 
80 or so patients taking part in the research project. As the project was coming to an 
end and the participants were to be integrated into the regular patient roster, the 
psychosocial counsellors were asked to assist in the adherence counselling of all the 
ward’s HIV patients.  
 
The four women mediators are lay counsellors hired under the French-funded 
ESTHER project. One senior doctor described them as follows: “they are the bridge 
between the patients and the doctors”. Their duties on the ward include booking 
appointments and taking out patient files, arranging for the meals of the hospitalized 
patients, psychosocial counselling of patients and their caregivers, adherence 
counselling, and occasional home visits. They are the first point of contact for 
patients on the ward. The mediators also play a central role in tracking patients who 
are lost to follow-up. I was told by several people that the ESTHER project will be 
coming to an end in the coming years and no one seemed quite too certain whether or 
not the mediators would remain on the ward thereafter. 
 
Site Two: Ward B 
Care of HIV patients is somewhat new in Ward B. As mentioned above, all HIV 
patients were previously transferred to Ward A. In 2004, according to the head nurse, 
the ward was officially recognized as an HIV care centre. At the time, most HIV 
patients treated here presented with dermatological problems and later tested 
seropositive.  
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The core of the ward’s staff consisted of the following: the Chief of Ward B (present 
only on Wednesdays), a senior doctor in charge of HIV patients and the ATARAO 
research project, a specialist doctor, five nurses, four medical interns, four orderlies, 
and a secretary. Two ATARAO interviewers, both women, were also present on the 
ward on a daily basis. A third doctor who cared for HIV patients on Friday afternoons 
accepted a position at a hospital in a rural region shortly after my arrival on the ward, 
as mentioned in the “Methods” section.  
 
At the time the fieldwork for this study was conducted, none of the nurses and only 
one of the doctors had participated in the DIU programme on HIV care. All providers 
involved in patient care had, however, received some form of in-house training in the 
care of HIV patients.  
 
There are two types of HIV patients cared for in Ward B: those with dermatological 
problems and those referred by HIV care NGOs, whether or not they have 
dermatological problems. The number of patients in the second category increased 
dramatically in the initial months of my fieldwork and tapered off by the end for 
reasons that will be discussed shortly.  
 
 
Adherence infrastructure 
 
Patient adherence to ART was a central preoccupation of all health providers 
interviewed. My initial interview guide was composed of two sections: questions 
relating to the general care of HIV patients and questions relating specifically to how 
ART adherence among HIV patients is addressed. I quickly realised, however, that 
the two were so closely entwined that trying to separate them was unfeasible.  
 
Each of the three sites had implemented, to varying degrees, procedures to monitor 
patient adherence to treatment – an “adherence infrastructure” as I have dubbed it. 
Site One provides an example of a tight-knit circuit where patient care is both 
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familiar and easily monitored. Ward A, on the other hand, disposes of a fairly 
elaborate adherence infrastructure integrating various tools and types of providers for 
monitoring patient adherence. Ward B disposes of a limited adherence infrastructure 
and struggles to track its recent influx of patients.  
 
This section will provide an in-depth discussion of the adherence infrastructure at the 
three sites. It aims to illustrate that how the differences in the contexts of HIV care 
led to variations in the organizational structure of adherence services implemented on 
each ward. Despite these variations, each ward had invested in some form of 
adherence infrastructure.  
 
Site One 
Site One provides a continuum of care to patients and their families. For instance, if a 
patient is followed here for HIV, she usually also receives free formula milk for her 
baby from the neonatology ward. When the patient picks up her supply of formula 
milk, the nurse will ask her when the last time she saw her doctor was and when her 
next appointment is scheduled for. Nurses and midwives from neonatology also 
conduct home visits as a means of patient follow-up. If a patient misses several 
appointments, it is usually relatively easy to track her. 
 
“But also, as the centre is large: we have the weigh-in for the pregnant 
women in Mother and Infant Health, we have the neonatology ward, where 
the milk is given. So, we always manage to track our patients”. (Doctor, Site 
One) 
  
Each patient is given a blue carte de suivi (monitoring card) once she is referred to 
the adult HIV ward and is added to the patient roster. The cards are an initiative of the 
Ministry of Health. They are used in a slightly different manner at Site One as 
compared to Ward A and not at all in Ward B. One side of the card indicates patient 
information such as file number, name, sex and year of birth. The other side displays 
a table of months across the top and years down the side. Each cell is subdivided into 
two: one section indicates the date of the appointment and the second the date that the 
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patient actually came. The card is used at Site One to monitor patient adherence to 
medical appointments. The first month that a patient begins treatment, she is seen 
every two weeks. From months two until six she comes once a month, and thereafter 
every two months. Each time she goes directly to the doctor, without passing through 
an intermediary.  
 
Patients are informed early on in the process of HIV care about treatment.  
 
“Every six months you will monitor your CD4s, until the time when you start 
treatment. He knows for now he won’t start, but he knows that one day he may 
start…The person is already prepared psychologically” (Midwife, Site One).   
 
Patients meet with the doctor a minimum of three times before ART is prescribed. 
The first time, the physician performs a clinical exam and assesses the patient’s WHO 
clinical stage of HIV. At this point the doctor also prescribes laboratory tests for the 
patient to complete, including CD4 count. When the patient returns with her results, 
the doctor can then assess whether or not she is ready to begin treatment.  
  
“It’s the CD4 count that will determine whether you put the patient on ARVs 
or whether you don’t put him on ARVs. Even if the person is stage 1 or 2 
(WHO) but his CD4s are under 200, we recommend that the person be put on 
ARVs. And the patients who are stage 3 and 4, no matter what the CD4 count 
is, we automatically put them on ARVs.” (Doctor, Site One) 
 
Before prescribing ART, however, the doctor first prescribes cotrimoxazole (an 
antibacterial drug used to prevent and treat opportunistic infections) for a period of 
two weeks. Following this trial stage, the patient returns and together they determine 
whether she is ready to begin treatment; that is, whether she will be adherent.  
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Pill counting and questions about pill-taking behaviour are the main strategies used to 
monitor patient adherence to ART. The process is transparent and shared between the 
patient, the doctor and the midwife.  
 
“Because there are some who will initially say, ‘no, I’ve never forgotten’. But 
when we base ourselves on pill counting we realise that there were some 
misses.” (Midwife, Site One)  
 
If problems are detected they try and find a solution together. Similarly, if the 
ATARAO interviewer detects adherence problems during one of her interviews she 
advises the doctor.  
 
“If there is a problem like that, of adherence, that is serious enough, even if it 
is not serious, if there is a problem that I detect during my interview, from 
what he is saying, then I signal it.” (Interviewer, Site One) 
 
One doctor says patients display few adherence problems in the beginning. Problems 
arise once the patient has been on treatment for some time, a phenomenon also 
observed by the other local doctor who treats HIV positive adults not seen in the 
PMTCT circuit.  
 
“From six months onwards. Six months, one year. Because the first six 
months, even the first year, generally the patients are adherent. Because of the 
benefits of the treatment, life has changed. They try to be maximally adherent. 
But after a year they are a little tired of always taking the products. They have 
already forgotten what they have lived before as well”. (Doctor, Site One) 
 
According to the doctor, most of the adherence support is provided by an NGO 
initiated by Site One patients in 2004. The organization caters particularly to the 
needs of HIV positive mothers and their children and offers a range of services, 
including counselling and adherence support clubs. The hospital staff members 
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readily extol the role the NGO plays in ensuring patient adherence to ARVs. “The 
brunt of the work is done by the association” (Doctor, Site One). Women patients, 
particularly expectant mothers, are systematically informed about the NGO when 
they begin receiving care at Site One and are encouraged to join the organization.  
 
 “The problem is that we don’t have a psychologist to see. Because they have 
done the test, it’s positive, morally they are not well, they have to, well…The 
advice that we give them is that they have to join an NGO. We have had to 
give that advice often, to show them where the organization is.” (Midwife, 
Site One)  
 
“And so, usually, those patients who have difficulty accepting their state, we 
refer them directly to the NGO where they chat with other people who are like 
them, who have had negative babies. It stimulates, it helps them to easily 
adhere to the therapy.” (Doctor, Site One)  
 
In summary, the adherence infrastructure at Site One is mainly built around close 
relationships and centralized care. Medical follow-up, ART, and adherence 
counselling are all dispensed at the same time, in the comfort of the doctor’s office, 
and this for both PMTCT-referred patients and other adult HIV patients. The centre’s 
family-focused care also means that patients can easily be traced since in general they 
use services in more than one ward; this is particularly the case for patients with 
children. The health providers have responded to the gap in psychosocial services at 
the centre by systematically referring patients to NGOs where they receive additional 
support.  
 
Site Two: Ward A 
As described previously, Ward A is a specialized HIV ward in one of the country’s 
major referral hospitals. Not only do they have significantly more patients on their 
roster than Site One (about 2000 versus over 800), but more staff is involved in the 
care process. Patients must follow an elaborate circuit of care that involves meeting 
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with diverse categories of healthcare providers and – before the advent of the Day 
Hospital in November 2007 – visiting several offices around the hospital.  
 
As at Site One, patients receive their first prescription for ART from their doctor after 
clinical and laboratory exams have assessed readiness for treatment. As a general 
rule, those persons with a CD4 count of less than 200 are eligible for ART. This 
process usually involves a minimum of two visits to the doctor and laboratory tests in 
between. Once the doctor has written the prescription, the patient is sent to one of the 
two nurses trained in adherence counselling for their pre-ART counselling session. If 
the nurses are busy, the doctors sometimes call upon the ATARAO interviewer, one 
of the psychosocial counsellors, or even one of the mediators, to conduct the pre-
ART counselling sessions.  
 
During the pre-ART counselling session, the patient is encouraged to choose two 
daily medication times, twelve hours apart that are conducive to his schedule. He is 
advised about adherence, side effects, nutrition and positive living. One of the nurses 
referred to this as “therapeutic education.” This is not the first time the patient will 
have heard about treatment. In the HIV care circuit, starting with VCT, the patient is 
often informed about treatment options. According to the ATARAO interviewer, the 
patients arrive ready to begin treatment. 
 
“When we refer a patient, it is with the goal of beginning treatment. We see 
that the patient himself will come prepared. He comes for this, to have 
treatment.” (Interviewer, Ward A)  
 
Following the pre-ART counselling session, the patient must go and pick up his 
medication. If he is considered too poor to pay the monthly fee for treatment, he first 
visits the Social Services office of the hospital. There he will receive a stamp on his 
prescription indicating that he is exempted from payment (see section on “ARV 
Lifecycle”). He then goes to the ARV pharmacy to pick up his prescription.  
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There are two ARV pharmacies at the hospital where all HIV patients go to pick up 
their prescriptions: a central one where the pharmacists have their office (located on 
the first floor of the main hospital building), and an auxiliary one. When I began my 
fieldwork, the auxiliary pharmacy was located on the third floor of the hospital, just 
outside Ward A. The door leading to it was unmarked to preserve the confidentiality 
of the HIV patients (see section on “Daily life”). At the time, the patients were 
referred to one of the two to pick up their prescriptions, depending on the pharmacy 
schedule. In November 2007, the auxiliary pharmacy was transferred to the Day 
Hospital along with the rest of outpatient services. Thereafter, patients were able to 
procure themselves of their monthly supply of ARVs at one location. According to 
the ARV pharmacist, patients receive information about their medications and 
adherence at the level of the pharmacy. This claim, however, was not corroborated by 
observation data and seemed unlikely given the long queues of patients outside the 
pharmacy door on renewal days.  
 
Patients receiving a supply of ARVs for the first time are asked to return to Ward A 
to the nurse or the doctor (depending on availability) where together they go over the 
modalities of pill-taking. The patient is asked to return in 14 days to see the nurse. At 
this time they discuss how he is responding to treatment and if he is experiencing side 
effects. If all is well, the nurse will give him a second prescription for the remaining 
14 days in the month. In case of problems, he is referred to the doctor. The patient 
will return again in two weeks for his third prescription. From this point onwards, he 
will come once a month to have his prescription renewed by one of the nurses. If a 
problem arises in the meantime, however, the patients are encouraged to return to the 
doctor on the ward as soon as possible.  
 
“As soon as they have a problem, they just have to come back.” (Nurse, Ward 
A) 
 
Prescription renewal sessions are scheduled for Tuesday and Thursday mornings, 
though it seemed patients came in most mornings (aside from Wednesdays which 
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were reserved for the rounds of hospitalized patients). Patients go directly to the 
Adherence Room – an office reserved mainly for the nurses and psychosocial 
workers, though sometimes the mediators worked there as well - and place the blue 
carbon copy of last month’s prescription at the bottom of the pile that grows steadily 
throughout the morning. The patient then goes to wait in the cramped hallway. One of 
the two trained nurses then copies out a new prescription on a prescription pad. The 
date on the old prescription is used to verify whether or not the patient is refilling his 
medication on time – a strategy for monitoring adherence. The renewal appointment 
is set for one week before the supply of medication runs out. The patient receives two 
copies of the prescription: a white one to be given to the pharmacist and a blue one to 
be used for next month’s renewal. A third pink copy remains in the prescription pad 
and is thrown out with the pad once it is full. While one nurse is busy copying out 
prescriptions, the other nurse (or sometimes the mediators) calls out patient names to 
come forward and retrieve their new prescriptions.  
 
When all the patients have been attended to, the old blue prescriptions are used to fill 
out the blue stock-card monitoring card. Only patients on treatment receive this card, 
unlike at Site One where all patients, regardless of treatment status, receive a card. 
The cards are kept in a long wooden box on a table in the Adherence Room instead of 
with the patient as is done at Site One to avoid the possible stigmatization of HIV 
patients (see section on “Daily life”).  
 
The monitoring card is the same as the one used at Site One. Here, the table is used to 
track the prescription renewal date and the date the patient actually came to renew. 
Along with the blue prescriptions it is another strategy used to monitor patient 
adherence to treatment. The process was not as thorough as the nurses and mediators 
would have liked it to be. According to the mediator I interviewed prior to the move 
to the Day Hospital, she and one of the nurses planned to overhaul the system once 
they were settled in the new building. Indeed, within the first month at the Day 
Hospital I witnessed her meticulously going through the cards.  
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“(He) confirmed to me that when we move we will take everything out, to find 
the mistakes, to put everything in order. Otherwise, I can see on the cards that 
they didn’t check them. The patients came, but they didn’t check them. But 
since I arrived, I have been trying. Each patient who comes, I go, I check, I go 
I check. Because if we don’t check them, we can’t know if the patient comes.” 
(Mediator, Ward A)  
 
Every trimester, the ART pharmacist and assistant pharmacist send out an Excel file 
to each ward containing the names of all patients in the hospital on treatment. The 
nurses, with help from the mediators and the doctors, are asked to update the file with 
information on patient deaths and transfers. Like the monitoring cards, it is a way to 
determine which patients have been lost to follow-up. The mediators will 
occasionally be given funds to contact these patients by phone or even to conduct 
home visits, although this is quite rare.  
 
The nurses, and sometimes the doctors, take the time to counsel patients who have 
manifested adherence difficulties - detected mainly by missing doctor or prescription 
renewal appointments. They will first try to “diagnose” what the problem is – how 
many pills he has skipped, since when, etc. They will then counsel him and suggest 
solutions, taking into consideration his personal situation. These individualized 
counselling sessions were the main adherence support strategy used at all three sites 
studied.  
 
“Really, the recommendations depend on the difficulty we discover” (Doctor, 
Ward A).  
 
The two nurses trained in the DIU are the professionals officially designated to 
address adherence in the ward. Indeed, everyone I interviewed said that adherence 
was largely their responsibility. Most, however, also maintained that everyone in the 
ward plays a role in supporting patient adherence.  
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“They work together. That’s not to say they do the same thing. But, it’s all a 
framework. Therefore, it’s a system…Therefore, really, they are people who 
work together…. I want to say that (adherence support) is not a detached role 
here that we are able to say ‘that person completely takes care of adherence’. 
Like I told you, it’s all within a framework (system). That is to say it is at 
different levels that we can talk about adherence.” (Interviewer, Ward A)   
 
“Well, everyone is involved in the organization. Often, well, we guide the 
patients, everyone is involved.” (Nurse, Ward A) 
 
“Well, everyone takes care of it. Because when you follow the…for example, 
when we give the appointments, the day of the consultation you realize that 
there was a patient who was supposed to come and didn’t, you signal it first to 
the mediators so that they can try and find out. And then you go to see at the 
level of the pharmacy if he goes to get his medications. And when he doesn’t 
come and get his medications, well, the mediators look for him and when he 
comes back we say, well, we have to go talk to him a bit.” (Doctor, Ward A)  
 
The doctor is ultimately the person who takes the final treatment decision if the 
adherence problem is serious enough, for instance if a patient has stopped taking his 
treatment altogether.  
  
“We talk to him here. We tell him of the risk he is running if he continues. 
Now, if the length of time is long, we send him to the doctor. Or if he did it 
(missed appointments/doses) up to two times, we send him to see the doctor.” 
(Nurse, Ward A) 
 
The outpatient services were transferred to the Day Hospital in November 2007, as 
mentioned previously. The adherence infrastructure remained largely the same but 
the centralization of most services in one location greatly facilitated the patient circuit 
of care. Patients are now able to consult their doctor, renew their prescriptions, 
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benefit from adherence counselling and fill their prescriptions at the pharmacy on the 
same floor of one building. There are also plans for the staff of the Social Services to 
train the mediators in providing exemptions for treatment costs, which would avoid 
patients having to go to the Social Services in the main building. Eventually, the only 
services that will not be available at the Day Hospital are laboratory tests, for which 
the patient will continue to go to the main hospital test centre.  
 
In summary, the adherence infrastructure in Ward A is a highly developed system 
dependent on various types of health providers and monitoring tools. This system was 
developed over time as the patient roster increased with improved availability of ART 
in Burkina Faso. The ward benefits from the added support of personnel hired with 
the funds of externally funded (both national and international) projects (i.e. 
mediators and psychosocial counsellors). Despite the large number of patients who 
consult in Ward A the infrastructure allows the staff to at least target those patients 
who clearly manifest adherence difficulties.  
 
Site Two: Ward B 
The patient circuit in Ward B is similar to that of Ward A but much of the adherence 
infrastructure is missing. One of the most noticeable differences is the absence of the 
mediators. At Ward B it is the nurses and, recently, the ATARAO interviewers, who 
are responsible for most duties ranging from prescription renewal to psychosocial 
counselling.  
 
As mentioned in the section on “Context of care”, until recently most HIV patients in 
Ward B were receiving treatment for dermatological problems. At the time I 
conducted my fieldwork, however, patients were avidly being recruited to initiate 
treatment (and to participate in the ATARAO research project) from NGOs where 
treatment was no longer available4.  As a result, staff were adjusting to a change in 
                                                
4 During the same period, many NGOs were struggling with funding uncertainty. According to one 
NGO representative, this uncertainty was largely due to the approaching end of the World Bank-
funded Treatment Acceleration Program (TAP) which had financed the initiation of ART for many 
HIV patients. As a result, many NGOs stopped accepting new patients and began referring them to 
medical centres. Through conversations at the XVII International AIDS Conference with an employee 
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both the number and the type of HIV patients they were seeing; patients (with or 
without dermatological problems) now arrive with a referral sheet from an NGO or 
other health structure indicating his HIV status and type. The nurse then completes a 
form for the patient to undergo laboratory tests, including CD4 count if required. As 
some organizations conduct CD4 tests, a patient may arrive with these results. This 
procedure diverges from that of Ward A where it is the doctor who prescribes the 
laboratory tests after meeting with the patient for the first time. Laboratory test results 
are usually ready within 72 hours. 
 
Once the patient has the results of his laboratory tests, he comes back to the ward to 
see the doctor. At this point, he will be prescribed ART if he is eligible (according to 
the same criteria used at the other two sites). He is then directed to either the nurses 
or the ATARAO interviewers for pre-ART counselling. The information provided to 
the patient during pre-ART counselling is theoretically the same as described for 
Ward A. Once that is complete, he goes to the pharmacy to pick up his prescription 
(detouring by the social services if he is determined to be indigent) before coming 
back to have the dosages explained for a second time by a nurse or an ATARAO 
interviewer.  
 
The whole process of treatment initiation is completed rather quickly as compared to 
the other sites and two of those interviewed expressed concern that this rapidity 
negatively affects patient adherence. As will be discussed in a later section, these two 
respondents blamed the ATARAO research project for an increased speed of ART 
prescribing. This concern about adherence may have been compounded by the fact 
that an “adherence infrastructure” was not in place here as it was in Ward A. Ward B 
did not have mediators or psychosocial counsellors to provide psychosocial support 
to patients, nor did they have the blue monitoring cards to tangibly monitor patient 
adherence to prescription renewal. Indeed, these “tools” were suggested by the 
providers I interviewed as a way that adherence support could be improved. 
                                                                                                                                      
of the SP/CNLS-IST in Ouagadougou, who works on the GFATM portfolio, and an employee of 
Sidaction in France, I learned that GFATM had agreed to cover the funding of TAP. NGOs were, 
therefore, beginning to accept new patients again.  
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Furthermore, only one of the doctors and none of the nurses had participated in the 
DIU on HIV care (though they had all received some HIV training at the level of the 
hospital). Adherence was monitored mainly through the verification of the date on the 
previous month’s blue copy of the prescription (as in Ward A) and individualized 
counselling sessions.  
 
In summary, Ward B had the least developed adherence infrastructure of the three 
sites studied. This lack of infrastructure was aggravated by a recent influx of HIV 
patients (see section on “External pressures”) and an insufficient number of staff who 
had not received specialized training in the care of HIV patients.  
 
 
Systemic Adherence Inhibitors  
 
The term “systemic adherence inhibitor” was coined in the present study. It implies 
determinants at the ward (hospital), health system, societal, and international levels 
that can potentially obstruct the adherence support provided by individual health 
providers, and that ultimately may prevent patients from being optimally adherent to 
treatment regimens. As illustrated by the diagram at the beginning of the results 
section, these determinants range from the micro level of the ward to the macro 
societal and international contexts.  
 
This section presents four broad themes: ART supports, daily life, the ARV lifecycle, 
and external pressures. Two of the four themes discuss systemic adherence inhibitors 
with respect to a particular system (i.e. ART supports and daily life); the other two 
include determinants that initiate at a particular level but produce impacts on other 
systems (i.e. the ARV lifecycle and external pressures).  
 
ART supports: not only a matter of giving drugs 
New international funding for treatment means ART is more accessible in Burkina 
Faso now than ever before. The difficulty lies in ensuring that providers and patients 
have all the necessary tools to maximize treatment efficacy, ranging from laboratory 
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tests to psychosocial support, from medication for opportunistic infections to 
sufficient health professionals.   
 
This section will discuss “ART supports” - the auxiliary tools that the health system 
must supply in order to ensure effective adherence monitoring - and their present 
scarcity in the three sites studied.   
 
Laboratory tests  
Several of the providers interviewed cited availability and access to laboratory tests 
such as CD4 counts and viral load testing as a main difficulty in efficiently 
monitoring patients on treatment. Such tests are not available free of charge to 
patients which means that the majority cannot afford to have them done on a regular 
basis. (Exemptions for tests may be granted from the Social Services, but apparently 
they are not as easy to obtain as for ART and not all tests are eligible.) 
 
“At times we are missing resources, in particular, you can ask for a test and 
the test does not come. When it’s like that, you as a doctor, it puts you, it 
limits your actions. You wait for the test to be able to do something.” (Doctor, 
Ward A) 
 
Furthermore, even when patients are able to pay for the tests, they are not necessarily 
available. In the past, there have been supply breaks in CD4 testing as a result of lack 
of reagents or even- as two doctors mentioned - a lack of forms to prescribe the tests. 
Viral load testing was either non-existent at Site Two or sporadic; it was never quite 
clear to me what the situation was.  
 
“Presently we can’t even do the viral load. That has also stopped. I don’t 
know if it’s a problem of materials, what’s going on, but there are patients 
who have been waiting for months and still don’t have their results…We want 
to know if the medications they are taking are still working, or if they have 
developed a resistance.” (Doctor, Ward B)  
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At Site One, viral load testing was available, but again access was contingent on the 
patient’s ability to pay.  
 
“And now, after six months we redo all the exams. And now, if possible, if the 
patient has the financial possibility to do the….viral load, we ask him to do 
the viral load.” (Doctor, Site One) 
 
Lack of these laboratory exams made it difficult for doctors to make clinical 
decisions about treatment and compromised continuity of care as a result.  
 
Psychosocial care  
Several providers interviewed cited social problems as the main barriers to patient 
adherence to ART.  
 
“Generally, there is always something that explains it, particularly social 
factors and also not having enough to eat, or the patient is hospitalized 
somewhere.” (Doctor, Ward A) 
 
“…it’s mainly social problems that cause patients to not be adherent. It’s true 
that a small number of patients who haven’t shared their serology with their 
partners which poses problems, work, but it’s really social phenomena that 
cause patients to be non-adherent.” (Doctor, Ward A)  
 
Ward A benefited from the presence of the mediators and psychosocial counsellors 
who, along with the specially trained nurses, were responsible for psychosocial 
counselling on the ward. Due to the high volume of patients, however, providers were 
not able to spend a sufficient amount of time on psychosocial counselling.  
 
“It’s mainly the number of patients. We have lots of patients…and we don’t 
manage to follow the entire group of patients, as we would like to. That, 
really, is a weakness. We don’t really manage to get our hands on all our 
patients. Well, put our hands on is perhaps too harsh. What we would have 
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wanted is that each patient has an (adherence) consultation appointment, 
where we would get to discuss with him. But we are not able to do so because 
there are too many patients. What we manage to do, during renewals, the 
patients who are in trouble, of adherence, or just in trouble, we try to discuss 
with them. With them in particular. But, we should be doing it even with those 
for who the treatment is working; normally we should be talking to them 
because you never know.” (Nurse, Ward A)  
 
In Ward B, as there were no mediators or psychosocial counsellors, psychosocial 
support was provided mainly by the nurses and the ATARAO interviewers. The 
presence of the ATARAO research project on the ward had the positive impact of 
rendering psychosocial counselling more available to patients, despite increasing the 
workload on the ward overall (see “External Pressures” section).  
 
“Yes, there is an impact – it’s positive. Because the support that we provide to 
the employees on the ward, we help them as well. There’s that. There’s also 
the fact that we cheer up the patients during our interviews. We contribute to 
adherence.” (Interviewer, Ward B) 
 
At Site One the psychosocial support deficit was managed by developing a close 
relationship with an NGO, as discussed previously. According to one doctor, most of 
the adherence support is provided by the NGO through a range of activities, 
including: counselling, support groups, adherence clubs, nutritional support, and 
income-generating activities. Adherence clubs are led by members of the 
organization who have special training in ART and adherence from one of the 
national NGOs5. At adherence club meetings, members – both those who are on ART 
and those who are not – ask questions and discuss their concerns relating to 
treatment.  
 
                                                
5 Five members of the NGO had been trained either by the Programme d’appui au monde associatif et 
communautaire (PAMAC) or the Centre d’information, de conseil et de documentation sur le Sida et 
la tuberculose (CIC-doc), two NGOs operating at the national level.  
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All those interviewed across the three sites considered that one of the ways adherence 
care could be improved is by introducing more psychosocial activities on the ward: 
support groups, adherence clubs and home visits. Many of the providers interviewed 
at the hospital suggested hiring more lay counsellors like the mediators to respond to 
the psychosocial needs of the patients. In settings of limited resources, however (such 
as the ones studied), additional services are contingent on funding.  
 
 “If we have (grants) we will add (activities)” (Doctor, Ward A) 
 
Medication for opportunistic infections  
One of the main difficulties faced by the pharmacists and, in turn, by the doctors, is 
the supply of medications to treat opportunistic infections. Supply problems are the 
result of both breaks in supply and actual unavailability.  
 
“Well, the difficulties are only at the level of certain products. Certain 
products. For the ARVs, really, it’s ok. But at the level of medications for 
opportunistic infections, we have many supply breaks. The demand is very 
high.” (Assistant pharmacist, Site Two) 
 
The ART pharmacist at Site Two reported that international and national 
organizations often donate a limited shipment of medications to treat opportunistic 
infections on a periodic basis. This contributes to rendering the supply irregular as the 
donations inevitably run out.  
 
The range of products available is also limited and even further constricted by the 
patient’s socioeconomic status. This ultimately impacts on the provider’s ability to 
efficiently treat patients. 
 
“Well, the difficulties related to patient care are especially tied to treatment 
because we are often confronted with patients who are financially destitute. 
So, when you prescribe a treatment, he comes back to say that he was not able 
to buy it. So, already at the level of prescriptions we are limited because we 
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have to take into account the socioeconomic status of the patients and see 
what medications are available, are made available free of charge for 
opportunistic infections. And to see if among these medications we can 
prescribe for the pathology we want to treat. It’s not always possible because 
there are not a lot of things that are free of charge.” (Doctor, Ward B) 
 
Both the ART pharmacist and assistant pharmacist believed that adherence support 
could be improved by making medications for opportunistic infections more available 
and accessible to patients. Recommendations by several providers, particularly 
physicians, echoed this claim.  
 
Insufficient healthcare providers  
As discussed in the literature review section, the healthcare provider is an integral, 
but often overlooked component of any health intervention. Several of those 
interviewed found that the number of personnel was insufficient to respond to the 
needs of the increasing number of HIV patients on their wards.  
 
“In terms of doctors we are not many which means that the workload is 
enormous.” (Doctor, Ward A) 
 
The number of HIV patients consulting at Site Two has drastically increased over the 
past few years with improvements in availability of ART. “Taskshifting” (UNAIDS 
& PEPFAR, 2007) has been used as a method to address this situation. For example, 
specially trained nurses at Site Two are responsible for ARV prescription renewals 
and adherence counselling, rather than doctors. In Ward A there are only two nurses 
who are authorized to renew prescriptions.  
 
“…in the beginning it was the doctors who did it themselves. They saw that it 
was really…That it was a bit difficult because there were many patients. They 
had to renew before they began consulting. I believe it was, yes, it was in 
February 2006 that I began this.” (Nurse, Ward A) 
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Since one nurse began renewing prescriptions in 2006 the number of patients on ART 
has more than doubled; from 600 to about 1500.  
 
According to one of the nurses, one of the difficulties of the added task of 
prescription renewal is that they are still expected to carry out regular nursing duties 
on the ward – including nightshifts. On days when there are dozens of patients 
waiting for their prescriptions, if one nurse comes off night duty he is expected to 
stay and help his colleague until the flow of patients has ebbed somewhat. He 
suggested that work conditions would be better if the two DIU-trained nurses were 
discharged from regular nursing duties to concentrate on adherence counselling and 
prescription renewal. This, of course, implies hiring further nursing staff to replace 
them. After the transfer to the Day Hospital one of the two nurses was discharged 
from regular nursing duties to concentrate on “therapeutic education” but it is 
unclear whether or not another nurse was hired to replace him on the ward.  
 
The staff on Ward B ward came to rely heavily on the ATARAO interviewers for 
tasks ranging from counselling to appointment scheduling to prescription renewal.  
 
“Well, I think that it’s mainly due to their workload; their workload because 
there is not enough personnel. Also, I think that it’s the different trainings I’ve 
received because firstly through ATARAO I received training in counselling 
and also, under Ward B, I participated in a training session on adherence.” 
(Interviewer, Ward B) 
 
As mentioned in the previous section on psychosocial support, a critical lack of 
personnel impacts on the quality of care patients receive. This is particularly the case 
with respect to adherence support which, in the present adherence infrastructure, is 
highly dependent on provider availability. With the current number of patients, 
doctors do not have enough time to properly counsel patients about adherence.  
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“Really, if it’s concerning adherence, each time we meet a patient we at least 
ask him ‘are you taking your medication properly?’ At least that question. 
Each time we meet the patient we at least ask him that question. But now we 
don’t have time to go into detail.” (Doctor, Ward A)  
 
The deficit in staff becomes even more marked when part of the adherence 
infrastructure goes awry. One doctor at Site One talked about how patients who miss 
their appointments and arrive unexpectedly throw her whole schedule off kilter, 
leaving her with insufficient time to conduct proper consultations.  
 
“And then those who miss appointments are obliged to come another day 
either because the products (ARVs) are finished or to restock before the 
products are finished. Then it swells the queue waiting in such a way that the 
time you spend with each patient is insufficient. I can recognize it myself, but I 
can’t do otherwise because if I want to give more time I’ll never finish. So you 
are obliged to go fast, and it is when you go fast that problems arise. You need 
a lot more time, to chat with the person, so that the person opens up. It also 
contributes to good adherence (to treatment).” (Doctor, Site One) 
 
A lack of personnel not only compromises current quality of care but impedes the 
ability of wards to introduce new services for patients. The pharmacist, for instance, 
proposed that adherence monitoring could be improved by using pill-counting as a 
strategy. She thinks this would be ideal but the current patient load makes it 
unrealistic.  
 
“I think we want to but with the number…it’s not easy. (laughs). Unless they 
send us personnel.” (Pharmacist, Site Two)  
 
Several providers interviewed maintained that in order to respond to the psychosocial 
needs of the patients more personnel needed to be hired. As mentioned previously, 
  
77 
they recommended hiring lay counsellors highlighting the notion that added 
personnel need not be highly trained.  
 
Summary 
The majority of the interviews and observation periods conducted revealed that 
accessing ART itself was not the main problem in ensuring adherence support for 
patients. Rather, this support was compromised by a lack of “ART supports” in the 
health system such as laboratory tests, psychosocial supports, and medications for 
opportunistic infections. Furthermore, a critical lack of all categories of personnel 
across the sites meant that the quality and degree of implementation of both present 
and proposed adherence interventions was jeopardized.   
 
Daily life: the socioeconomic and cultural context of Burkina Faso 
The conceptual model of the present study was founded on the premise that health 
care centres are not distinct from the world outside their gates. Rather, they are 
microcosms of society where existing socioeconomic, political, and cultural forces 
are at play. In the previous section it was discussed how the health system (in 
collaboration with the NGO sector) must ensure more than just access to drugs in 
order to efficiently support and monitor adherence to ART among patients.  
 
In this section it will be argued that even more macro societal factors have an impact 
on both the ability of the health provider to care for the patient and patient adherence 
behaviour. In the present study, these factors include: poverty, illiteracy, and stigma 
and disclosure of HIV status. In North American studies on ART adherence, such 
determinants are often classified under patient factors (Golin, et al., 2002). In this 
study, however, it was considered more relevant to consider them societal factors, as 
they are broadly distributed throughout.  
 
Poverty 
Poverty among patients is one of the main challenges those interviewed face in the 
accomplishment of their daily duties. According to several participants, it is the major 
underlying force compromising adherence to ART and impacts on all the aspects of 
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care, from accessing drugs to medical follow-up. Impoverished socioeconomic status 
affects both prescribing practices (as noted in the above section on medications for 
opportunistic infections) and continuity of care (discussed in the sections on the ARV 
lifecycle and ART supports).  
 
“Now, for the difficulties we face, it is the poverty of our patients. That is to 
say, it’s not all medications that are exempted downstairs…at the hospital 
pharmacist. We have difficulty prescribing other medications which means 
that on the therapeutic action plan we often have problems.” (Doctor, Ward 
A) 
 
“It’s not all exams that the Social Services exempt. We have difficulties at that 
level. Especially, especially at that level we run into problems.” (Doctor, 
Ward A) 
 
Poverty, of course, leads to numerous other problems. Food security was mentioned 
by providers as a challenge faced by numerous patients.  
 
Poverty is widespread in Burkina Faso and the state does not possess an elaborate 
social security infrastructure. In this setting, it is the NGOs who have stepped in to 
provide much-needed socioeconomic support to impoverished HIV patients. Most 
patients at both sites are referred to organizations where they often benefit from 
nutritional support, psychosocial counselling services, and occasionally income-
generating activities. This is well illustrated in the example provided by Site One.  
 
Many of those interviewed suggested that similar activities be implemented at the 
hospital level, though a few conceded that perhaps a hospital is not an appropriate 
setting for such programmes. Instead, they suggested improved collaboration with the 
NGO sector.  
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“We really need to resort to the organizations. Resort to the organizations. 
And if it was up to me to put in place a programme, it would be a programme 
that works in collaboration with the organizations.” (Interviewer, Ward A) 
 
As will be elaborated upon below, however, access to services provided by NGOs is 
often hindered by the patient’s fear of stigma and discrimination if their serostatus is 
exposed.  
 
Illiteracy  
Illiteracy is endemic in Burkina Faso; three out of four adults in the country are 
unable to read. This is a potential challenge to a patient’s ability to be adherent to 
ART. Many cannot read the time, making strict respect of ART dosage times difficult 
for some.  
  
“The problem of non-adherence is also tied to illiteracy. There. That is to say 
we have a lot of people who are not educated, so they don’t know how to read 
or write. Often it is very hard to be adherent.” (Interviewer, Ward A) 
 
Despite this challenge, providers adapt to this constraint by finding creative ways of 
helping patients remember the times to take their medications.  
 
“There are also patients who have not gone to school…Well, we can explain 
how to take the products on time…There are some who are Muslim. We can 
point out prayer time in the morning at seven thirty, in the evening at seven 
thirty…We ask them about the activities they do. The women who get up at 
seven to go to the garden, or those who watch a soap opera at 10pm, we try to 
find out how they can manage not to miss (a dose).” (Mediator, Ward A) 
 
“Often it is illiterate women, who don’t have watches. Well, they manage like 
that, they listen to the radio. They still try to take (their ARVs), maybe not at 
exact hours, perhaps a few minutes early or a few minutes late” (Midwife, 
Site One) 
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Despite the problem of illiteracy being evoked in several interviews, only one person 
– an ATARAO interviewer – suggested that literacy support should be included in a 
programme designed to support adherence.  
 
“So, if the programme could also put an emphasis on training, literacy, 
education even. Or else training. We can no longer take them to school but we 
can teach them what is necessary, just to know the time, to read the 
prescriptions, and so on.” (Interviewer, Ward A) 
 
Stigma & Disclosure of HIV Status 
The issue of stigma and discrimination still greatly impedes access to services for 
HIV patients and, in turn adherence to treatment. Anecdotes of patients who pick up 
their prescriptions straight from the doctor, go directly to the distributor to have them 
filled, and then take their drugs in hiding were common. Patients often refuse to join 
NGOs despite the range of services they provide for fear of being labelled as HIV 
positive.  
  
“There are those who do not want to go to the NGOs because then many 
people will know (that they are HIV positive): ‘when they see me go inside the 
organization they’ll know that I am…’, and so on’. (Doctor, Site One) 
 
Helping patients disclose their HIV status to their partners – referred to as ‘partner 
notification’ in the public health literature - was a difficulty cited by providers at both 
sites.  
 
“And the other difficulty is serodiscordant couples. There are couples where, 
well, the woman is on treatment and she does not want to reveal her status to 
her husband. So often it creates a problem because if we explain prevention 
through condom use how will she explain to her husband?” (Doctor, Ward A) 
 
One midwife talked of feeling helpless when her pregnant patients are too afraid to 
notify their partners that they are HIV positive.  
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“Sometimes it’s hard because you find yourself in a situation where you really 
don’t know how to resolve a problem. The woman says ‘Ah! I don’t know how 
to tell my partner that I’m HIV positive’ and ‘my husband told me that if I do 
the test and I am seropositive he will kick me out.’ So often we are at home 
thinking about this, how to resolve the problem. It’s the main difficulty in this 
line of work. You test the woman, she’s there, and she doesn’t know how to 
tell her partner who is threatening to kick her out. Or else she tells him and he 
says ‘get out’. We’ve had cases like that many times.” (Midwife, Site One) 
 
Recognition of existing stigma and discrimination in society against people living 
with HIV ultimately affects the way care is organized, in particular at Site Two. This 
was illustrated by the following three examples: patient monitoring cards are kept on 
the ward so patients would not be labelled if seen carrying them around; an annex 
ART pharmacy existed behind an unmarked green door near Ward A (prior to the 
move to the Day Hospital); and home visits were rarely conducted partially due to 
difficulties in obtaining patient consent.  
 
“But here, in the beginning, they told us to give the cards to the patients. But, 
when people see certain patients they automatically know which category of 
patients he belongs to.” (Nurse, Ward A) 
 
Shortly after outpatient services were transferred to the Day Hospital, I questioned 
one nurse about whether the issue of stigma had been raised by patients. The centre is 
a distinct structure from the main hospital building and despite being officially 
labelled as part of Internal Medicine, I wondered how long it would take before it was 
tagged as a ward for HIV patients.  
  
“Even if they are used to coming to the hospital, well, upstairs it’s true that 
the ward was labelled (an HIV ward) but as it was part of the big building 
and, well, it was internal medicine over there; there were many types of 
patients. Well, they didn’t feel too self-conscious. But here, the fact that it’s 
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isolated, they say that maybe – some, not all, but some – say that it will be a 
bit stigmatising…But the majority of patients find that they will be better off 
here because there is enough space, there are enough resources.” (Nurse, 
Ward A) 
 
Patients I spoke with in the days following the transfer of services to the Day 
Hospital were very pleased with the new centre and preferred it to the third floor 
ward. In any case, plans were underway to build a wall around the new centre with an 
entrance at the back allowing patients to avoid passing through the main hospital 
gates.  
 
“There will be a wall. Well, it’s certain patients that wanted it to be that 
way.” (Nurse, Ward A) 
 
Summary 
HIV patients face a number of difficulties imposed by their socioeconomic context. 
These factors impact both the provider’s ability to care for the patient, as well as the 
patient’s capacity to access essential services in HIV care. These societal 
determinants also influence the logistical organization of care.  
 
The ARV lifecycle: from manufacturers to patients  
Ensuring the supply of drugs from manufacturer to patient is a complex feat and one 
of the main systemic inhibitors of adherence support that became evident during 
interviews. The “ARV Lifecycle” refers to the pathway ARV drugs follow from entry 
into the country until they reach the patient (Reynolds Whyte, Whyte, Meinert, & 
Kyaddondo, 2006). Several issues related to the ARV lifecycle were raised in 
interviews at both the Site One and Site Two. However, as I had the chance to 
interview both the ART pharmacist and assistant pharmacist at Site Two, most of the 
data in this section is based the information they provided.  
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Figure 2. The ARV lifecycle in the public health sector 
 
The majority of ARVs in Burkina Faso are presently financed by the GFATM, whose 
current round comes to an end in 2011 (The Global Fund to Fight AIDS, 2008). 
When I asked the assistant pharmacist what will happen afterwards, he responded:  
 
“We don’t know. We’ll have to wait and see (laughs).” (Assistant pharmacist, 
Site Two)  
 
Both the pharmacist and the assistant pharmacist maintain that there have been no 
supply problems with ARVs since they began working at Site Two in 2006. 
However, as will be discussed below, the procurement process is a complex 
procedure for both providers and patients and a delay at any one of the steps along the 
way may compromise a continuous supply of ARVs for the patient.  
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The present section has been divided into “Supply” and “Demand” in order to discuss 
the procurement process for both the provider and the patient. The Supply side 
discusses the procurement procedure providers must follow to ensure adequate stocks 
of ARVs at the site of distribution. The Demand side, on the other hand, clarifies the 
trajectory of the patient in accessing drugs each month, according to the provider’s 
understanding. The aim of this discussion is to show how ensuring an uninterrupted 
supply of ARVs – an essential condition to optimal adherence – is an issue that 
extends beyond the responsibility of the patient and the provider and depends on 
facilitating factors at the level of the hospital, the health system, as well as the greater 
international context.  
 
Supply Side6 
The main task of the ART pharmacists at the Site Two is to make medications for 
HIV patients available. These include both ARVs and drugs for opportunistic 
infections. To do so, they must first have the correct information from each ward 
about how many patients are on treatment, how many new patients are expected to be 
prescribed treatment and which regimens of medication are required.  
 
In the wards where HIV care is undertaken, a senior doctor is responsible for 
submitting a request for ARVs for new patients to the pharmacy each trimester. 
ARVs for patients already receiving treatment (“old patients”) are ordered 
automatically by the pharmacists as they are already included on the pharmacy roster. 
The request includes the predicted number of new patients who will be put on 
treatment over the next four months and is based on the patient roster of each ward. A 
senior doctor is responsible for predicting both the number of patients who will begin 
treatment and the types of medications that are required.  
 
                                                
6 This is the ARV supply chain observed in Burkina Faso’s public health sector in urban areas. An 
employee of the CMLS informed me that the procedure is slightly different in rural areas; due to 
decentralization initiatives, requests for patients already on treatment are addressed to the district level 
and only requests for new patients are forwarded to the central CMLS. In the private sector, some 
NGOs continue to receive a portion of their drug supplies directly from generic pharmaceutical 
companies in Brazil and India (via France).  
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If a ward has not requested a certain regimen, it should not be prescribed to a patient. 
During an interview with the assistant pharmacist, an employee from the maternity 
ward came in to collect ARVs for one of her patients. The pharmacist chastised her 
because she requested drugs that were not included on the list of regimens of the 
maternity ward. It was not her fault – the patient was referred to the ward with this 
prescription. He reluctantly gave her the medications but told her that the patient must 
be transferred to the patient roster of Ward A to continue receiving those particular 
ARVs. 
 
The head ART pharmacist assured me that if more patients than predicted are 
prescribed treatment in a trimester they normally do not run into supply problems - 
the supplier (CAMEG) usually stocks up to a month of drugs as a buffer. The doctor I 
interviewed at Site One does not have the same luxury; near the end of a trimester she 
sometimes ends up with a list of treatments that are not compatible with patient 
needs. For instance, she may find herself with a list of regimens containing Efavirenz 
and none containing Nevirapine. Efavirenz is potentially teratogenic and cannot be 
prescribed to the pregnant women that make up a significant portion of her patient 
roster. 
 
The requests from the wards, coupled with the existing pharmacy patient roster, are 
sent to the Comité ministériel de lutte contre le Sida (Ministerial Council on 
HIV/AIDS - CMLS) to be approved. The CMLS is under the direct supervision of the 
Ministry of Health. Its mission is to organize, coordinate and strengthen the activities 
in line with the fight against HIV/AIDS and sexually transmitted infections across the 
country (Ministère de la santé du Burkina Faso, 2005b). “It acts as a bridge between 
the Ministry of Health and the Permanent Secretariat of the National Council for the 
Struggle against HIV/AIDS and STIs” (Ministère de la santé du Burkina Faso, 
2005b).  
 
I once visited the CMLS, housed in a small building adjacent to the hospital. There I 
met with the person who handles the orders, a pharmacist by profession. He informed 
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me that before agreements are signed with donor organizations, consensus is reached 
on the number of new patients who can begin ART each year. When the CMLS 
receives requests for new patients, he must ensure that donor funds can accommodate 
them.  
 
Once the order is approved by the CMLS, the pharmacist can go pick it up at the 
CAMEG, the country’s non-profit pharmaceutical distributor (see “Context” section). 
Approval, however, is not automatic. Doctors sometimes request certain types of 
medications that are no longer available, or have been substituted with equivalent 
drugs. The assistant pharmacist gives the example of Viracept that was recalled 
because “it was badly produced”. In such a case, the patient is changed to an 
equivalent regimen. Furthermore, he tells me “There are many problems between the 
CMLS and the CAMEG that we don’t know about” (Assistant pharmacist, Site Two) 
 
As the CAMEG’s procurement procedure requires international tender with contracts 
awarded to the lowest bidder supplying high quality pharmaceuticals7, distributors 
and brands often change. This results in frequent changes in the packaging of the 
medications and even the number and appearance of pills one must take, despite the 
equivalent chemical composition. The pharmacists and other providers are constantly 
required to explain these changes to the patients. For instance, if a patient is used to 
receiving Duovir but the CAMEG has replaced it with Combivir, they write “Duovir” 
on the package so that the patient knows it is the same product. The pharmacist 
considers these variations to be problematic.  
 
“You always have to explain that the box has changed, that it’s the same 
product, the box has changed. So it’s a problem, we always have to 
explain…It inconveniences us because we always have to explain to the 
                                                
7 According to the CAMEG’s website, quality assurance of products is a top priority. A rigorous 
quality control process is carried out at the level of the supplier, the distributors, and the CAMEG 
itself. When new stocks of drugs arrive, they are tested for quality in large part by a quality-control 
laboratory in Belgium (SGS LABO SIMON) as well as by the Laboratoire Nationale de Santé 
Publique au Burkina Faso.  
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patients. It even bothers the patients. They think that the products aren’t good 
and that’s why they are being changed.” (Pharmacist, Site Two) 
 
While a couple of nurses I consulted on the wards did not find these frequent changes 
to be particularly problematic, they admitted often having to explain the substitutions 
to the patients. Some patients, they told me, will not ingest a new medication they 
receive from the pharmacy before confirming with the provider that it indeed 
corresponds to their prescription.  
 
The pharmacists find out a brand has been changed when they arrive at the CAMEG 
to pick up the order; no information is communicated by either the CMLS or the 
CAMEG to advise them about product changes.  
 
“If we say ‘Crixivan’ and they give us Indinavir, we know there is no Crixivan 
[left in stock]. Yes, it’s the same product.” (Pharmacist, Site Two)  
 
There is also the risk that some patients will believe that a certain product is better 
than its equivalent. The assistant pharmacist recounted the story of a patient who 
believed that Duovir was superior to Lavocom even though both contain the same 
active drug combination of AZT and 3TC. 
  
“What did we do? We took the Lavocom and we poured it into a Duovir box. 
We gave it to him like this saying ‘the box is open but we counted and the 
number of pills is correct.’ He left and then came back the next month saying 
‘with Duovir there is no problem!’” (Assistant pharmacist, Site Two)  
 
The issue of medications that are appropriate to the African context is also raised by 
the assistant pharmacist as being a barrier to adherence.  
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“There are also certain products that we had here, like Kaletra and Norvir 
that should be kept in a cool place. For the patients who travel, the cold chain 
will break at some point...” (Assistant pharmacist, Site Two) 
 
He tells of patients who deliberately leave their ARVs behind when they travel for a 
few of days because they know they will not be able to store them in a cool place.  
 
“We need products that are adapted to our climate. If we could have Norvir 
that does not need to be stored in the fridge that would be good.” (Assistant 
pharmacist, Site Two) 
 
While the pharmacists know the products well, other health professionals may not. 
The assistant pharmacist confides in me that an intern may prescribe one brand and 
when the patient returns with another brand he will send the patient back to the 
pharmacy thinking it is a mistake, despite the fact that they are equivalent. It also 
happens that errors are made in the prescriptions because some doctors do not master 
the chemical composition of the medications. The pharmacy staff members try to 
catch these errors at the level of the pharmacy. On the wall near the door there is a list 
of ARVs that cannot be prescribed together.  
 
While procurement of ARVs at the hospital pharmacy is a logistical juggling act for 
the health provider, and most notably for the pharmacist, ensuring that one has a 
continuous supply of drugs is a daunting task for Burkina Faso’s mainly 
impoverished HIV patients. The following section discusses the obstacles the patient 
faces in ensuring his monthly supply of drugs; the second half of the discussion on 
the ARV lifecycle.  
 
Demand side 
At the time this study was carried out, patients were asked to pay a monthly 
contribution of 5000 fCFA (about US$10) for their supply of ARVs – a prohibitively 
expensive amount for the vast majority of HIV patients in the country.  
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A patient may be exempted from payment if he is determined be indigent. At both 
Site One and Site Two the exemption process is largely subjective and determined by 
the healthcare provider. At Site One, for instance, as the patient receives all HIV care 
from the doctor, it is he who decides if she is indigent or not.  
 
“Well, here it is done by the doctor. In the worst cases, the patient confides in 
you (that he does not have the money). Otherwise, once they are starting 
therapy we tell them that there is a contribution. Now, if they balk already 
‘well, if it’s like that it will be hard, I won’t be able to’ and so on it’s up to the 
doctor to see. Sometimes also the NGO tells us, ‘that one used to pay 5000 
and take (his drugs) but if you could give them to him today because he lost 
his job’, or some other concern.” (Doctor, Site One)  
 
At Site Two, patients who tell their health provider that they are unable to pay for 
their drugs are sent to the Social Services to receive an exemption. At Ward B 
especially, this seemed to be almost an automatic detour. For instance, I observed that 
even patients who did not look especially poor (a subjective judgement to be sure) 
were referred to the Social Services. One nurse in Ward A estimated that at least 80% 
of patients are exempted from payment. One of the ATARAO interviewers explained 
the exemption process in Ward A to me as follows:  
 
“So, if it comes out of the (pre-ART) counselling session that the patient is not 
able to each… to give out 5000 fCFA each month for ARVs, we refer the 
patient. The patient is referred to the social services downstairs to take what 
we call an exemption. The exemption allows the patient to come and take his 
products for free.” (Interviewer, Ward A) 
 
The Social Services office at Site Two is a dimly lit, small, cluttered room on the 
main floor of the hospital, beside the central ART pharmacy. There was often a queue 
of patients waiting outside the door of the Social Services; the office is not exclusive 
to HIV patients and any category of patient requiring an exemption is referred there. 
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There, the patient meets with one of the two women employees and pleads his case as 
an indigent. If the exemption is granted, the patient receives a stamp on his 
prescription and his name is recorded in the large ledger that sits on the desk in front 
of the woman.  The exemption process at Site Two is tiresome and requires the 
patient to visit yet another office in the hospital. It can also be humiliating as the staff 
of the Social Services often mistreats them, as one psychosocial worker told me (I did 
not have the chance to validate this claim with other providers or patients). As 
discussed previously, Ward A staff hoped that the social services for HIV patients 
would eventually be added to the duties of the mediators at the Day Hospital.  
 
Normally, a patient who is labelled indigent does not have to return each month to the 
Social Services for an exemption. However, according to the assistant pharmacist 
those who are not considered to be very poor may only be exempted one out of every 
two months - a practice that impacts negatively on adherence.  
  
“There’s the example of those who are not too poor. The social services does 
them a favour, exempts one box (of ARVs) every two months. That is, if he 
takes one box, it is exempted, if he comes back the next month, it is not 
exempted. So, what does the patient do? The month he is exempted, he comes, 
the month he has to pay, he doesn’t come.” (Assistant pharmacist, Site Two) 
 
To avoid the issue of cost and exemptions, some patients take advantage of the NGOs 
that provide ART free of change on an occasional basis. It happens that a patient will 
do the rounds of the different organizations and come to the hospital only when those 
other sources have dried up.  
 
“Often there are patients who we see in their files; in our files…we say that 
they are not adherent. But, they are adherent. They are with the NGOs. They 
take products here, they take products at such and such organizations, they 
take at another organization. You see?... So they are in fact adherent in the 
process, but here they are not adherent.” (Assistant pharmacist, Site Two) 
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“…they didn’t understand why at certain NGOs it was free when in state 
structures they say you have to pay 5000. They didn’t understand that. So, 
people prefer to go to the organizations.” (Nurse, Ward A) 
 
This practice is considered problematic not only for continuity of care, but for 
therapeutic outcomes. One nurse in Ward A told me of patients who arrive on the 
ward with resistance to all classes of available ARVs in the country.  
 
“For instance, he goes to the NGOs because he heard it is free there. In the 
meantime, he decides that over there doesn’t meet his needs, so he goes to 
another organization…As soon as he changes organizations, he doesn’t tell 
them ‘I’ve taken such and such a product.’ No. ‘It’s the first time I’m coming 
(for treatment).’…So, it came to a time, I think we had to do a resistance test, 
we found that he was resistant to every ARV available in Burkina here!” 
(Nurse, Ward A) 
 
It is not only gratuity of care in the NGO sector that poses problems; particular 
cohorts of patients within the hospital itself may receive ART free of charge for a 
limited amount of time under certain projects. One such programme – a research 
project - was coming to an end during my time at Site Two. About 80 patients had 
been receiving treatment for free for the past three years but as the project came to a 
close, they had to be integrated into the regular patient roster. This did not necessarily 
imply that they would now have to pay for their ART but they would have to learn 
the Social Services exemption process. This meant that the doctor and psychosocial 
counsellor in charge of these patients were required to carefully explain the procedure 
to each patient. One of the psychosocial workers interviewed believed offering ART 
at no cost for a certain period of time poses a serious problem.  
  
“It is such a serious problem because the outcome of the project is anything 
but (free)…It’s the same problem that we have in all the NGOs with the TAP 
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(Treatment Acceleration Programme) World Bank8 project…It’s the aftermath 
of TAP that poses problems. What can you do about it?” (Psychosocial 
worker, Ward A) 
 
Patients who are newly prescribed ART are required to go back to see the nurse on 
the ward to have the doses explained once they get their drugs from the pharmacy, as 
discussed in the section on “Adherence infrastructure”. This procedure can also be a 
way of ensuring at the ward level that the patient received the same medications that 
he was prescribed. I once witnessed one of the ATARAO interviewers catch such a 
mistake in Ward B. A woman had returned from the pharmacy with two different 
medication boxes, as prescribed. When the interviewer took the containers out of the 
boxes to explain the dosage to the patient, however, she realized they were the same. 
The interviewer then returned to the pharmacy with the woman to have the problem 
corrected. In this example the checks and balances of the adherence infrastructure 
worked efficiently. This procedure, however, is only used for the first prescription. At 
subsequent renewals the onus is on the patient to verify that the contents of his pill 
containers comply with his prescription, a considerable challenge given that the 
brands and, in turn, the appearance and number of pills often change.  
 
Summary 
The complexity of the ARV lifecycle in Burkina Faso – getting drugs from the 
pharmaceutical manufacturers to the patients – poses a challenge for both healthcare 
providers and patients. Deviations in this lifecycle – from inadequate needs 
assessments at the level of the hospital to availability of ARVs and their equivalents, 
and from payment exemptions to appropriate medications – pose a threat both to the 
provider’s ability to support patient adherence and the patient’s capacity to adhere 
                                                
8 During the same period, many NGOs were struggling with funding uncertainty. According to one 
NGO representative, this uncertainty was largely due to the approaching end of the World Bank-
funded Treatment Acceleration Program (TAP) which had financed the initiation of ART for many 
HIV patients. As a result, many NGOs stopped accepting new patients and began referring them to 
medical centres. Through conversations at the XVII International AIDS Conference with an employee 
of the SP/CNLS-IST in Ouagadougou, who works on the GFATM portfolio, and an employee of 
Sidaction in France, I learned that GFATM had agreed to cover the funding of TAP. NGOs were, 
therefore, beginning to accept new patients again.  
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successfully to his medication regimen. As illustrated, these factors extend far beyond 
the individual to the greater hospital, health sector, and international systems.  
 
External pressures: interventions with the best intentions  
The response to the HIV epidemic in Burkina Faso has been largely driven by 
external funding (see “Context” section). Interventions aimed to increase the 
availability of ART (ESTHER, HIPC, World Bank, GFATM), reinforce the 
capacities of the health structures to respond to the HIV epidemic (ESTHER), and 
conduct essential research (ATARAO) are well intentioned and ultimately seek to 
improve the lives of people living with HIV in the country. Nonetheless, these 
programmes often produce unintended phenomena: uncertainty with respect to 
funding and project longevity, increased workload for providers, and flooding of the 
system by HIV patients leading to a divergence of scarce resources away from non-
HIV patients.  
 
This section will highlight the potential impacts on the local context of an externally-
funded multi-country project through use of the ATARAO research project as an 
example.  
 
Achieving externally-defined objectives  
The main doctor responsible for HIV care in Ward B is the Burkina Faso principal 
investigator of the ATARAO project. One of the two project coordinators is also a 
nurse on the ward. Project activities officially began in March 2007. In practice, 
however, recruitment on the wards only started almost six months later, near the end 
of August 2007. The objective of the project was to recruit 400 patients newly 
initiated on ART over a one year-period at three sites in Ouagadougou. This implied 
recruiting over 100 patients at each site. The late start to recruitment significantly 
delayed the project in terms of recruitment objectives as the initial project deadlines 
were maintained.  
 
In an effort to recruit more patients to meet the project objective, the nurse 
coordinator did the rounds of HIV care NGOs where he had contacts and encouraged 
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them to refer their patients in need of treatment to Ward B9. This procedure was an 
initiative of the country team leaders and was not communicated to the Montreal 
team (I myself only became aware of it through interviews when the practice was 
mentioned by a doctor and an interviewer on the ward, as well as an individual on 
another ward who headed one of the NGOs). This active recruitment meant that Ward 
B quickly surpassed the other two sites in numbers of participants recruited, despite 
not being particularly specialized in HIV care.  
 
Ethnographer: “If ATARAO didn’t exist, there wouldn’t be such a large 
number of (HIV) patients here?” 
Interviewer: “No. Because, in fact, we would have limited ourselves to the 
cases requiring more advanced medical care or those who came with 
dermatological problems and who are then diagnosed with HIV. We would 
have been limited to those cases.” (Interviewer, Ward B) 
 
The patient normally arrives in Ward B with a referral sheet indicating his HIV status 
and type. The nurse then prescribes laboratory tests and asks the patient to return with 
the results. As mentioned in the section on “adherence infrastructure”, this procedure 
differs from that of Ward A where it is the doctor who prescribes the laboratory tests 
after meeting with the patient for the first time. One doctor I interviewed believed 
that this was done to speed up the prescribing process, although the head nurse 
maintained that the system had been in place since they began caring for HIV 
patients.  
 
“In this study (the nurses prescribe laboratory tests) to go faster, I think. I think.  
I don’t quite understand the whole study.” (Doctor, Ward B) 
 
ART is prescribed by the physician if the patient is determined to be eligible through 
clinical and laboratory assessment. The time between the patient’s first visit to Ward 
B until he leaves with an initial supply of ARVs can take as little as 72 hours. A 
                                                
9 See footnote on pages 93. 
  
95 
doctor and one of the nurses interviewed were extremely frustrated at the speed of 
this process and blamed it on the ATARAO research project.  
 
“I prefer to proceed more slowly. The first time I see a patient I do not want to 
be obliged to prescribe because I do not even know if he has already had a 
counselling session, if we have already told him what ARVs are, how long 
they last, what they do and all. I do not know what happens before and after 
the patient arrives in my office.” (Doctor, Ward B) 
 
Both of these interviewees also had strong reservations about the impact that 
precipitated prescribing had on adherence.  
 
“Well, now we don’t have the time to converse well with the patient. Because 
ARV treatment is not an emergency. So, time is really needed to converse with the 
patient, before he consents (to initiate treatment). As a result of wanting to 
include the highest number of patients (in the study) I question whether adherence 
will be good. That’s my worry.” (Nurse, Ward B) 
 
“If we are not sure the patient will take the medications all the time, we shouldn’t 
prescribe. We first have to be sure of this; if his social milieu will allow it. 
Intellectually, morally do we feel that the person is ready to do it? The first 
consultation does not allow us to know that. Even…when I prescribe, even if the 
nurse did the adherence counselling, I get the impression that it’s only once and 
there you go. He takes the prescription and the voucher and goes to get served at 
the pharmacy, the same day. I think we really have not taken the time to evaluate 
the adherence capacity of the patient. It’s my opinion. And the proof is that many 
come back to say things aren’t going well, they stopped because…Now there’s at 
least three or four. There was even one who came back right away.” (Doctor, 
Ward B)  
 
  
96 
This concern about adherence may have been compounded by the fact that an 
“adherence infrastructure” was not as developed here as it was in Ward A, as 
discussed in the section on adherence infrastructure. Furthermore, the objectives of 
the study had not been clearly communicated to all staff members on the ward, which 
fostered confusion and resentment.  
 
Coupled with the frustration of being pressured to prescribe was a general sense 
among those interviewed on Ward B that the project was greatly adding to their 
workload. This rapid flooding of the system by HIV patients was perceived by some 
as an infringement on the care of Ward B patients without HIV. Initially, a special 
consultation time was reserved on Friday afternoons for HIV patients without 
dermatological problems. It seems, however, that with the increased recruitment of 
HIV patients that they soon began to come most days aside from Wednesdays.  
 
“The way we manage the HIV patients is really in a manner such that we 
abuse the consultation days, the consultation hours for the regular 
patients…You take the appointment schedule and you see that there are 
maybe 15 patients registered for appointments. You go to consult and there 
are 30 patients…There are 15 registered, but 30 patients. And you know the 
other 15 who come are often HIV patients that we add to the roster.” 
(Medical intern, Ward B) 
 
 Ethnographer “So, in July (2007) was the recruitment as fast?” 
 Doctor: “No, not as fast.”  
 Ethnographer: “So now…” 
Doctor: “It’s since September. October even when there are some every day. 
Every day I include patients in the study. Before it was Friday afternoons. 
Now it’s every day, at each consultation.” (Doctor, Ward B) 
 
Though I had been advised not to involve myself too heavily with the ATARAO 
cohort project as I was there to carry out my own sub-study, distancing myself from it 
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was difficult, if not impossible in Ward B. Out of six interviews I conducted, five 
participants took the opportunity to voice their concerns about the ATARAO project. 
As a result, my impressions of the ward are ambiguous and challenging to reconcile – 
the research project grew to be so entwined with regular ward activities that it was 
problematic to distinguish the two. Furthermore, as the research situation deteriorated 
over the months that I was there, so did my morale. I often left Ward B feeling 
discouraged and exhausted at the state of affairs and my relative powerlessness to 
improve the situation, despite the unvoiced expectancies that I could read in the 
imploring eyes of the staff (and sometimes the patients).  
 
To be fair, ATARAO’s impact on the ward was not entirely negative. In fact, one of 
the main positive outcomes of the study was the increased psychosocial support of 
HIV patients provided by the two ATARAO interviewers, as discussed in the section 
on “psychosocial support”. Both interviewers were readily available to meet with 
patients who manifested a need to discuss their problems, even those who were not 
part of the study.  In a way, it seems as if the interviewers progressively filled the gap 
in psychosocial support in the ward and became their own version of the coveted 
mediators in Ward A.  
 
Summary  
Resources to respond to the HIV epidemic in LMIC are largely provided by national 
and international programmes – programmes that must themselves provide 
justification and results to the agencies that fund them. Continued financial support is 
frequently contingent on reaching objectives defined in terms of quantitative 
indicators. The obligation to reach pre-determined objectives is often translated into 
added pressure for those implementing projects on the field, as was seen in the case 
of the ATARAO research project.  
 
It must be noted, however, that this pressure to recruit was not felt at the two other 
study sites. In those sites, the research project remained peripheral to the ward’s main 
activities, as intended. In Ward B, the pressure seemed driven by the fact that the 
study co-investigator and one coordinator worked on the ward, compounded by the 
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fact that they did not have the appropriate “adherence infrastructure” in place to 
respond to the increased number of patients that the project drew to the ward and had 
not sufficiently engaged staff members in the research process.  
 
 
The evolving context of care  
 
As the HIV epidemic continues to evolve throughout Burkina Faso, so too does the 
industry of care surrounding it. Only a few short years ago, ART in the country was 
only available in private health centres at costs prohibitive even for the well-off, or 
through drug donations from western friends (see “Context” section). Today, access 
to ART and an associated continuum of care continues to expand throughout Burkina 
Faso. Despite the shortcomings discussed in the previous sections, the magnitude of 
such improvements was not lost on the providers; most of whom had seen the HIV 
care situation evolve from palliative to therapeutic.  
 
This final section of results will illustrate the evolving context of HIV care with a 
concrete example: the implementation of the Day Hospital at the Site Two as an 
outpatient centre for HIV patients.  
 
New and improved physical infrastructure 
The transfer of outpatient HIV services to the Day Hospital greatly facilitated the 
patient circuit of care by centralizing most services in one location, as mentioned in 
the section on adherence infrastructure.  The new building also provided much-
needed workspace for the staff. Despite the insufficient number of health providers at 
Site Two, the workspaces available to them were formerly inadequate and often cited 
as a major problem in both Ward A and Ward B. Positive reactions by the staff at the 
new building were unanimous among those I spoke with. 
 
“Ah! Really, the new building, we are comfortable. The place is big, we do as 
we please. So, in any case, it’s good.” (Mediator, Ward A)  
 
  
99 
“There have been lots of changes. First, we are in brand new offices…It’s a 
pleasant environment. Much more adapted. Not only for the personnel, but 
especially for the patients because when they come there is a waiting room, 
it’s a nice building.” (Nurse, Ward A)  
 
The Day Hospital also includes two waiting areas for patients – a luxury as compared 
to the tight, standing-only corridors of the “other side”, as people began to refer to the 
third floor wing of Ward A. Within days of the move, I noticed a distinct change in 
socializing behaviour among patients sitting in the waiting room, an observation that 
was not lost on one mediator.   
 
Mediator: “I noticed. In any case, I noticed.” 
Ethnographer: “It does them good; they are no longer all squeezed into the 
hallway!  
Mediator: “On the other side space was tight. They are there; we also need to 
get through. They are turning around, around to see how they can manage to 
move between themselves. In any case, yesterday in the garden they were 
paired up, talking. Each one was explaining how they experienced the 
illness.” 
Ethnographer: “They were talking about their illness?” 
Mediator: “Yes! They were talking about their illness. They talked about how 
it’s been since they found out they had HIV. Others talked about the day they 
did the test and it turned out positive. There was one beside me who said, 
‘really, my main concern now is that I want a child’. The other one said ‘no, 
you already have one, you must be patient.’ They were giving each other 
ideas. I was sitting beside them listening (laughs).” (Mediator, Ward A) 
 
Resistance to change  
Not everyone is pleased with the Day Hospital, however. Patients from an ambulatory 
care centre were infuriated by the news that they would have to transfer there to 
continue receiving treatment. A petition was submitted to the Ministry of Health, to 
no avail. Funding for their centre had run dry and was forced to close. The patients – 
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approximately 3000 of them – and some staff, were to be transferred to the Day 
Hospital at the beginning of 2008. As of December 2007 staff at the Day Hospital 
was not quite sure of the logistics of the transfer.   
 
“The (Chief of Internal Medicine) told us that when we moved here we would 
have lots of duties, more duties to take care of…Here, we don’t know how we 
will do it, because there is a project, a team who will come from the other side 
(Ambulatory Care Centre). When they come, we will know how we’ll organize 
it. For now, we don’t know. But it’s in January.” (Mediator, Ward A)  
 
Enhanced organization of care  
Once the staff had settled into the new building, several changes were made to the 
organization of care. The mediators developed a new system of overseeing patient 
appointments at the behest of the Chief of Internal Medicine: each day one mediator 
is assigned to a doctor. She is then responsible for that doctor’s patients for the day. A 
schedule is posted on the door of the filing room. The mediators also created 
numbered tickets out of card stock for each doctor. When a patient arrives for an 
appointment, he is given a number with the doctor’s name on it. This way the 
mediators only have to call out numbers to keep track of patient order. One of the 
mediators began going through the wooden box of blue patient monitoring in an 
effort to make the adherence monitoring system more efficient.  
 
There was one change the mediators were concerned about: they will be required to 
work full day shifts due to an increase in the number of consulting hours (formerly 
they only worked mornings). Prior to my departure, they were discussing ways of 
organizing their new schedule amongst themselves and planned to meet with the 
Chief of Internal Medicine to reach a solution.  
 
There were also changes to the nurses’ duties. One nurse was completely detached 
from regular nursing duties related to the hospitalized patients. In 2008, he was to 
become the Coordinator of Therapeutic Education and had registered for an online 
degree on the subject. His role will be to oversee all those involved in patient 
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adherence (aside from the doctors); that is nurses, psychosocial counsellors and 
mediators.  His vision is to better integrate therapeutic education into the ward’s 
activities to improve adherence.  
 
“Well, therapeutic education is very broad. It takes into account the patient 
information, learning about health problems, treatments…well, it’s a set of 
activities. Everyone involved in patient care (will be involved). So, once 
everyone is trained in therapeutic education, I think that with the personnel 
that we have, we’ll be able to follow all the patients.” (Nurse, Ward A)  
 
Room to grow  
One of my last interviews was with a senior doctor of Ward A. Like his colleagues, 
he seemed generally content with the care of HIV patients on the ward. According to 
him the Day Hospital offers the advantages of more space and day hospitalisations, 
but care will continue much as before.  
 
When questioned about whether he thinks it is necessary to add more activities to 
enhance patient adherence to ART he responded that they are limited only by 
available funds. “If we have (grants), we will add (activities)”.  For him, what is 
important is to build a solid foundation of care provision.  
 
“We need a base to take root. If we are well-rooted we will be able to evolve 
correctly. We can add activities. We can get rid of other activities that are less 
efficient.” (Doctor, Ward A)  
 
Summary 
The context of care for HIV patients continues to evolve in Burkina Faso, despite the 
above-mentioned systemic adherence inhibitors. Improvements in physical 
infrastructure, service organization, and service availability affect not only the quality 
of care that patients receive, but health worker satisfaction and motivation. Though 
they were largely pleased with these improvements, the providers nonetheless, 
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recognize that there is still room for improvement; improvement that is largely 
contingent on the availability of external financial support.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER SEVEN: DISCUSSION 
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OVERVIEW 
 
The findings discussed in the above section suggest three main conclusions that can 
be drawn from the provider’s perspective on the provision of adherence support to 
patients on ART. First, organization is important in the delivery of adherence support 
services. Second, providing ART within a comprehensive package of care is an 
essential part of adherence support. Third, there is a need for better coordination of 
nationally and internationally-led HIV programming in order for coherent service 
provision at the site of ART distribution.  
 
These three broad conclusions are elaborated upon in this section, supported by both 
the results of the present study and previously published findings.  
 
 
Conclusion One: The importance of organization in the 
delivery of adherence support 
 
ART scale-up must be carried out within a functional infrastructure in order to be 
sustainable. This warning, voiced by Harries (2001) in the initial years of the 
expansion of treatment availability across sub-Saharan Africa, is as pertinent today as 
it was then.  
 
The results of this study indicate that ART distribution sites need to invest in some 
form of “adherence infrastructure” in order to effectively support patients on 
treatment. The organization of adherence support is essential both in terms of 
logistics and materiality. Furthermore, this infrastructure must extend beyond the 
level of the ward and permeate the level of the health sector where policies are often 
more deterministic of ensuing realities on the field, rather than vice-versa.  
 
Logistics of adherence infrastructure 
Adherence support was one of the main tasks of most providers interviewed and all 
were aware of its importance in ensuring positive treatment outcomes. Each of the 
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three wards had developed a particular adherence infrastructure. Site One offered 
family-oriented HIV care in a community medical setting. Site Two, on the hand, 
disposed of a more elaborate infrastructure, reflecting its status as a national hospital 
centre with a high patient volume. Comparisons between Ward A and Ward B at Site 
Two reflected the difference between a site experienced in care for a high volume of 
HIV patients and one unaccustomed to a sudden influx of HIV patients.  
 
The organization of adherence infrastructure must take into account available 
resources on the ward. Site One, for instance, developed a close relationship with an 
NGO in order to fill the deficit in psychosocial resources at their centre. Ward A took 
advantage of additional human resources (lay counsellors) to respond to the 
psychosocial needs of patients. Ward B, on the other hand, lacked the necessary 
human resources to provide comprehensive care to their patients. As a result, they 
developed a highly dependent (and unsustainable, given the project’s limited 
duration) relationship with the research interviewers who came to play a significant 
role in patient adherence counselling.  
 
In the context of Ward B, a different model of adherence infrastructure than Ward A 
would perhaps be more appropriate, given human resource constraints. For instance, 
group adherence counselling has been used elsewhere in Africa with some success 
(Tu, Kos, Culbert, Migabo, & Amisi, 2004). A group approach to adherence is 
common in the NGO sector in Burkina Faso, often referred to as “clubs 
d’observance” (adherence clubs). In Mali, where the other half of the ATARAO 
project is carried out, patients receive group adherence counselling prior to treatment 
initiation at certain centres (M.Sicotte, personal communication, July 21, 2008). The 
findings from this study indicate that adherence infrastructure is not a “cut-and-paste” 
concept and should be tailored to the particular needs of each ART distribution site.  
 
Though the adherence infrastructures of the three settings varied in scope and 
available resources, they nonetheless shared certain similarities: uniform prescribing 
criteria (consistent with national and WHO guidelines), an individual-based 
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counselling approach, and patient monitoring cards (except in Ward B). All three 
sites attempted to address patient-related factors of adherence by adapting adherence 
advice to the individual’s condition (e.g. recall strategies for those who could not 
read, referral to NGOs). This patient-focused approach is consistent with WHO 
recommendations on adherence to long-term therapies through improving the 
efficacy of interventions targeting patient-related factors: “Patients need to be 
informed, motivated and skilled in the use of cognitive and behavioural self-
regulation strategies if they are to cope effectively with the treatment-related 
demands imposed by their illness” (WHO, 2003a).  
 
The three wards rely on providers to actively seek out adherence problems among 
patients and to formulate recommendations based on individual needs. This strategy 
is emphasized in the national guidelines of care for HIV patients (Groupe d'Experts 
Burkinabè, 2003). It is also reflected in Burkina Faso’s 2006-2010 Strategic 
Framework on HIV/AIDS. Under the second main objective of strengthening access 
to medical and community care for people living with HIV, “organization of 
adherence to treatment support” is listed as one of ten priority areas and is described 
as follows:  
 
“Respect of the medical prescription and of the therapeutic plan by the patient 
is the principal indicator of treatment success…The actions of health system 
actors and community actors should be reinforced and improved for a better 
follow-up of patients. This  will consist in particular of strengthening the 
capacities of actors, of promoting positive experiences in relation to adherence 
to treatment, as well as new practices in health structures.” (Secretariat 
Permanent CNLS-IST, 2005) 
 
This strategy places the onus for adherence support on individual capacities – both 
patient and provider – and overlooks more systemic issues such as the availability of 
resources and the socioeconomic context. Furthermore, the impact of such a strategy 
on the work condition of the provider must be considered. Several providers 
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interviewed bemoaned the fact that the current patient volume does not allow them to 
spend an adequate amount of time counselling each patient on adherence. Lehman 
and Zulu (2005) have reported low morale and frustration among nurses in South 
Africa trying to deal with a rise in the number of HIV patients. Given the already 
critical shortage of health professionals in Sub-Saharan Africa, it is important to take 
into account the impact of health services organization on the working conditions of 
staff so as not to increase the possibility of burnout or migration from the workforce 
(Industrial Health Research Group and the South African Municipal Workers Union, 
2005).  
 
The importance of material infrastructure  
Material resources played an important role in detecting adherence problems among 
patients and, as a result, acting to address these problems. Site One and Ward A both 
used the blue patient monitoring cards to ascertain whether patients were seeking care 
and renewing their supply of ARVs in a timely manner. Patient rosters at the level of 
the wards and the pharmacy were also used to identify patients who were either late 
for appointments or lost to follow-up. Prescriptions from the previous month’s ARV 
renewal were another method employed at Site Two to detect timeliness. There was a 
clear difference in patient monitoring at Site Two between Ward A, where a variety 
of material monitoring tools were used, and Ward B, where only patient prescriptions 
and, presumably (though I never witnessed this) the pharmacy roster were used.  
 
A prime example of the impact of material infrastructure in supporting patient 
adherence is the opening of the Day Hospital at Site Two. As discussed previously, 
the patient circuit was greatly facilitated in Ward A following the transfer of 
outpatient services to the Day Hospital. Furthermore, the new physical infrastructure 
had a visible positive effect on the morale of the health providers – a finding that has 
been previously reported elsewhere (Mathauer & Imhoff, 2006). Comfortably 
installed in their new quarters, the health providers undertook plans to strengthen the 
adherence infrastructure: overhauling the monitoring card system, developing a new 
method of organizing patient appointments, and making plans for a revamped 
“therapeutic education” procedure.  
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In settings of limited resources, the success of health interventions is largely 
dependent on health workers, as discussed in previous sections (A. K. Rowe, et al., 
2005). The effects of enhancement of organizational infrastructure – both logistical 
and material - on the morale of health providers should not be undervalued. Such 
improvements may ultimately contribute to the provision of higher quality services to 
HIV patients, as well as to worker retention (McCarthy, O'Brien, & Rodriguez, 
2006). 
 
Adherence infrastructure beyond the ward 
ART distribution programmes are complex endeavours requiring concerted action at 
various levels, from the site of distribution, through the health system, to higher 
national and international policy levels. Factors inherent to the health system have 
been found to have an impact on the adherence capacity of patients to long-term 
therapies (WHO, 2003a), though little research has been done on this subject in the 
context of ART. The need for a commitment at all levels to ensure that systemic 
determinants facilitate, rather than impede, patient adherence is cogently illustrated in 
this study by the discussion on the ARV lifecycle.  
 
The findings of the present study illustrate that the provision of a continuous supply 
of ART to HIV patients – a fundamental prerequisite in ensuring adherence to 
treatment - is a complex process. The convoluted nature of ART distribution in an 
African setting has been discussed elsewhere (Reynolds Whyte, et al., 2006). In 
Burkina Faso, efforts have been made to regularize the supply of ART in the country 
with the implementation of the CAMEG. Access to ART has markedly improved 
since the publication of a historical perspective of the situation by Nguyen and 
colleagues (2003) in which difficult decisions had to be made by health providers as 
to which individuals should access limited quantities of antiretroviral drugs.  
 
This study found that patients in Burkina Faso continue to negotiate a logistical maze 
in order to access their monthly supply of treatment. The patient pathway at Site Two 
is particularly ridden with complexity; requiring individuals to visit doctors, nurses, 
the social services, and the pharmacist (with varying waiting periods at each stop 
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along the way) before finally leaving the hospital with a plastic bag of drugs. Some 
patients, discouraged by cost and bureaucracy, procure themselves of treatment at 
NGOs when possible, rendering continuity of care ever more precarious.  
 
The procurement process described by the pharmacists is a logistical obstacle course, 
requiring providers to predict treatment needs on each ward, to update the hospital 
patient roster, to communicate needs to the CMLS, to obtain approval by the CMLS 
(who ensures that demands are consistent with national resources), and finally to 
procure the drugs at the CAMEG where the brands ordered may not be the ones 
available. This complex procedure is not particular to Site Two, having been 
developed at the national level (Sanou, 2008). In fact, complexity is a theme 
consistent throughout Burkina Faso’s response to HIV/AIDS.    
 
Nonetheless, the pharmacist and assistant pharmacist interviewed maintained that 
there had been no breaks in supply since they began working there two years ago. 
This finding is consistent with evidence reported in a recent WHO update on ART 
scale-up where the majority of 66 LMIC surveyed reported no disruptions in ARV 
stocks (WHO, 2008b). As scale-up is a relatively new process in most African 
countries it will be essential to monitor the procurement procedure over the coming 
year to ensure its sustainability. This issue will become more pertinent as the current 
round of GFATM nears its end (Wyss & Wiess, 2005).  
 
Summary 
In order for health professionals to provide adherence support for patients on ART, 
investments must be made at various levels into ensuring that certain facilitating 
conditions exist. At the ward level, the organization of adherence services needs to 
take into account existing resources and health provider capacities. Furthermore, the 
physical organization is an often-overlooked factor that has been found to affect both 
the morale of health providers and service provision. This study suggests that 
physical infrastructure should be arranged, if possible, in such a way that responds to 
provider space needs and facilitates the patient pathway. At the health system level, 
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measures need to be taken that recognize the role of systemic determinants of 
adherence such as ARV procurement policies and financing mechanism, among 
others. Finally, advocacy at the international level must continue in an effort to 
facilitate acquisition of generic ARVs for LMIC and reduce the surrounding 
bureaucracy of the procurement process. Castro (2005) has pressed for more studies 
that assess the effects of such systemic determinants on patient adherence to ART.  
 
 
Conclusion Two: The provision of ART within a 
comprehensive package of care is essential to effective 
adherence support 
 
The strengthening of health systems has often been cited in the literature as a 
prerequisite to the scaling up of ART (Buvé, et al., 2003) and much advocacy exists 
to ensure that ART distribution programmes adopt a horizontal approach to the 
implementation of expanded treatment access (Chopra, 2005; EQUINET, 2004). 
Such an approach has the dual benefit of improving health service provision for the 
entire population as well as ensuring that HIV patients receive a comprehensive care 
package. As mentioned in previous sections, a comprehensive package of care is 
crucial to effectively responding to the HIV epidemic (Harries, 2002). This involves 
equipping providers with tools to assist them in their clinical practice (laboratory 
monitoring, treatment for opportunistic infections, and additional staff) as well as 
mechanisms for them to help patients negotiate the trials of daily life (gratuity of 
care, literacy support, psychosocial support).  The delivery of these services is, of 
course, dependent on effective management and administrative systems (McCoy, et 
al., 2008).  
 
The findings of this study support the perspective that expanding access to ART must 
involve more than just the provision of HIV drugs by demonstrating that some of the 
main challenges faced by providers were not ARVs themselves but a lack of 
peripheral adherence supports in the health system, such as laboratory tests, 
medications for opportunistic infections, psychosocial services for patients and staff.  
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The national guidelines for the care of HIV patients in Burkina Faso recognize the 
need for certain pre-existing conditions in order for ART to be successful, including: 
trained and competent prescribers, the availability of complementary laboratory tests, 
authorized treatment centres, a continuous supply of antiretroviral drugs, patient 
adherence, and optimal conditions for patient adherence (Groupe d'Experts 
Burkinabè, 2003). The findings of this study, however, imply either a gap in 
implementation, a lack of resources, or both.  
 
Tools to Assist Clinical Practice  
The providers interviewed in the present study face a number of difficulties in their 
clinical practice related to a lack of resources, not least of which is a shortage of 
health professionals themselves to assist in the follow-up of HIV patients. The 
following section relates these findings to the current literature, reinforcing the 
perspective that peripheral supports in the health system play an essential role in the 
delivery of a comprehensive package of HIV care.  
 
Laboratory monitoring  
There is a debate in the academic literature on the need to provide laboratory 
monitoring for patients on ART in settings of limited resources, such as CD4 and 
viral load testing, in order to better inform clinical decision-making. The current state 
of laboratory capacities in Sub-Saharan Africa requires considerable investments in 
both material and human resources to improve services (Petti, Polage, Quinn, Ronald, 
& Sande, 2006). A computer simulation modelling study suggested that CD4 and 
viral load monitoring were only marginally more successful in predicting patient 
survival than clinical observation alone (Phillips, et al., 2008). The authors concluded 
that these techniques were not cost-effective in resource-limited settings where 
emphasis on expanding access to ART should continue to be the priority of funding. 
In a comment to the editor that appeared in the same journal issue as the above study, 
Moore and Mermin responded favourably to these findings, adding that it is unclear 
that better monitoring would translate into improved clinical outcomes (Moore & 
Mermin, 2008). Others have also argued that costly laboratory monitoring should 
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gradually be improved over time but should not divert resources away from the more 
important goal of making treatment available to a greater number of individuals 
(Koenig, et al., 2006).  
 
On the other side of the debate, researchers advocate that improved laboratory 
capacity can translate into better diagnoses and monitoring, leading to improved 
clinical outcomes (Bates & Maitland, 2006; Petti, et al., 2006). Although the WHO 
encourages prescribing ART on the basis of clinical indicators when CD4 count tests 
are unavailable, it states “wider availability of appropriate and affordable CD4 testing 
and plasma viral load testing should be advocated in order to guide decision-making 
on when to switch ART regimens in resource-limited settings” (WHO, 2006a). 
Results from Mali and Burkina Faso from the Pro-ARV group support the 
implementation of more widespread availability of viral load monitoring for HIV 
patients (Pirkle et al., 2009). It has also been recommended that drug resistance be 
monitored at the population level in all ART programmes (Harries, et al., 2001). In a 
study of 97 treatment naïve individuals in Burkina Faso, 8% were found to have 
mutations associated with drug resistance (Vergne, et al., 2006). Similar findings 
were also reported in Mali by the ATARAO group (C. Tremblay, personal 
communication, June 11, 2008).  
 
These findings, combined with those of the present study, suggest that effective 
laboratory monitoring for patients on ART is an integral component of a 
comprehensive package of HIV care. Investments in laboratory capacity can 
contribute to more informed decision-making by healthcare providers about treatment 
options for their patients, ultimately favouring better clinical outcomes.  
 
Medication for opportunistic infections  
Several providers, namely the pharmacists and doctors, cited lack of an appropriate, 
inexpensive and continuous supply of medications to treat opportunistic infections as 
a difficulty. Interview data implied that this problem extended beyond the hospital 
system to the national health sector and was also sometimes contingent on 
international donations. Treatment of opportunistic infection is yet another 
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component considered to be part of the continuum of care required for the holistic 
treatment of patients with HIV (Harries, 2002).   
 
Improving the availability of such medications is listed as one of the secondary 
objectives in the 2006-2010 National Strategic Framework to Fight HIV/AIDS and 
STIs (Secretariat Permanent CNLS-IST, 2005) and is listed under the second main 
objective of Burkina Faso’s proposal to the sixth round of the GFATM (SP/CNLS-
IST, 2006).  
 
“The efforts already underway for acquiring and making available 
medications to fight opportunistic infections in health centres and care 
associations should continue.” (Secretariat Permanent CNLS-IST, 2005) 
 
It remains to be seen, however, how this conceptual objective will translate into 
practice. Close monitoring of national implementation of the objective is necessary to 
ensure increased availability and affordability of medications for opportunistic 
infections at the level of the hospital.  
 
Human Resources  
Human resources are recognized as a critical factor in the implementation of ART 
programmes (and all health programmes for that matter) (UNAIDS & PEPFAR, 
2007). This study found that health professionals were generally pleased with the 
quality of care provided to HIV patients (aside from in Ward B). Furthermore, almost 
all providers interviewed across the three sites reported significant satisfaction in 
caring for HIV patients. Similar results were described in a South African study 
where ART roll-out had inspired and motivated staff to provide comprehensive care 
to their patients (Stein, Lewin, & Fairall, 2007).  
 
The findings of this study nonetheless indicate that the existing basin of human 
resources at the three sites studied is inadequate to respond to the needs of a growing 
number of HIV patients on ART. This echoes a study in four Southern African 
countries that found lack of human resources to be the single greatest constraint to 
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treatment scale-up (Kober & Van Damme, 2004a). The fact that the providers at Site 
Two considered there to be an insufficient number of staff to deal with the patient 
load is particularly worrisome given that this institution benefits from the highest 
concentration of health workers in the country by far (Ministère de la santé du 
Burkina Faso, 2005a). This finding reinforces the recommendation Bodart et al. 
(2001) made several years ago that human resources for health be considered a 
priority issue in health reforms in Burkina Faso.  
 
A frequent response to the issue of human resources has been to implement various 
training activities (Chopra, 2005). Indeed, it was observed in this study that most 
providers in contact with HIV patients had participated in a variety of training 
opportunities. The country also benefits from a regional HIV care training 
programme (DIU) run by the Chief of Internal Medicine at Site Two through which 
several providers in Ward A had already been trained. It has also been reported that 
staff training in the context of ART roll-out has contributed to improved morale by 
providing workers with new skills and professional opportunities (McCarthy, et al., 
2006). There is limited evidence, however, on how such training initiatives impact 
clinical outcomes for patients (McCarthy, et al., 2006). Furthermore, training 
activities should not replace the strengthening of supportive supervision and feedback 
procedures in the workplace (Chopra, 2005).  
 
Another response to the lack of human resources for health in LMIC has been to 
delegate certain tasks to personnel who are less highly trained. This approach, 
referred to as “taskshifting” has been advocated by UNAIDS, PEPFAR and others as 
a way of “strengthening and expanding the health workforce to rapidly increase 
access to HIV and other health services” (UNAIDS & PEPFAR, 2007). The strategy 
involves shifting duties traditionally undertaken by highly qualified health workers to 
less qualified personnel who are more easily and rapidly trained and has been found 
to be effective in a number of LMIC contexts (Ivers, 2008; Kamoto, 2008). 
Taskshifting was observed at Site Two where nurses were assigned prescription 
renewal duties and lay counsellors (mediators) played a significant role in providing 
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psychosocial support to patients. Providers believed that the hiring of lay counsellors 
could improve the quality of psychosocial care offered to patients. This finding is 
pertinent as it indicates acceptability of a relatively inexpensive taskshifting approach 
by providers.   
 
Concern has been raised, however, about the assurance of quality of care when 
employing a taskshifting approach (Philips, Zachariah, & Venis, 2008). Taskshifting 
implies increased supervision requirements to monitor the actions of providers 
carrying out tasks that were formerly not part of their work description. It has 
therefore been suggested that taskshifting “must be part of an overall strategy that 
includes measures to increase, retain, and sustain health staff” (Philips, et al., 2008).  
 
The findings of the present study indicate that considerable investments need to be 
made in the area of human resources in the burkinbè health sector. Despite the 
adoption of a taskshifting approach, healthcare providers are still struggling to meet 
the needs of an ever-increasing number of HIV patients. Training and taskshifting 
alone will not solve this deficit. These strategies must be a part of a larger, national 
level human resources for health strategy.  
 
Mechanisms to help patients negotiate daily life 
It has been suggested that while health systems cannot be expected to completely 
remove the barriers of adherence posed by the greater socioeconomic and political 
context, mechanisms may be developed to moderate these effects (Travis, et al., 
2004). Chopra suggests that the current predominantly biomedical approach to the 
HIV epidemic through ART scale-up may ignore “political, social, and economic 
determinants of poverty and the AIDS pandemic” (Chopra, 2005).  
  
Social factors were considered by providers to have a profound impact on both their 
ability to adequately care for patients and the patient’s capacity to adhere. This 
finding diverts from a previous study on systemic determinants of adherence among 
patients in Bolivia in which the providers were not sensitive to such issues (Greene, 
2004). A review of the contextual relationships of adherence included the following 
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remark: “Individuals cannot be separated from their social context, which is a 
powerful influence on their lives” (Goudge, et al., 2004). This passage aptly 
summarizes the findings of the present study.   
 
Gratuity of Care  
The impoverished socioeconomic status of patients was one of the main difficulties 
faced by providers in carrying out their work. Similar findings were reported from a 
study of health providers involved in ART distribution in South Africa (Stein, et al., 
2007). Poverty was also considered by providers to be the main socioeconomic 
barrier to adherence. Comparable results were found in a quantitative investigation of 
patients and their health providers in Bostwana (Weiser, et al., 2003). The researchers 
predicted that adherence levels would increase from 54% to 74% if cost was removed 
as a barrier.  
 
Castro maintains that the majority of studies conducted in poor contexts do not take 
into account direct and indirect financial impacts on households of ART (e.g 
transport and medical exams). “Although these costs may seem minimal to health 
professionals and decision makers, bearing these costs often translates into difficult 
household decisions about who eats, who works, or who goes to school” (Castro, 
2005).  The opportunity costs of buying ART for impoverished Ugandan families was 
described as follows:  
 
“The long-term commitment of buying ARVs is difficult for individuals and 
families to maintain in situations where needs are so abundant. The medical 
consequences of these family dilemmas are nonadherence to treatment 
regimens and the possibility of ‘antiretroviral anarchy’ with dangers of 
developing resistance that experts fear” (Reynolds Whyte, et al., 2006).   
 
Food security has been found to be particularly problematic for HIV patients 
(Bukusuba, Kikafunda, & Whitehead, 2007). A study in Accra, Ghana, found the cost 
of food to be a financial barrier in ensuring adequate nutrition among a sample of 50 
HIV patients (Wiig & Smith, 2007). The vulnerability of HIV patients may be 
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attributed to both the high cost of accessing HIV medical care and decreased 
economic productivity, resulting in less disposable income to purchase food 
(Bukusuba, et al., 2007). Food security is a particularly worrisome issue in Burkina 
Faso where in 2008 mass public demonstrations were staged to protest the rising 
costs of basic necessities (see “Context” section).  
 
Papers presented at a symposium in Burkina Faso on “Access to Antiretroviral 
Therapy: Lessons Learned” (24-25 June 2008, Ouagadougou) discussed significant 
financial barriers to accessing ART for patients. Despite the fact that at some sites of 
HIV care 80% of patients receive exemptions for monthly treatment payments, 64% 
of patients claimed that costs related to treatment were problematic for them 
(Bocoum Yaya, 2008). These included complaints of high costs related to nutrition 
(90.7%), medications to treat opportunistic infections (84.7%) and transport (74.5%). 
These findings were also supported by a qualitative study (Bila, 2008). 
 
Interestingly, in the national guidelines on care of HIV patients, non-adherence due to 
cost barriers is listed as an acceptable reason to alter treatment regimens, though this 
point is not elaborated upon further (Groupe d'Experts Burkinabè, 2003). Free HIV 
(including testing, laboratory monitoring, and associated drugs) care has been 
advocated as being an essential factor in achieving universal sustainable access to 
ART (Souteyrand, Collard, Moatti, Grubb, & Guerma, 2008; Whiteside & Lee, 
2005).  
 
Several providers in the present study recommended gratuity of care as an essential 
factor in supporting patient adherence to ART. The above-mentioned symposium of 
politicians, researchers, community experts, and health providers recently debated the 
necessity of providing ART free of charge in Burkina Faso (Livre des résumés, 
2008). Though there is strong advocacy for gratuity of HIV care that is supported by 
local research results, resistance persists at the political level to implement the policy 
(V. Ridde, personal communication, June 2008).  It must be recalled that public 
health services are dispensed on a cost-recovery basis in Burkina Faso and that user-
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fees have been found to act as a significant barrier to access for poorer households 
across all categories of patients (Nougtara, et al., 2008). As such, it can be expected 
that granting gratuity of care for HIV patients will have wide-ranging policy 
repercussions across the health sector. Nonetheless, the findings of the present study 
and those mentioned above consider it an essential step toward achieving both equity 
in access to ART and positive, sustainable treatment outcomes.  
 
Literacy Support  
Illiteracy was considered by several providers to act as barrier to adherence for 
patients. Some also reported that it added difficulty to their task of adherence support 
as they spent more time explaining dosage procedures to these patients. Previous 
studies in the United States have found that low levels of education and literacy were 
associated with lower levels of adherence (Kalichman, Ramachandran, & Catz, 
1999).  
 
Providers in the present study dealt with this challenge by helping patients to develop 
innovative medication recall strategies, such as listening to the radio and abiding by 
Muslim prayer times. In a context of such endemic illiteracy, such as in Burkina 
Faso, it may not be feasible to implement large-scale literacy interventions in the 
health care setting. A more realistic option, perhaps, is to develop time-efficient 
interventions designed specially to assist illiterate patients to adhere to ART. 
Diagrammatic representations, for instance, may be useful for such a population.  
 
Psychosocial Support 
Several providers reported that social issues were the root cause of adherence 
problems among patients and presented a significant challenge to their work. For 
instance, widespread stigma of HIV in burkinabè society affects how services for 
HIV patients are organized (e.g. monitoring cards, pharmacy) and can impede 
providers from carrying out certain tasks (e.g. home visits). Fear of stigma, 
discrimination, and abuse also prevented many patients from disclosing their HIV 
status to their sexual partners – a challenge to providers both in terms of care and 
prevention.  
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The deleterious effects of stigma and discrimination of HIV in Africa have often been 
discussed in the literature (Rankin, Brennan, Schell, Laviwa, & Rankin, 2006). Rowe 
et al. (2005) reported fear of stigmatization as one of the barriers to adherence to 
tuberculosis preventive therapy for HIV patients in South Africa (K. A. Rowe, et al., 
2005). A study of HIV providers in South Africa likewise found that stigma and 
disclosure were particularly challenging issues and time-consuming to address in 
clinical practice (Stein, et al., 2007).  
 
The providers interviewed in the present study expressed concern about their inability 
to spend adequate amounts of time responding to the psychosocial needs of patients. 
This finding supports a previous study that reported psychosocial demands of clients 
to be the greatest challenge to healthcare providers (Stein, et al., 2007). The national 
HIV care guidelines of Burkina Faso stipulate that nurses and midwives should be 
attentive to all needs of patients.  
 
“The global care of people living with HIV is complex and may require 
multidisciplinary interventions. The care provided should be holistic (global)” 
(Groupe d'Experts Burkinabè, 2003) 
 
The adherence activities reported in this study are highly dependent on the ability of 
the nurse/midwife to spend appropriate amounts of time with each patient, identifying 
difficulties and solution strategies adapted to the patient’s individual condition. Given 
the high patient volume and lack of personnel identified in this study, effective 
implementation of this approach may not be realistic.  The providers interviewed 
recommended that further psychosocial services were required to help patients deal 
with stigma, disclose their HIV status to their families and sexual partners, as well as 
address other social problems. Several participants suggested working in closer 
collaboration with the NGO sector. This recommendation was recently put forward 
by a leading HIV researcher in Burkina Faso who recommended formalizing the 
complementarity between the NGO sector and medical centres so that patients may 
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benefit from more comprehensive care, ranging from medical to community services 
(Kouanda, 2008).  
 
Summary  
The majority of the population struggles to meet daily needs in the impoverished 
socioeconomic context of Burkina Faso. Findings from this study and others support 
the idea that HIV patients are a particularly vulnerable group as financial and social 
barriers compromise access to comprehensive HIV care, including adherence support. 
In order to support patient adherence to ART, providers must be equipped with tools 
to effectively carry out their tasks and to help patients negotiate the greater 
socioeconomic context in which they live.  
 
It is recognized that a comprehensive care package contributes to greater probability 
of treatment success.  
 
“The availability of a system through which patients who miss clinic visits can 
be promptly identified, an organized patient medical record that includes a 
description of a patient’s clinical as well as psychosocial status, and 
mechanisms for tracking patients in the community are all components of an 
effective HIV care programme” (El-Sadr & Abrams, 2007).  
 
Such a system is more compatible with an integrated (horizontal) implementation 
approach. Not only does this approach have the capacity to strengthen health services 
for all patients, but also it avoids scarce health providers being diverted toward 
specialized HIV care. Though integrated HIV care tends to be more complex to 
implement initially and may not yield immediate results, findings from the present 
study indicate that it may be more sustainable and apt to providing appropriate 
conditions to supporting patient adherence to ART.  
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Conclusion Three: The need for improved coordination of 
nationally and internationally-led programming for coherent 
service provision at the local level 
 
Unprecedented amounts of money from national and international donors have been 
invested to render life-saving ART more accessible to individuals across Sub-Saharan 
Africa (WHO, 2008b). Despite the positive implications of these commitments, 
nationally and internationally-led interventions have their setbacks. A limited amount 
of funding over short time periods means that HIV programmes are often 
implemented in a vertical, patchwork manner within existing health and HIV 
services, as was observed in this study.  As a result, ART programmes are plagued by 
uncertainty, limiting the ability to make long-term plans in service provision. This 
issue was highlighted particularly well in the present study on three occasions: first, 
the long-term availability of material and human resources on the wards; second, the 
patchwork exemption process for indigent patients; and third, the impact of an 
external project on working conditions and service provision.  
 
Long-term uncertainty 
Uncertainty about the long-term availability of resources was a common thread in 
several interviews. For instance, most, if not all, providers seemed aware that current 
funding for ARVs had been made available through international donors for a limited 
time-span. When questioned about what would happen when the funding period 
expired, none had an answer. This concern has also been voiced in academic journals 
(Wyss & Wiess, 2005). The pharmacists at Site Two attributed supply breaks in 
medications for opportunistic infections to irregular donations by international 
partners. Ward A benefited from both mediators and psychosocial workers through an 
international partnership and a research project, respectively. Though it was widely 
recognized that the mediators had a positive impact on the delivery of psychosocial 
services for patients, it was questionable whether their contracts would continue 
beyond the lifespan of the project. It is unclear however, whether this information 
was unavailable or simply not shared with the lower categories of health 
professionals. Ridde (2008) has described the Mossi culture – predominant in the 
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study area of Ouagadougou - as a strict hierarchy. Though this factor may have 
contributed to the lack of insight about long-term plans among the staff members 
interviewed, uncertainty with respect to funding in HIV programmes is a perpetual 
problem, even at the international level (UNAIDS, 2007). 
 
The patchwork indigent exemption process 
The selection process for the exemption of fees for indigent patients further exposes 
how patchwork provision of services is not sustainable. It was reported in the present 
study that the majority of patients were granted exemptions for ART, a finding which 
has been corroborated by other national studies (Bocoum Yaya, 2008). However, this 
exemption process is ambiguous, subjective and often a logistical challenge to the 
patients. Furthermore, the assistant pharmacist raised the issue of “not-very-poor” 
patients who were not consistently exempted from payment. He maintained that this 
strategy had a negative impact on patient adherence. It also compromises the 
continuity of care by pushing patients to seek free services in the NGO sector on an 
irregular basis. This is indicative the phenomenon of “irrational” use of ARVs 
described by Nguyen et al. (2003) that perpetuates in Burkina Faso to this day and 
justifies concern about “antiretroviral anarchy” (Harries, et al., 2001).  
 
In a context of endemic poverty, the identification of indigents is a complex issue. 
One research project in Burkina Faso is currently studying the use of specific criteria 
established by community members for the selection of indigents by nurses at local 
health centres (Ridde, in  press). Similar research may prove useful in the context of 
HIV care. Nonetheless, the negative effects of non-standardized, irregular fee 
exemption procedures on patient adherence behaviour provide further argument for 
the implementation of gratuity of care as a national policy put forward in the previous 
section.  
 
The impact of external interventions 
External interventions – both nationally and internationally led must be sensitive to 
the local contexts in which they are implemented. In the present study, this issue was 
illustrated through the discussion about the impacts of the ATARAO research project. 
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Despite being led by a local team of HIV experts and of a relatively small scale, the 
project exerted a significant amount of pressure on the settings in which it was 
implemented, particularly in Ward B. Staff complained of increased workload and 
came to rely heavily on the research staff to help dispense care. Two providers also 
reported concern about the effects of precipitated prescription of ART on patient 
adherence. Given how crucial optimal adherence for positive individual and public 
health outcomes, the WHO recommends delaying treatment initiation until the patient 
fully understands the demands of ART and feels ready to begin (WHO, 2003a). This 
finding illustrates how the use of quantitative indicators (in this case the objective of 
400 patients newly initiated on ART) may inadvertently negatively impact both the 
working conditions of providers and patient care. The observational study design of 
ATARAO meant that there should have been no pressure on the local researchers to 
recruit participants. Nonetheless, it was clear for many of those interviewed that for 
the project to continue, donor expectations would have to be met – and this meant 
increasing the rate of recruitment.  
 
Apprehension was voiced by providers in the Ward B where a substantial increase in 
HIV patients occurred over a short period of time as a result of the recruitment efforts 
for the research project. Two providers expressed concern that the growing number of 
HIV patients infringed upon the time spent attending to non-HIV patients. The 
concern about HIV programmes diverting scarce resources away from other health 
problems has been expressed elsewhere (Chopra, 2005).  
 
ART scale-up is a relatively new phenomenon in Africa and the effect of increased 
availability of ART on existing health services is currently under-studied (El-Sadr & 
Abrams, 2007; Wyss & Wiess, 2005). As this study illustrates, vertically-
implemented external interventions may unknowingly add considerable pressure to 
fragile health services by encouraging an influx of HIV patients. This may not only 
translate into reduced quality of care for HIV patients – including attention paid to 
treatment adherence- but also compromise the care received by non-HIV patients. 
The deleterious impacts on service provision observed as a result of the relatively 
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small ATARAO research project provide grounds for concern about the effects of 
larger HIV programmes, with respect to both intervention and research.  
 
An integrated approach to ART distribution that strengthens existing health services 
has been put forward as a strategy to avoiding these pitfalls (Chopra, 2005; 
EQUINET, 2004). This echoes the discussion in the above section on providing a 
continuity of services for HIV patients. As discussed previously, this requires 
investing in range of resources, both material and human. An investment in research 
on the scale-up process has also been cited as essential in comprehending how 
programmes are functioning (Jaffar, et al., 2005).  
 
Efforts are already underway in Burkina Faso to coordinate the donor response, a 
condition required for financial support by the GFATM. As the second round of 
funding is currently in its early stages, it remains to be seen how this will play out on 
the ground. Furthermore, it is unclear whether improved coordination will extend 
beyond the provision of HIV services to include other areas of service delivery, 
including research. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER EIGHT: CONCLUSIONS 
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CONTRIBUTIONS OF THE STUDY 
 
Ethnographic studies in hospital setting often provide evidence upon which to build 
future research and interventions (Savage, 2000). Qualitative methods have been 
found to be useful in clarifying the dynamics of adherence (Sankar, et al., 2006). The 
findings of the present study have led to several research and practice 
recommendations.  
 
Contributions to Practice 
The findings of the present study have the potential to make modest contributions to 
clinical practice, mainly at the three sites studied, and potentially in other settings in 
Burkina Faso. First, interviews allowed providers to express their perspectives on 
adherence and work conditions. Two participants explicitly thanked the ethnographer 
for this “auto-evaluation” opportunity. 
  
“We’ve never been evaluated. I think that over time, at a certain point you 
need to evaluate to see how the components work. It’s important. It allows 
(us) to really confront what should be done with what is done and the 
difficulties people face to implement their programmes.” (Psychosocial 
worker, Ward A) 
 
The second participant mentioned the importance of an outsider’s perspective of a 
phenomenon but insisted that in order to be useful, the results must be shared. In 
response to these concerns, a research report summarizing the findings (in French) 
will be presented to the co-researchers of the ATARAO project.  Based on these two 
positive reactions to the study, it is recommended that feedback mechanisms be 
implemented on the wards that allow providers to express their experiences and 
concerns to supervisors on a regular basis. This suggestion is consistent with previous 
recommendations in the literature (Chopra, 2005).  
 
Second, consistent with the first conclusion of the study, the adherence infrastructure 
at each site should be revisited. Efforts could be made both to facilitate the patient 
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pathway and adapt the infrastructure to available resources on the wards. This may 
imply redefining the roles of all actors along the way to ensure efficacy and 
coherence. As of the end of 2007, a group of experts had met to revise the national 
care guidelines (S. Koala, personal communication, November 2007). Once the new 
guidelines are formalized, it will be important to communicate any changes in 
protocol or tasks in a transparent manner to the health providers. This could be 
accomplished either through a ward or a hospital meeting. This recommendation 
recalls the importance in transmitting information to staff to promote greater 
organizational awareness (Franco, et al., 2002). It goes without saying that 
communicating changes to the patient pathway to the patients themselves in a clear 
and timely manner is essential.  
 
Third, the study identified potential areas for improvement in service provision. As 
discussed in the results section, these primarily involve ensuring the necessary 
support services (laboratory, psychosocial) at the level of the hospital. The results 
provide evidence to advocate for the greater inclusion of such tools by demonstrating 
the challenges health providers face in working without them. The findings also 
clearly communicate a need for improved human resources for health planning at the 
national level.  
 
Fourth, in designing future adherence interventions, particular attention should be 
paid to ensuring the peripheral supports in the health system are available, as well as 
tools for providers to assist patients in negotiating their socioeconomic condition. 
This recalls the need for an integrated, comprehensive approach to ART scale-up 
(Buvé, et al., 2003), as discussed previously. Furthermore, responding to the 
difficulties evoked by the providers shows concern for their work conditions and has 
the potential to positively impact staff morale. Consideration for the well-being of the 
health workforce is of utmost importance given the crucial role it plays in the success 
of health interventions such as ART scale-up (Wyss, 2004), particularly in the context 
of the human resources for health crisis (Stein, et al., 2007).  
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Fifth, given that the main recommendation of providers was to reinforce psychosocial 
care of patients, a more clearly defined protocol for these types of services should be 
elaborated. For instance, referral to NGOs is presently a verbal recommendation and 
largely based on the provider’s awareness of available services in the community 
sector. Referral to medical centres, however, is accomplished with a form specially 
designed for this purpose. It is therefore suggested that the referral procedure to the 
associative sector be formalized along with a review of current psychosocial services 
in view of improving them. This recommendation has been echoed by other 
burkinabè researchers (Kouanda, 2008).  
 
Sixth, the national body spearheading the response to HIV/AIDS, the SP/CNLS-IST, 
along with other national and international organizations should pursue plans to 
improve coordination of activities. This has been included as an objective in Burkina 
Faso’s present grant agreement with the GFATM (SP/CNLS-IST, 2006). Such 
coordination has the potential to contribute to more coherent service provision at the 
level of ART distribution and avoid the patchwork nature of care observed in the 
present study.  
 
Contributions to Research 
Results from the present study will serve to inform both present and future research. 
First, as the ATARAO study is still continuing in Mali, these findings can serve to 
inform data analyses, as well as future phases, by accentuating the importance of an 
in-depth understanding of the context of research; that is, a comprehension of the 
interplay of factors at various levels of the system that influence both the research 
process and subsequent results.  
 
Second, findings may influence future study designs on adherence. Interestingly, in a 
study by Weiss et al. (2003), patients who were non-adherent to medication due to 
barriers in drug procurement or access to alternate regimens – factors that are 
described as systemic determinants in this study- were categorized apart under “gaps 
in treatment”. This is an important distinction to recall in future study designs since 
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classification of determinants of non-adherence may ultimately improve the design of 
future interventions.  
 
Third, results from this study indicate that the process of selecting indigent patients 
for payment exemptions is largely subjective and based on the health provider’s 
interpretation of the patient’s socioeconomic situation. This question requires further 
study with respect to ART scale-up. The impact of treatment costs on households has 
previously been studied in the burkinabè context and found to be detrimental 
(Bocoum Yaya, 2008) 
 
Fourth, the findings reported validate the argument that further research is required 
on how ART scale-up is carried out - including which services are made available 
and which are overlooked – as well as how it impacts on existing health services (El-
Sadr & Abrams, 2007). 
 
 
Limitations of the Study  
 
There are several limitations to this study. First, the scope of the present study is 
limited to the provider’s perspective. A more complete discussion on adherence 
support could be obtained through the inclusion of the patient’s viewpoint.  
 
Second, cross-cultural research presents particular challenges. The researcher may be 
oblivious to certain cultural practices and beliefs that impact the findings. As a white 
woman in an African, patriarchal society, many of my interviews and observations 
were likely coloured by gender and racial expectations conjured by the study 
participants and myself. This barrier was addressed by adopting a reflexive approach 
to data collection (Giacomini, et al., 2000) and attempting to triangulate findings 
using several methods and sources of information (Mays & Pope, 2000).  
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Third, providers may have felt as though they were being evaluated, leading them to 
be more inclined to provide socially desirable responses. In response to this 
challenge, I paid careful attention to the formulation of my questions. For instance, 
instead of questioning which improvements participants considered necessary on the 
ward, I asked them to describe the components of an ideal adherence support 
programme. Reluctance to appear as an evaluator occasionally prevented me from 
delving deeper into certain issues. This was particularly the case with respect to the 
question on the difficulties faced by health providers in their daily work.  
 
Fourth, three months of fieldwork is a relatively short time period during which to 
conduct ethnography. As a result, there are several ideas discussed in the above 
results section that warrant further study, including: the identification of indigents, 
higher-level systemic factors that impact on adherence support (e.g. international 
funding, national decision-making), and cultural barriers to adherence. The 
drawbacks posed by a limited time-frame were attenuated somewhat by the fact that 
this was not my first trip to West Africa, including to Ouagadougou. Also, I have 
been a member of the ATARAO research group since November 2006 and 
participated in weekly discussions on activities and challenges in the field. I was thus 
relatively well-informed as to the overall circumstances of the project in Burkina 
Faso.  
 
Fifth, language posed a significant barrier during many of the observation sessions. 
Most of the conversations between patients and staff, and often among staff, were 
carried out in the local language Mooré. As such, much of my observation of patient-
provider and provider-provider interactions was limited to body language. Though 
this evidently posed certain challenges in understanding, it also provided a unique 
perspective, as I was obliged to pay particular attention to non-verbal cues. This 
allowed me to triangulate verbal and non-verbal information.  
 
Finally, due to the discontinuation of the study in Burkina Faso, triangulation of 
results with the burkinabè partners was less feasible than desired. Ideally, results 
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would have been corroborated with the principal co-investigator in Burkina Faso, 
project coordinators, interviewers and key informants. In the absence of this 
possibility, results were discussed with the Montreal principal investigator and 
coordinator, both of whom have spent a considerable amount of time working on the 
issue of HIV and ART in Burkina Faso.  
 
Rigor  
 
There are three views on how ethnographic research should be evaluated: (1) using 
the same set of criteria as quantitative studies, implying a global set of indicators 
upon which to judge research; (2) employing a separate set of criteria compatible 
with the distinct character of qualitative research; and (3) avoiding the use of criteria 
since the notion of set criteria is discordant with the qualitative approach 
(Hammersley, 1992). Mays and Pope propose a set of criteria upon which to evaluate 
qualitative research based on the premise that all research seeks to represent a certain 
reality (Mays & Pope, 2000). From this perspective, the quality of research may be 
assessed in the common terms of validity and relevance, adapted to the needs of the 
type of research (i.e. qualitative or quantitative). The relevance of this study has been 
previously discussed in this document. Six criteria have been suggested to assess 
validity: triangulation; respondent validation; clear exposition of methods of data 
collection and analysis; reflexivity; attention to negative cases; and fair dealing. Each 
of these will be discussed in relation to the present study with the caveat that this is 
not an attempt to reduce the notion of quality to a simple “checklist” (Barbour, 2001) 
but rather to assure the reader that a just representation of the reality of the topic of 
study was of utmost concern to the researcher.  
 
Triangulation refers to the use of two or more data collection methods, or two or 
more data sources (Mays & Pope, 2000). The results of this study are based on a mix 
of interview, observation data, and document review. When possible, more than one 
person belonging to a particular category of professionals on each ward was 
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interviewed in an effort to triangulate data sources. For example, two nurses were 
interviewed in both Ward A and Ward B.  
 
Respondent validation seeks to confirm the researcher’s findings through consultation 
with study participants (Mays & Pope, 2000). As mentioned in the limitations section 
above, this method was not employed to the extent that the researcher had hoped. 
Nonetheless, certain findings were corroborated through informal interviews as well 
as two second interviews during the research process.  
 
The present document includes an elaborate description of the methods and analysis 
used, as well as the researcher’s position, in an effort to elucidate the entire research 
process for the reader.  
 
Conducting fieldwork requires the researcher to reflect on how her presence in the 
setting may influence her findings, a process referred to as reflexivity (Giacomini, et 
al., 2000). This approach is especially apparent in the account of the ethnographer’s 
position, as well as in the section on “External pressures: interventions with the best 
intentions” of the results. As mentioned in the limitations of the study, my white, 
student, female identity, likely influenced how people responded to my presence on 
the wards. In general, I felt that my identity was helpful in integrating the setting, as 
providers did not view me as a threat. I also made a considerable effort to not appear 
as an evaluator during interviews, as discussed previously.  
 
If information arose during an interview that was contradictory to data obtained from 
another participant I sought to clarify the issue either by asking the participant to 
explain himself/herself further or by confirming the information with another 
participant. No great disparities in information collected were noted.  
 
“Fair dealing” aims to ensure that a variety of perspectives is included in the 
analyses. This method was ensured by both the objective of the study – that is, to 
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collect the viewpoints of a variety of healthcare providers – as well as in the data 
collection approach described previously.  
 
In summary, several measures were taken to ensure the rigor of the present study. 
Needless to say that given the above-mentioned limitations to the study there is room 
for improvement. Nonetheless, it is the researcher’s contention that the present 
findings provide a realistic illustration of the phenomenon studied.  
 
 
CONCLUSION 
 
The objective of this ethnographic project was to study the perspectives of healthcare 
providers on the issue of adherence support for HIV patients on ART. In doing so, it 
addressed several gaps in the literature. Primarily, it responded to the call for more 
operations research on how treatment scale-up is affecting service provision at local 
sites of distribution.  
 
The study led to three broad conclusions. First, good organization is imperative in the 
delivery of adherence support services. Second, providing ART within a 
comprehensive package of care is an essential component of effective adherence 
support. Third, there is a need for improved coordination of nationally and 
internationally-led HIV programming for coherent service provision at the local level. 
The study findings are innovative in that they draw attention away from the 
individual provider behaviour and instead focus on factors that inhibit adherence 
support at various levels of society – the ward, the health system, society and the 
international context. This perspective thus avoids placing a disproportionate amount 
of responsibility on the individual and attempts to identify areas for improvement at 
macro levels that are often overlooked. 
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It is clear from the study findings that it is only through the sustained engagement of 
actors at all levels of society that the effective provision of adherence support 
services for patients on ART can be ensured.   
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APPENDIX 1. STUDY PARTICIPANTS BY SITE 
 
 
Category of Health 
Professional 
Site 
One 
Site Two: 
Ward A 
Site Two: 
Ward B 
Site Two: 
Pharmacy 
Total  
Doctor 2 3 2  7 
Nurse  2 2  4 
Midwife 1    1 
Pharmacist    2 2 
Lay Counsellor  2   2 
Research interviewer 1 1 2  4 
NGO representative 1    1 
TOTAL 5 8 6 2 21 
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APPENDIX 2. SEMI-STRUCTURED INTERVIEW GUIDE 
 
Questions démographiques 
1. Quel est votre âge? 
2. Quelle est votre profession?  
3. Où avez-vous complété votre formation? 
4. Depuis combien de temps pratiquiez vous cette profession? 
5. Depuis combien de temps pratiquiez vous dans ce service?  
 
Prise en charge générale 
1. J’aimerais que vous me décrivez comment la prise en charge des patients VIH 
se passe à/au ____________ (lieu : Médecine C, Dermatologie, Ste Camille) 
(Imaginez qu’un patient VIH sous traitement entre dans le service. Qu’est-ce 
qu’il fait?)  
2. Quel est votre rôle dans cette prise en charge? 
a. Quelles sont vos tâches? 
3. J’aimerais que vous me parliez de comment vous vivez cette prise en charge. 
a. Quels sont les aspects positifs? 
b. Quelles sont les difficultés auxquelles vous faites face?  
 
Prise en charge de l’observance 
Maintenant, j’aimerais que vous me parliez de la prise en charge de l’observance aux 
ARV chez les patients VIH. 
1. Quels sont les services offerts aux patients pour répondre aux questions 
d’observance aux ARV?  
a. Qui est/sont la/les personne(s) qui gère(nt) ces services?  
2. En tant que ______________ (catégorie de professionnel de la santé), quel est 
votre rôle par rapport à l’observance des patients aux ARV? 
a. Pouvez-vous me lister les tâches reliées à ce rôle?  
3. De quelle manière  aborder-vous le sujet de l’observance avec vos patients qui 
prennent les ARV? 
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a. À quel(s) moment(s) les patients reçoivent-ils des informations sur la 
prise de médicaments?  
b. Pouvez-vous me donner des exemples  de recommandations que vous 
offrez à vos patients concernant l’observance aux ARV? 
c. Si vous percevez qu’un de vos patients exerce des difficultés avec 
l’observance aux ARV, quelles recommandations offrez-vous? 
4. Selon vous, qui est la personne/catégorie de professionnel de la santé qui 
devrait être principalement chargé d’assister les patients avec l’observance 
aux ARV? Pourquoi?  
a. Quelles seraient les tâches de cette personne?  
5. J’aimerais que vous me parliez de la communication entre les professionnels 
de la santé au sujet de l’observance aux ARV.  
a. Par exemple, parlez-vous au __________ (une autre catégorie de 
professionnel) à propos de l’observance des patients aux ARV?  
6. Si on vous demandait de planifier et d’implémenter un programme pour 
répondre aux besoins d’observance aux ARV, quels genres de services 
prévoyez-vous? 
a. Qui serait chargé à gérer ces services? 
i. Quelles seraient les tâches de cette personne?  
b. Qui seraient les autres professionnels impliqués? 
i. Quelles seraient les tâches de chacun?  
7. Avez-vous d’autres commentaires à ce sujet que nous n’avons pas abordés?  
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APPENDIX 3. INFORMED CONSENT FORM 
                                                                      
FORMULAIRE DE CONSENTMENT 
Rôle que jouent les professionnels de la santé dans l’observance des patients aux 
traitements antirétroviraux 
 
On vous invite à participer à cette étude en tant que participant. L’objectif de ce projet de 
recherche est de mieux comprendre le rôle que jouent les professionnels de la santé dans 
l’observance de leurs patients aux traitements antirétroviraux (TARV). Ce projet s’effectue 
avec une collaboration entre le Centre hospitalier national Yalgado Ouédraogo, le Centre Oasis, 
et l’Université de Montréal.  
 
Description du projet 
Ce projet de recherche tente de mieux comprendre le rôle que jouent les diverses catégories de 
professionnels de la santé dans l’observance des patients aux TARV. Dans ce but, différentes 
catégories de professionnels de la santé seront interviewées.                                                       
 
Procédures 
Les thèmes qui seront discutés porteront sur le rôle que jouent les professionnels de la santé 
dans l’observance des patients aux TARV, incluant des mesures qui pourraient être prises pour 
améliorer les services rendus. La durée de l’entretien est d’environ une heure. Un endroit et une 
heure appropriée seront convenus selon votre disponibilité et vos préférences. Un appareil 
d’enregistrement de la voix sera utilisé avec votre permission. La chercheuse principale dirigera 
l’entrevue.   
 
Résultats attendus et bénéfices pour participants et pour la société 
Participants: Il n’y a pas de bénéfices directs de votre participation dans l’étude. Cependant, au 
terme de l’étude, les résultats seront partagés avec vous.  
 
Société: Les résultats attendus contribueront à une meilleure compréhension du rôle que jouent 
les professionnels de la santé dans l’observance des patients aux TARV. Ces résultats pourront 
mener à des interventions pour mieux répondre aux besoins des patients par rapport à 
l’observance aux TARV, ainsi que des changements dans l’organisation des services de la 
santé.    
  
Risques et inconvénients 
Il n’y a pas de risques attendus pour le participant. Cependant, il sera demandé de partager son 
temps avec la chercheuse.  
 
Confidentialité.   
Les entretiens seront enregistrés avec un appareil d’enregistrement de la voix, avec la 
permission du participant. Postérieurement, l’information sera transcrite à un système 
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informatique. Un code numérique sera assigné à chaque participant pour assurer que 
l’identité de chacun reste confidentielle.  Les codes numériques ne seront pas 
partagés à l’extérieur de l’équipe de recherche. Les données informatisées seront 
gardées sur l’ordinateur portable de la chercheuse principale (Kimberly Munro) et un 
mot de passe sera nécessaire pour y accéder. Seulement la chercheuse principale et 
les investigateurs principaux auront la permission de consulter les documents.  Les 
données, incluant les enregistrements et les transcriptions, seront détruites 5 ans après 
la fin de l’étude. 
Éventualité d'une suspension de l'étude                                                                   
La participation à cette étude peut être interrompue par la chercheuse si elle croit 
que c’est dans l’intérêt du participant ou pour toutes autres raisons.  
Liberté de participation et liberté de retrait de l'étude                                      
Votre participation à cette étude est tout à fait volontaire. Vous êtes donc libre 
d’accepter ou de refuser d’y participer et vous pouvez vous retirer de l’étude en 
tout temps, sans conséquences. Si vous  retirer votre participation de l’étude, toute 
information déjà transférée sur l’ordinateur sera supprimée.   
Compensation                                                                                                                
Il n’y a pas d’incitatifs offerts pour votre participation dans l’étude. Cependant, l’entretien 
s’effectuera durant les heures de travail et vous ne serez pas pénalisé.  
Personnes ressources 
Si vous avez des questions concernant l’étude, vous pourrez contacter :  
 
Personne-ressource neutre au Burkina Faso 
Dr. Marcel Lougué  
Chargé de programme au Programme d’appui au monde associatif et communautaire de lutte 
contre le SIDA 
 
Personnes en contact direct avec les participants 
Kimberly Munro- Chercheuse principale  
 
Abdoul Kadre Kargougou- Coordinateur de recherche au Burkina Faso  
 
Investigateurs de recherche associés 
Pr Pascal Niamba, MD 
Centre hospitalier national Yalgado  Ouédraogo 
 
Vinh-Kim Nguyen, MD/PhD 
Département de médecine sociale et préventive 
Université de Montréal 
 
Rôle que jouent les professionnels de la santé  dans l’observance des patients aux traitements 
antirétroviraux 
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Déclaration du participant 
J’ai lu et compris le contenu du présent formulaire. Je certifie qu’on me l’a expliqué 
verbalement. J’ai eu l’occasion de poser toutes les questions concernant ce projet de recherche 
et on y a répondu à ma satisfaction. Je certifie qu’on m’a laissé le temps voulu pour réfléchir et 
prendre ma décision. Je sais que je pourrai me retirer de ce projet en tout temps. 
 
Je, soussigné(e), accepte de participer à cette étude 
 
_________________________________ 
Date 
 
________________________________   __________________________ 
Nom du participant      Signature du participant 
 
Je consens à ce que les entretiens soient enregistrés: oui ___     non ___. 
 
Je certifie a) avoir expliqué au signataire les termes du présent formulaire de consentement; b) 
lui avoir clairement indiqué qu’il reste à tout moment libre de mettre un terme à sa participation 
et que je lui remettrai une copie signée du présent formulaire; et je m’engage à préserver la 
confidentialité de l’identité du participant  
 
________________________________   _______________________ 
Nom de l’intervieweur        Signature de intervieweur 
 
Je certifie avoir expliqué au participant les objectifs de l’étude et j’accepte de garder 
confidentiel l’identité de tous participants recrutés. 
 
 
_____________________________          _______________________ 
Nom du recruteur      Signature du recruteur 
 
Information additionnelle  
Une copie sera fournie au participant et une autre sera gardée par l’équipe de référence.  
Ce projet à été approuvé par le CERFM de l’Université de Montréal (comité d’éthique)  le 
(date et numéro de certificat).  Dernière révision du formulaire de consentement: le 2 août, 
2007. 
 
 
